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Thesis	Outline	and	Project	Background 
This	project	 is	 a	 joint	 collaboration	between	academic	 (Dublin	City	University)	 and	 industrial	
(EKF	Diagnostics	Limited)	partners,	with	the	financial	backing	of	the	Irish	Research	Council.	EKF	
Diagnostics	 is	 a	 global	 medical	 diagnostics	 company	 which	 specialises	 in	 the	 development,	
production	and	distribution	of	a	range	of	IVD	products	for	Point	of	Care	and	Central	Laboratory	
testing,	with	 a	 focus	on	detection	 and	management	of	 diabetes,	 anemia,	 lactate	 and	organ-
related	diseases.		
	
Acute	 pancreatitis	 (AP)	 is	 a	 complex	 inflammatory	 disease	 with	 varying	 etiology	 and	
presentation	of	severity.		It	has	a	clinical	course	that	is	difficult	to	predict	and	is	associated	with	
local	 and	 systemic	 complications,	 organ	 failure	 and	death.	 The	 intra-pancreatic	 activation	 of	
trypsinogen	 to	 trypsin	 is	 recognised	 as	 one	 of	 the	 earliest	 events	 in	 the	 onset	 of	 AP.	 The	
simultaneous	and	proportional	release	of	trypsinogen	activation	peptide	(TAP)	into	the	blood	
and	urine	therefore	offers	a	potential	biomarker	of	this	disease.	The	initial	development	of	a	
TAP	radioimmunoassay	by	the	Hermon-Taylor	group	at	St.	George’s	Hospital,	London	(Hurley	
et	 al.,	 1988)	 was	 swiftly	 followed	 by	 the	 licencing	 and	 commercialisation	 of	 a	 promising	
polyclonal	 enzyme-linked	 immunosorbent	 assay	 (ELISA)	 format	 developed	 by	 Biotrin	
International	 Limited.	 Significant	 literature	 (Huang	et	 al.,	 2013)	was	 published	 exploring	 and	
suggesting	the	utility	of	TAP	as	a	biomarker	for	prediction	of	disease	severity	in	AP.	However,	
failure	 to	 achieve	 reproducibility	 in	 the	 performance	 of	 this	 product	 due	 to	 the	 nature	 of	
polyclonal	 antibody-based	 technology	 led	 to	 significantly	 reduced	 interest	 in	 the	 TAP	
biomarker.	 Recently,	 a	 monoclonal	 anti-TAP	 antibody	 was	 produced	 for	 evaluation	 as	 a	
solution	to	this	issue.	
	
This	thesis	entails	the	development	of	a	competitive	ELISA	and	rapid	lateral	flow	immunoassay	
(LFIA)	for	the	detection	of	TAP.	It	was	anticipated	that	these	prototype	devices	would	provide	
the	basis	for	a	clinical	feasibility	study	of	TAP	as	a	predictor	of	severity	 in	AP.	The	findings	of	
such	a	study	represent	the	opportunity	to	re-open	the	dialogue	on	the	clinical	utility	of	TAP	at	
a	 time	where	 there	 is	greater	understanding	of	AP	 through	pathological	 re-classification,	 the	
incidence	 of	 the	 disease	 appears	 to	 be	 increasing,	 and	 the	 advent	 of	 effective	 point-of-care	
(POC)	 technologies	 make	 the	 approach	 a	 legitimate	 prospect	 for	 application	 in	 patient	
management.	
	 	 	xii	
Aims	of	the	Research	
	
The	specific	undertakings	of	this	research	can	be	divided	into	the	following	sections:	
	
Chapter	2	describes	the	materials	and	methods	used	within	this	research.	
	
Chapter	 3	 focuses	on	 the	development	 and	optimisation	of	 a	 reproducible	monoclonal	 anti-
TAP	 ELISA	 with	 clearly	 defined	 performance	 characteristics	 and	 the	 ability	 to	 function	 as	 a	
“gold	standard”	reference	tool	for	the	subsequent	LFIA	work.	
	
Chapter	4	describes	the	development	of	an	anti-TAP	LFIA	prototype	capable	of	quantifying	and	
distinguishing	 between	 varying	 urinary	 TAP	 concentrations	 through	 the	 use	 of	
superparamagnetic	particle	labels	and	a	commercially	established	point-of-care	instrument.		
	
Chapter	5	investigates	the	clinical	utility	of	the	TAP	biomarker	for	the	stratification	of	patients	
with	acute	pancreatitis	(AP)	based	on	disease	severity	as	defined	by	the	Adelaide	and	Meath	
National	 Children’s	 Hospital	 clinical	 treatment	 criteria	 and,	 the	 internationally	 recognised	
Atlanta	 classification.	 The	 ability	 of	 TAP	 to	 predict	 disease	 severity	 is	 also	 explored.	 This	
analysis	was	achieved	using	an	exploratory	cohort	of	patients	with	AP	and	the	anti-TAP	ELISA	
from	 chapter	 3.	 The	 feasibility	 of	 the	 anti-TAP	 LFIA	 prototype	 to	 distinguish	 between	 TAP	
positive	and	negative	urinary	samples	is	also	discussed.	
	
Chapter	6	covers	the	overall	conclusions	of	this	project	and	the	future	work	that	is	envisaged.	
	
	
Publications	
	
Connolly,	 R.	 and	 O’Kennedy,	 R.	 (2017),	 Magnetic	 lateral	 flow	 immunoassay	 test	 strip	
development	–	considerations	for	proof	of	concept	evaluation.	Manuscript	in	preparation.	
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Abstract	
	
Acute	 Pancreatitis	 (AP)	 is	 an	 inflammatory	 condition	 of	 the	 pancreas,	 presenting	 initially	 as	
severe	upper	 abdominal	 pain.	 This	 disease	 can	 range	 from	mild	AP	 to	moderately	 severe	or	
severe	 AP,	 with	 development	 of	 local	 and	 systemic	 complications	 and	 a	 diverse	 range	 of	
outcomes.	 Consequently,	 it	 is	 imperative	 to	 diagnose	 and	 predict	 disease	 severity	 at	 the	
earliest	juncture.	Numerous	guidelines	exist	for	the	management	of	AP,	 including	the	revised	
Atlanta	classification	system.	This	guideline	does	not	have	the	capacity	to	predict	the	degree	of	
disease	 severity	 from	 hospital	 admission.	 Thus,	 the	 availability	 of	 a	 predictive	 biomarker,	
working	 in	 conjunction	 with	 the	 established	 classification	 system,	 would	 be	 advantageous.	
Several	markers	such	as	amylase,	lipase	and	C-reactive	protein	are	used	for	the	diagnosis	of	AP	
by	 hospitals	 at	 present.	 However,	 it	 is	 now	 fundamentally	 agreed	 that	 the	 early	 intra-
pancreatic	activation	of	normal	protein	digestion	enzymes	 is	associated	with	development	of	
AP.	 Trypsinogen	 Activation	 Peptide	 (TAP)	 is	 a	 potential	 predictive	 biomarker	 of	 AP	 that	 is	
proportionally	 produced	 and	 rapidly	 excreted	 into	 the	 urine	 following	 cleavage	 of	 the	
zymogen,	trypsinogen,	to	trypsin.	Herein,	the	establishment	of	a	gold	standard	ELISA	(with	an	
intra-	and	inter-assay	coefficient	of	variation	of	1.7	–	10.1%	and	4.8	–	10.4%,	respectively)	and	
the	development	of	a	lateral	flow	test	strip	for	urinary	TAP	are	described.	An	exploratory	study	
(n	=	15)	using	the	ELISA	prototype	to	determine	the	clinical	utility	of	TAP	for	early	prediction	of	
AP	severity	demonstrated	that	TAP	is	superior	to	CRP	for	the	stratification	of	patients	with	mild	
and	 moderate	 AP.	 The	 sensitivity,	 specificity,	 negative	 predictive	 value	 (NPV)	 and	 positive	
predictive	 value	 (PPV)	 of	 TAP	 to	 predict	 the	 development	 of	 moderate	 AP	 at	 48h	 after	
admission	was	85.7%,	100.0%,	90.0%	and	100%,	respectively.	The	sensitivity,	specificity,	NPV	
and	PPV	of	CRP	to	predict	the	development	of	moderate	AP	at	48h	after	admission	was	85.7%,	
69.2%,	90.0%	and	60.0%,	respectively.	The	lateral	flow	device	also	demonstrated	the	ability	to	
distinguish	between	TAP	positive	and	TAP	negative	clinical	urine	samples.	In	conclusion,	TAP	is	
a	promising	biomarker	for	the	early	prediction	of	severity	in	AP.	
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1.1	 The	pancreas	–	function	and	malfunction	
	
The	pancreas	 is	 the	second	 largest	gland	connected	to	the	digestive	tract	after	 the	
liver,	 and	 is	 found	 in	 the	 upper	 abdominal	 cavity,	 posterior	 to	 the	 stomach	 and	
anterior	 to	 the	 kidneys.	 This	 complex	 organ	 is	 capable	 of	 both	 exocrine	 and	
endocrine	 functions	within	 the	human	body	 (see	Figure	1.1.1).	 The	 larger	exocrine	
portion	 of	 the	 pancreas	 (up	 to	 98%	 of	 pancreatic	 tissue)	 consists	 of	 lobed	 ducts	
called	 acinar	 cells	 that	 produce	 digestive	 enzymes	 for	 transport	 from	 the	 main	
pancreatic	duct	to	the	duodenum	of	the	small	 intestine	in	response	to	food	intake.	
The	different	endocrine	cells	of	the	pancreas	exist	as	islets	of	Langerhans	grouped	in	
the	 surrounding	 tissue	and	are	 responsible	 for	 the	 secretion	of	hormones	 into	 the	
blood	for	delivery	throughout	the	body	(Sargent,	2006).	These	hormones	include	the	
blood-sugar	regulators	glucagon	and	insulin,	the	multi-tasking	inhibitor	somatostatin	
and,	pancreatic	polypeptide,	an	 inhibitor	of	gastrointestinal	emptying	and	exocrine	
secretion	(Koska,	2004;	Sargent,	2006).	
The	complexity	and	functional	demands	placed	on	the	pancreas	require	that	
this	 organ	 is	 highly	 innervated	 and	 vascularised.	 The	 involuntary	 parasympathetic	
and	 sympathetic	 nerves	 stimulate	 and	 inhibit	 the	 secretion	 of	 digestive	 enzymes	
from	 the	 pancreas,	 respectively	 (van	 Orshoven,	 2008).	 The	 release	 of	 digestive	
enzymes	 aids	 in	 the	 degradation	 of	 food	 products	 such	 as	 fats,	 proteins	 and	
carbohydrates	 into	 absorbable	 nutrients	 for	 the	 body	 (Sargent,	 2006).	 These	
enzymes	 are	 stored	 as	 inactive	 or	 “zymogen”	 pro-enzymes	 inside	 intracellular	
vesicles	of	acinar	cells	within	the	pancreas	(Hammer,	2014).	The	secretion	of	these	
zymogens	occurs	 through	the	process	of	exocytosis	whereby	the	vesicles	 fuse	with	
the	acinar	cell	membrane	to	form	a	pore	or	channel	for	excretion	of	the	zymogens	
into	 the	 pancreatic	 duct	 and,	 subsequently,	 the	 gut.	 The	 process	 of	 exocytosis	 is	
generally	 triggered	 by	 a	 rise	 in	 cytosolic	 calcium	 ions	 (Ca2+)	 following	 extracellular	
entry	 through	 the	 cell	membrane.	However,	 this	differs	 for	acinar	 cells,	where	 the	
initial	Ca2+	stimulation	is	supplied	from	preexisting	intracellular	provisions.	This	finely	
tuned	Ca2+	signaling	pathway	has	the	potential	to	become	unbalanced,	leading	to	a	
sustained	 elevation	 in	 Ca2+	 stimulation	 and	 subsequently,	 excessive	 intracellular	
release	 and	 extracellular	 access.	 In	what	 can	 be	 termed	 a	 vicious	 circle,	 sustained	
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intracellular	 stimulation	 results	 from	 the	 release	 of	 Ca2+	 from	 the	 cell	 into	 the	
extracellular	matrix	 through	 channels	 formed	 in	 the	 plasma	membrane,	 depleting	
the	 intracellular	 Ca2+	 stores.	 Consequently,	 the	 cell	 must	 replenish	 these	 empty	
stores	 by	 activating	 additional	 channels	 to	 allow	 entry	 from	 the	 now	 Ca2+	 rich	
extracellular	 environment.	 This	 stimulatory	 effect	 can	 also	 be	 coupled	 with	 the	
neurotransmission	 of	 acetylcholine	 to	 acinar	 cells	 and	 presence	 of	 the	 circulating	
hormone	cholecystokinin.	The	 instability	of	 this	process	was	demonstrated	to	have	
the	capacity	to	kill	cells,	causing	necrosis	of	the	pancreatic	tissue	(Beger	et	al.,	2008).	
While	this	mechanism	is	still	not	fully	understood	and	additional	activation	pathways	
have	 been	 studied	 involving	 for	 example,	 damage	 by	 reactive	 oxygen	 species	
(Lankisch	 et	 al.,	 2015),	 it	 is	 widely	 agreed	 that	 the	 inappropriate	 activation	 of	
zymogens	within	acinar	cells	leads	to	the	auto-digestion	of	pancreatic	tissue	and	the	
release	of	digestive	enzymes	into	the	blood.		
Cleavage	of	the	zymogen	known	as	trypsinogen	by	enterokinase,	an	enzyme	
located	in	the	epithelial	cells	of	the	small	intestine,	to	form	trypsin	is	a	crucial	step	in	
normal	protein	digestion.	Trypsin	is	capable	of	self-activation	as	well	as	activation	of	
all	other	 zymogens	simultaneously	 (see	Figure	1.1.1).	 Several	mechanisms	exist	 for	
the	 regulation	 of	 trypsinogen	 activation.	 The	 process	 of	 regulation	 by	 serine	
protease	 inhibitor,	 Kazal	 type	 1	 (SPINK1),	 which	 can	 prevent	 auto-activation	 of	
trypsin,	is	the	most	understood	(Figure	1.1.2).		
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Figure	1.1.1	The	pancreas	and	normal	protein	digestion;	adapted	from	olivelab.org.	
Trypsinogen	cleavage	and	activation	by	enterokinase	or	trypsin	autocatalysis	and	the	
subsequent	 zymogen	 activation	 cascade	 are	 shown.	 During	 the	 activation	 of	
trypsinogen,	 the	 conserved	 peptide	 by-product	 of	 trypsinogen	 activation	 peptide	
(TAP)	 is	 formed	and	rapidly	released	 into	the	blood	and	urine	due	to	 its	small	size.	
This	peptide	will	be	discussed	at	length	later	in	the	chapter	(section	1.5.4).	
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Figure	 1.1.2	 Trypsinogen	 activation	 and	 inhibition	 pathways	 in	 human	 and	 rodent	
acinar	 cells;	 adapted	 from	 Frossard,	 2001.	 SPINK1	 inhibits	 the	 activation	 of	
trypsinogen	by	trypsin	(-).	In	rats,	the	inhibitory	capacity	can	also	prevent	activation	
by	 the	 cathepsin	 B	 enzyme,	 however,	 this	 has	 not	 yet	 been	 extensively	 proven	 in	
human	 studies	 (Lerch	 &	 Halangk,	 2006).	 Trypsin	 can	 also	 inactivate	 itself	 through	
hydrolysis	of	 the	globular	domains	of	 the	trypsin	enzyme.	 If	 this	negative	 feedback	
mechanism	should	be	overcome,	the	zymogens	(pro-enzymes)	can	become	activated	
inside	the	acinar	cell,	leading	to	cell	injury,	death	and	tissue	necrosis.	
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The	capacity	of	SPINK1	to	inhibit	trypsin	activity	can	become	uncontrolled,	leading	to	
excessive	 activation	 of	 trypsinogen	 and	 a	 cascade	 of	 inappropriate	 zymogen	
activation	 and	 auto-digestion	 of	 the	 pancreas.	 This	 is	 ultimately	 followed	 by	 the	
induction	of	leukocytes	to	release	pro-	(C-reactive	protein	(CRP),	interleukin	(IL)-1,	6,	
8	and	tumour	necrosis	factor	(TNF)-α)	and	anti-inflammatory	(IL-10)	cytokines	to	the	
immediate	area	(Jain	et	al.,	2011;	Hammer,	2014).	This	process	is	believed	to	be	one	
of	 the	 earliest	 occurrences	 leading	 to	 the	 development	 of	 the	 inflammatory	
condition	of	acute	pancreatitis	(AP).	AP	is	associated	with	intense	upper	abdominal	
pain,	 nausea,	 vomiting,	 jaundice	 and	 abdominal	 distension	 (Kingsnorth	 &	 O’Reilly,	
2006).	 The	 level	 of	 pain	 experienced	 by	 patients	 is	 not	 unusual	 due	 to	 the	 highly	
innervated	nature	of	the	pancreas.	These	nerves	are	sensitive	to	inflammatory	attack	
and	 increases	 in	 mechanical	 pressure	 from	 ductal	 obstruction	 (Vardanyan	 &	 Rilo,	
2010).	 Acute	 pancreatitis	 is	 an	 extremely	 aggressive	 condition	 that	 can	 lead	 to	
systemic	 inflammation,	 multiple	 organ	 failure	 and	 death.	 Initial	 localised	
inflammation	of	the	pancreas	can	rapidly	spread	to	surrounding	tissues	and	organs	
due	to	its	numerous	vascular	connections	and	proximity	to	vital	organs	such	as	the	
lungs	(Zhou	et	al.,	2010)	and	kidneys	(Petejova	&	Martinek,	2013).	Persistent	organ	
failure	accounts	for	one-third	to	half	the	deaths	in	AP	occurring	in	the	first	week,	a	
large	proportion	of	which	(50%)	is	associated	with	lung	injury	(Pastor	et	al.,	2003).	A	
second	wave	of	late	deaths	occurs	more	than	one	week	after	hospital	admission	and	
are	 usually	 associated	 with	 local	 complications	 of	 the	 pancreas,	 such	 as	 infected	
necrosis	and	sepsis	(Johnson	et	al.,	2004).	 
	
The	causes	of	pancreatitis	are	as	 complex	and	diverse	as	 the	organ	 itself.	 The	 two	
most	 common	causes	of	AP	are	alcohol	 and	biliary	obstructions	 such	as	 gallstones	
(Lankisch	 et	 al.,	 2015).	 Excessive	 alcohol	 or,	 more	 specifically,	 ethanol	 intake	 has	
been	demonstrated	to	increase	and	destabilise	the	zymogen	content	of	acinar	cells,	
sensitizing	them	to	premature	activation	and,	 in	the	presence	of	additional	factors,	
this	can	manifest	as	AP	(Gorelick,	2003;	Lerch	et	al.,	2003).	Alcohol	sensitisation	can	
also	 aid	 in	 the	 progression	 of	 AP	 to	 become	 a	 recurring	 issue	 with	 long-term	
inflammatory	episodes	leading	to	permanent	structural	changes	such	as	fibrosis,	and	
are	 described	 as	 chronic	 pancreatitis	 (Clemens	 et	 al.,	 2014).	 The	 formation	 of	
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gallstones	and	subsequent	blockage	of	bile	ducts	 leads	to	a	reduction	in	pancreatic	
juice	 secretion	and	 in	 turn	also	prevents	exocytosis	of	 zymogens	 from	acinar	 cells.	
Additional	 blockages	 can	 also	 arise	 from	 a	 pancreatic	 abscess,	 cyst	 or	 tumour	
(Wilmer,	2004).	Hundreds	of	drugs	have	been	included	as	potential	causative	agents	
of	AP	in	the	World	Health	Organisation	(WHO)	database;	however,	the	definitive	list	
currently	 includes	 drugs	 such	 as	 acetaminophen,	 cisplatin,	 enalapril,	 erythromycin,	
oestrogens,	 opiates,	 and	 steroids	 (Nitsche	 et	 al.,	 2012;	 Lankisch	 et	 al.,	 2015).	
Numerous	inherited	or	genetic	conditions	can	also	cause	AP,	such	as	mutation	of	the	
trypsinogen	 gene	 (Whitcomb	 et	 al.,	 1996)	 or	 the	 metabolic	 abnormalities	 of	
hypertriglyceridemia	 and	 hypercalcemia	 (Siva	 &	 Pereira,	 2006).	 In	 addition,	
accidental	 blunt	 abdominal	 trauma	 or	 post-operative	 trauma	 such	 as	 endoscopic	
retrograde	 cholangio-pancreatography	 (ERCP)	 for	 bile	 duct	 surgery	 and	 parasitic,	
viral	 or	 bacterial	 infection	 are	 also	 known	 causes	 of	 disease	 (Steinberg	 &	 Tenner,	
1994).	More	 recently,	 there	 is	 increasing	 evidence	 for	 smoking	 as	 an	 independent	
risk	factor	in	AP,	despite	its	regular	association	with	alcohol	(Schurmann	et	al.,	2009;	
Sadr-Azodi	 et	 al.,	 2012).	 Additional	 co-morbidities	 or	 inherited	 conditions	 such	 as	
diabetes	mellitus,	cystic	fibrosis,	Crohn’s	disease,	pancreas	divisum	and	Sphincter	of	
Oddi	dysfunction	are	also	increased	risk	factors	for	AP	(Lankisch	et	al.,	2015).	Finally,	
AP	can	also	be	caused	by	idiopathic	complications	(Van	Brummelen	et	al.,	2003).			
1.2	 Acute	pancreatitis	–	incidence	and	impact	
	
Reginald	Huber	Fitz	(1889)	compiled	the	first	modern	assessment	and	description	of	
acute	pancreatitis	(AP),	with	the	first	hypothesis	of	pancreatic	auto-digestion	coming	
several	 years	 later	 (Chiari,	 1896).	 Since	 then,	 this	 condition	 has	 been	 studied	 in	 a	
diverse	 range	 of	 animals,	 from	 the	 zebrafish	 (Lerch	 &	 Gorelick,	 2013)	 to	 dogs	
(Mansfield	et	 al.,	 2003).	 This	 exceptionally	 varied	 and	 often	 unpredictable	 disease	
can	 range	 from	 mild	 and	 non-threatening	 to	 severely	 aggressive	 clinical	 courses	
resulting	 in	high	morbidity	and	mortality.	While	the	majority	of	mild	cases	are	self-
resolving	 and	 have	 a	 mortality	 rate	 of	 less	 than	 1%,	 requiring	 only	 conservative	
medical	supervision	(Swaroop	et	al.,	2004);	up	to	30%	of	cases	can	develop	serious	
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life-threatening	 complications	with	 a	 subsequent	mortality	 rate	 as	 high	 as	 25-35%	
(Swaroop	et	al.,	2004;	Schepers	et	al.,	2013). The	increasing	incidence	of	AP	has	been	
reported	 internationally,	 in	 countries	 such	 as	 the	 United	 States	 (U.S.)	 (Frey	 et	 al.,	
2006;	 Fagenholz	 et	 al.,	 2007),	 Sweden	 (Appelros	 &	 Borgstrom,	 1999),	 Finland	
(Jaakkola	&	Nordback,	1993)	and	the	Netherlands	(Spanier	et	al.,	2013).	The	number	
of	cases	of	AP	has	also	doubled	in	the	UK	by	the	turn	of	the	21st	century	(McKay	et	
al.,	 1999;	 Goldacre	 &	 Roberts,	 2004).	 Increasing	 incidence	 of	 AP	 has	 also	 been	
reported	for	children	in	multiple	countries	with	a	64%	increase	by	the	year	2000	(Bai	
et	al.,	2011).	In	Ireland,	increasing	incidence	of	AP	has	largely	been	linked	to	alcohol	
abuse,	 particularly	 in	 the	 younger	 population	 (O’Farrell	 et	 al.,	 2007).	 This	 trend	
persists	worldwide	with	rises	in	per	capita	alcohol	consumption,	especially	amongst	
women	 (Williams	 et	 al.,	 2007).	 Despite	 a	 number	 of	 studies	 demonstrating	 that	
gender	can	be	an	independent	risk	factor	for	gastrointestinal	diseases	(Zarling	et	al.,	
1997),	 this	 does	 not	 appear	 to	 be	 the	 same	 for	 AP,	 even	with	 alcohol-induced	AP	
appearing	 to	occur	more	 frequently	 in	males	and	biliary	AP	 showing	prevalence	 in	
females	(Lankisch	et	al.,	2001).	There	are	simply	many	other	risk	factors,	such	as	age,	
which	 must	 be	 taken	 into	 account	 (Fagenholz	 et	 al.,	 2007).	 While	 increased	
awareness	 and	 improvements	 in	 diagnostic	 methods	 of	 AP	 may	 have	 somewhat	
contributed	 to	 the	 augmented	 incidence,	 there	 is	 no	 denying	 the	 enormity	 of	 this	
disease’s	 impact	 on	 hospital	 resources	 and	 the	 subsequent	 demand	 for	 effective	
treatment	 and	 patient	 management	 (Mofidi	 et	 al.,	 2007).	 The	 median	 length	 of	
hospital	 stay	 for	 patients	 of	 AP	 is	 7	 days	 (Fagenholz	 et	 al.,	 2007;	 O’Farrell	 et	 al.,	
2007),	 rising	 to	months	 in	 patients	with	 severe	 disease	who	will	 require	 intensive	
multidisciplinary	 and	 specialised	 care	 (Schepers	 et	 al.,	 2013).	 Consequently,	 the	
treatment	costs	associated	with	 these	patients	 is	 significantly	higher	 than	 those	of	
other	intensive	care	patients	(Neoptolemos	et	al.,	1998)	and	has	been	estimated	to	
be	 as	 high	 as	 US$	 2.6	 billion	 (Peery	 et	 al.,	 2012).	 To	 summarise	 this	 healthcare	
burden,	a	recent	U.S.	study	by	Peery	et	al.,	(2012)	found	AP	to	be	“the	leading	cause	
of	admission	 to	hospital	 for	gastrointestinal	disorders,	 the	second	highest	cause	of	
hospital	stays,	the	largest	contributor	to	aggregate	costs	and	the	fifth	leading	cause	
of	in-hospital	deaths”.		
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1.3	 Classification	and	staging	of	acute	pancreatitis	
	
1.3.1	 Physiological	disease	scoring	systems	
	
Diagnosis	 of	 AP	 is	 only	 a	 small	 step	 in	 the	 battle	 against	 a	 lethal	 disease	 that	 can	
manifest	as	a	myriad	of	complications.	The	greatest	challenge	facing	the	treatment	
and	management	of	AP	is	the	ability	to	predict	the	severity	of	disease	that	a	patient	
will	 develop.	 Numerous	 classifications	 and	 guidelines	 have	 evolved	 to	 aid	 the	
clinician’s	definition	and	prognosis	of	this	disease	 in	recent	decades.	This	approach	
has	directly	improved	patient	management	and	outcome	with	underlying	principles	
of	 simplified	 treatment	methods	and	avoidance	of	unnecessary	 surgery,	which	can	
often	 prove	 fatal	 (Uhl	 et	 al.,	 2002).	 Physiology-based	 scoring	 systems	 such	 as	 the	
Ranson	criteria,	Glasgow	Imrie	and	Acute	Physiology	and	Chronic	Health	Evaluation	
(APACHE)-II	have	previously	been	developed	and	validated	 for	use	with	patients	of	
AP	 (Ranson	 et	 al.,	 1974;	 Blamey	 et	 al.,	 1984;	 Larvin	 &	 McMahon,	 1989).	 These	
multifactorial	 criteria	 include	 measurements	 of	 various	 parameters	 such	 as	 age,	
blood	 glucose,	 urea	 and	 hematocrit	 levels	 and,	 patient	 heart	 and	 respiratory	 rate	
(see	 Table	 1.3.1).	 Organ-dysfunction	 criteria	 systems	 such	 as	 the	 Marshall	 score	
(Marshall	et	 al.,	 1995),	 sequential	 organ	 failure	 assessment	 (SOFA)	 (Vincent	 et	 al.,	
1996)	and	multiple	organ	dysfunction	score	(MODS)	(Marshall	et	al.,	1995)	have	also	
been	applied	to	patients	of	AP	due	to	the	disease	propensity	to	spread	systemically	
and	 attack	 other	 vital	 organs.	 However,	 these	 scoring	 systems	 are	 often	 complex,	
time-consuming	 in	 their	 application	 and	 can	 take	 several	 days	 before	 a	 clear	
conclusion	 can	 be	 made	 (Mofidi	 et	 al.,	 2007).	 Furthermore,	 they	 are	 intended	 to	
assess	the	current	severity	of	illness	and	likelihood	of	in-hospital	mortality.	They	do	
not	have	the	ability	to	predict	outcome	or	complications	in	patients	who	may	survive	
(Bouch	&	Thompson,	2008).		
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Table	1.3.1	Physiology-based	scoring	systems	for	acute	pancreatitis:	
	
Ranson	score	
Time	 Analysed	Criteria	(Units)	 Threshold	Level	 Total	Criteria	 Severity	Score	 Advantages	 Disadvantages	
At	admission	 Age	(years)	 >55		
11	
≥3	=	severe	AP							
0-2	=					2%	mortality		
3-4	=			15%	mortality	
5-6	=			40%	mortality	
7-8	=	100%	mortality	
Long	
established	
Complex,	time-
consuming	
WBC	count	(mL-1)	 >16,000	
Blood	glucose	(mg/dL)	 >200	
	 AST	(U/mL)	 	>250		
	 LDH	(U/mL)	 >350	
At	48h	 Hematocrit	(%)	 >10	↓		
	 BUN	(mg/dL)	 >5	↑		
	 Serum	Ca
2+	(mg/dL)	 <8	
	 PaO2	(mm/Hg)	 >60	
	 Base	deficit	(mEq/L)	 	>4	
	 Fluid	sequestration	(L)	 >6		
	 	 	 	 	 	 	Glasgow	Imrie	score	
Time	 Analysed	Criteria	(Units)	 Threshold	Level	 Total	Criteria	 Severity	Score	 Advantages	 Disadvantages	
At	admission	
and	48h	
WBC	count	(mL-1)	 >15,000	
8	 ≥3	=	severe	AP	
Reduced	
number	of	
criteria,	
simplified	
calculation	
48h	required	to	
complete	
Blood	glucose	(mg/dL)	 >180		
AST	(U/mL)	 >200			
LDH	(U/mL)	 >600	
BUN	(mg/dL)	 >45	
Serum	Ca2+	(mg/dL)	 <8			
Serum	albumin	(g/dL)	 <3.2		
PaO2	(mm/Hg)	 <60	
	 	 	 	 	 	 	APACHE-II	score	
Time	 Analysed	Criteria	 Threshold	Level	 Total	Criteria	 Severity	Score	 Advantages	 Disadvantages	
At	admission	
and	daily	up	
to	48h	
Temperature	 +	
14	 ≥8	=	severe	AP	
Validated	
for	
numerous	
diseases,	
can	be	
calculated	
daily	
Very	complex	
Mean	arterial	pressure	 +	
Heart	rate	 +	
Respiration	rate	 +	
PaO2	 +	
Arterial	pH		 +	
Serum	sodium	 +	
Serum	potassium	 +	
Serum	creatinine		 +	
Hematocrit	 +	
WBC	count	 +	
Glasgow	coma	scale	 +	
Age	 +	
Pre-existing	illnesses	 +	
	
	
		 		 		 		 		
	
WBC	=	white	blood	cell;	AST	=	aspartate	transaminase;	LDH	=	lactate	dehydrogenase;	BUN	=	blood	urea	
nitrogen;	 Ca	 =	 calcium,	 PaO2	 =	 blood	 gas/partial	 pressure	 of	 arterial	 oxygen;	 ↓	 =	 decrease	 by;	 ↑	 =	
increase	 by.	 Multiple	 point	 scores	 exist	 for	 each	 individual	 criteria	 of	 the	 APACHE-II	 score	 and	 are	
therefore	denoted	by	“+”	for	their	inclusion.	Adapted	from	Forsmark	&	Gardner	(2015).	
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1.3.2	 The	Atlanta	classification	
	
During	a	1992	symposium	of	international	clinical	experts,	the	Atlanta	classification	of	
AP	was	described	to	provide	a	consistent	and	universal	definition	of	disease	severity.	
This	 guideline	 was	 widely	 accepted	 and	 has	 subsequently	 been	 revised	 to	 reflect	
further	comprehensive	consultation	of	key	opinion	leaders.	UK	guidelines	have	aligned	
with	this	definition	(NHS	Trust,	2016).	It	is	now	understood	that	there	are	two	phases	
of	 the	 AP	 disease	 process	 (Figure	 1.3.2.1).	 In	 the	 early	 phase	 (lasting	 approximately	
one	 week),	 localised	 pancreatic	 inflammation	 can	 trigger	 a	 systemic	 inflammatory	
response	 syndrome	 (SIRS)	 through	 the	 mass	 release	 of	 cytokines.	 If	 this	 action	 is	
continuous	it	can	drive	organ	failure,	becoming	transient	(<48	hours)	or	persistent	(>48	
hours)	and	with	the	ability	to	affect	multiple	organs.	In	the	majority	of	cases,	the	initial	
inflammation	 remains	 localised	 to	 the	 pancreas	 and	 reasonably	 resolves.	 During	 the	
late	phase,	the	disease	progresses	with	the	development	of	local	complications	due	to	
peripancreatic	 fluid	 and	 necrotic	 tissue	 collections.	 The	 systemic	 inflammatory	
response	is	still	prevalent	with	organ	failure	remaining	transient	or	persistent	and	the	
body	 entering	 into	 a	 compensatory	 anti-inflammatory	 response	 syndrome	 (CARS)	 to	
offset	the	initial	inflammatory	events	(Banks	et	al.,	2012).	The	presence	of	CARS	leads	
to	deactivation	of	the	immune	system	in	an	attempt	to	restore	homeostasis.	However,	
this	 can	 facilitate	 infection	 of	 the	 pancreatic	 and	 peripancreatic	 tissue	 by	 bacteria	
trans-located	from	the	gut	and	is	thought	to	be	the	major	cause	of	late	morbidity	and	
mortality	in	acute	pancreatitis	(Phillip	et	al.,	2014).	The	co-existence	of	both	SIRS	and	
CARS	 can	 also	 develop	 and	 is	 referred	 to	 as	 a	mixed	 antagonist	 response	 syndrome	
(MARS),	which	can	be	associated	with	the	development	of	sepsis	in	the	case	of	SIRS,	or	
infection	in	the	case	of	CARS	while	the	body	struggles	to	balance	these	pro-	and	anti-
inflammatory	surges	(Ward	et	al.,	2008;	Novotny	et	al.,	2012).		
Taking	all	of	this	into	account,	the	revised	Atlanta	classification	defines	disease	
severity	based	on	the	persistence	of	organ	failure	and	the	presence	of	local	or	systemic	
complications.	 Three	 main	 categories	 of	 disease	 severity	 are	 defined	 for	 AP:	 mild,	
moderately	 severe	 and	 severe	AP.	Mild	AP	 is	 characterised	by	 the	 absence	of	 organ	
failure	 and	 local	 or	 systemic	 complications.	 Inflammation	 is	 usually	 localised	 to	 the	
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pancreas	and	very	low	rates	of	mortality	are	recorded.	Transient	organ	failure	and	the	
presence	 of	 local	 or	 systemic	 complications,	 with	 persistent	 inflammation	 and	 an	
increased	risk	of	mortality	are	observed	in	patients	with	moderately	severe	AP	(Banks	
et	al.,	2012).	However,	moderately	severe	AP	cannot	be	accurately	distinguished	from	
severe	pancreatitis	in	 the	 first	 48h	 until	 the	 extent	 of	 pancreatic	 necrosis	 is	 also	
determined	 (Kwong	et	 al.,	 2016).	 Persistent	 failure	 of	multiple	 organs	 from	an	 early	
stage	lasting	>48h	and	the	presence	of	one	or	more	local	complications	are	typical	of	
severe	AP.	 Extended	duration	of	 organ	 failure	 lasting	 three	or	more	days	 is	 strongly	
associated	with	the	risk	of	death	or	development	of	 local	complications	whereas	the	
resolution	of	organ	failure	within	48h	suggests	a	lower	(25%)	risk	of	local	complications	
and	death	 (Johnson	et	al.,	2004).	This	 is	where	 the	associations	between	severe	and	
moderately	severe	AP	can	be	made	with	the	modified	Marshall	scoring	system	defining	
organ	 failure	 (Banks	et	al.,	2012). Any	arising local	 complications	must	be	monitored	
closely	 in	 the	preceding	weeks	as	 the	development	of	 acute	necrotic	 collections	 can	
impact	long-term	patient	survival	and	be	a	significant	risk	factor	for	death	(Umapathy	
et	 al.,	 2016).	 Collections	 of	 necrotic	 tissue	 enclosed	 inside	 an	 inflammatory	 wall	
(walled-off	 necrosis)	 can	 form,	 remaining	 sterile	 and	 thus	manageable	or	 potentially	
becoming	 infected	 and	 life-threatening,	 requiring	 further	 specialised	 care.	 Through	
these	 definitions,	 the	 Atlanta	 classification	 condenses	 the	 significant	 stages	 and	
complications	of	AP. While	alternative	classification	systems	such	as	the	determinant-
based	classification	where	an	additional	(critically	severe)	category	have	subsequently	
also	been	suggested,	no	significant	improvement	over	the	revised	Atlanta	classification	
have	emerged	to	date	(Acevedo-Piedra	et	al.,	2014).	
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Figure	 1.3.2.1	 The	 progression	 of	mild	 and	 severe	 acute	 pancreatitis	 (adapted	 from	
Phillip	et	al.,	2014).	The	disease	phases	and	various	host	 inflammatory	responses	are	
also	displayed.	
	
1.4	 Management	of	acute	pancreatitis	
	
1.4.1	 Diagnosis	and	detection	
	
At	present,	diagnosis	of	AP	is	usually	made	upon	admission	to	hospital	and	based	on	
physical	 examination	 of	 symptoms	 determined	 at	 presentation	 such	 as	 acute	
abdominal	pain,	radiating	to	the	back	 in	some	cases	(Meher	et	al.,	2015).	Abdominal	
pain	 could	 also	 be	 due	 to	 a	 diverse	 number	 of	 other	 conditions	 such	 as	 gastritis,	
appendicitis	and	peptic	ulcer.	The	measurement	of	pancreatic	enzymes	such	as	serum	
amylase	 or	 lipase	 is	 therefore	 also	 recorded,	 with	 an	 elevation	 to	 three	 times	 the	
upper	 limit	 of	 normal	 signifying	 a	 diagnosis	 of	 AP	 (Neoptolemos	et	 al.,	 2001).	 If	 the	
levels	of	these	enzymes	are	below	the	threshold	value	and	diagnosis	is	still	uncertain,	
abdominal	imaging	can	be	preformed	using	contrast-enhanced	computed	tomography	
(CECT),	abdominal	ultrasonography	or	magnetic	resonance	imaging	(MRI)	(Arvanitakis	
et	al.,	2007).	However,	these	scans	are	not	without	their	disadvantages	with	expense,	
exposure	 to	 ionizing	 radiation	 and	 risk	 of	 nephrotoxicity	 from	 iodinated	 contrast	
medium	 (Arvanitakis	 et	 al.,	 2007)	 listed	 as	 concerns	 (Frossard,	 2001).	 Furthermore,	
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with	 a	 lack	 of	 sensitivity	 and	 specificity	 in	 the	 early	 stage	 of	 disease	 (<48h)	 and	 a	
significant	number	of	 self-resolving	mild	cases	 that	do	not	 require	 routine	scans,	 the	
prognostic	 value	of	utilising	 such	costly	equipment	needs	 to	be	evaluated.	However,	
the	value	of	 imaging	techniques	to	the	assessment	of	severe	AP	must	be	recognised.	
Indeed,	 CECT	 performed	 48-72h	 after	 the	 onset	 of	 symptoms	 is	 the	 gold	 standard	
(Arvanitakis	et	al.,	2007)	for	detection	of	necrotizing	pancreatitis,	with	sensitivity	close	
to	100%	(Wilmer,	2004).	Severity	 indexes	have	been	compiled	for	characterisation	of	
morphological	 changes	 to	 the	 pancreas	 that	 can	 correlate	 to	 patient	 outcome	
(Balthazar,	2002;	Mortele	et	al.,	2004).	However,	the	consensus	that	CECT	should	not	
be	 performed	 any	 earlier	 than	 48-72h	 after	 the	 onset	 of	 symptoms	means	 that	 this	
tool	 is	 better	 equipped	 for	 severity	 detection	 rather	 than	 prediction	 (Schütte	 &	
Malfertheiner,	 2008).	 MRI,	 or	 more	 specifically,	 magnetic	 resonance	 cholangio-
pancreatography	can	provide	detailed	assessment	of	the	biliary	system	and	has	been	
shown	to	be	a	comparable	to	CECT	in	diagnosis	and	staging	of	AP,	but	is	not	applicable	
to	 patients	 with	 metallic	 implants	 such	 as	 pacemakers	 or	 patients	 connected	 to	
supportive	systems	(Lippi	et	al.,	2012).	 It	 is	also	more	expensive	and	time-consuming	
than	 CECT	 (Schütte	 &	 Malfertheiner,	 2008).	 While	 the	 utility	 of	 abdominal	
ultrasonography	 for	diagnosis	and	severity	assessment	of	AP	 is	questioned,	 this	 low-
cost	technique	is	widely	available	and	considered	as	the	gold	standard	for	detection	of	
gallstones	(Lippi	et	al.,	2012).	Despite	the	relative	proficiency	of	these	approaches	for	
the	 assessment	 and	 prediction	 of	 disease	 severity,	 the	 search	 for	 a	 single	 analytical	
method	or	biomarker	capable	of	earlier	prediction	of	 severity	has	 remained	of	great	
interest.		
1.4.2	 Treatment	regimen	
	
Establishment	of	early	aggressive	treatment	is	essential	to	decreasing	the	likelihood	of	
developing	severe	AP	and	also	minimising	potential	complications.	In	general,	patients	
with	predicted	mild	AP	should	have	basic	vital	signs	monitored	and	intravenous	fluids	
administered. Nasogastric	 drainage	 is	 only	 necessary	 for	 patients	 with	 persistent	
vomiting	 (Grace	 et	 al.,	 2003).	 These	 patients	 can	 resume	 oral	 feeding	 as	 soon	 as	
possible,	with	this	shown	to	be	safe	and	leading	to	shorter	hospital	stays	(Schepers	et	
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al.,	 2013). Suspected	 cases	 of	 gallstones	 or	 biliary	 obstruction	 should	 undergo	
endoscopic	 retrograde	 cholangio-pancreatography	 (ERCP)	 prior	 to	 hospital	 discharge	
(Mayor,	2016).	Patients	with	predicted	severe	AP	should	be	admitted	to	the	intensive	
care	unit	(ICU)	where	central	venous	fluids	are	administered.	Hourly	monitoring	of	vital	
signs	 is	 required	 with	 close	 assessment	 of	 temperature,	 central	 venous	 pressure,	
arterial	 blood	 gases	 and	 respiratory	 rate.	 A	 urinary	 catheter	 should	 be	 used	 for	
monitoring	 urine	 output	 in	 case	 of	 kidney	 failure.	 Once	 again,	 nasogastric	 drainage	
may	be	necessary	with	persistent	 vomiting	 (Grace	et	 al.,	 2003;	 Sargent,	 2006).	 Early	
fluid	resuscitation	or	hydration	for	the	prevention	of	hypo-perfusion	and	organ	failure	
has	been	demonstrated	to	reduce	complications	and	mortality	(Wall	et	al.,	2011),	with	
an	infusion	rate	of	5-10	mL/kg/h	deemed	appropriate	(Schepers	et	al.,	2013.	The	use	
of	 broad-spectrum	 prophylactic	 antibiotics	 is	 recommended	 for	 the	 prevention	 of	
bacterial	 translocation	 from	 the	 gut,	 which	 has	 been	 linked	 with	 the	 infection	 of	
pancreatic	 necrosis.	 Pain	 management	 is	 prioritised	 through	 the	 administration	 of	
morphine	(Sargent,	2006)	with	paracetamol	and	non-steroidal	anti-inflammatory	drugs	
often	 proving	 insufficient	 (Wilmer,	 2004).	 Early	 enteral	 nutrition,	 preferably	 via	 oral	
intake,	 is	 favoured	 to	 maintain	 gut	 function	 and	 to	 limit	 gut	 permeability,	 thus	
potentially	 reducing	 the	 opportunity	 for	 bacterial	 translocation	 and	 infection.	
Probiotics	 are	 not	 recommended	 for	 patients	 with	 AP	 due	 to	 possibility	 of	 bowel	
ischemia	 and	 potential	 increased	 risk	 of	 death	 (Besselink	 et	 al.,	 2008).	 The	
recommended	 nutritional	 requirements	 for	 severe	 AP	 include	 protein	 at	 1.2	 –	 1.5	
g/kg/day,	 carbohydrates	 at	 3-6	 g/kg/day	 and	 lipids	 at	 2	 g/kg/day,	 along	 with	 strict	
blood	glucose	control	through	administration	of	 insulin	(Kingsnorth	&	O’Reilly,	2006).	
Previous	preferences	for	surgical	intervention	of	AP	have	been	replaced	and	it	is	now	
generally	 only	 applied	 in	 the	 presence	 of	 infected	 necrosis.	 Deferral	 is	 maintained	
while	 patients	 respond	 to	more	 conservative	 treatment	methods	 (Uhl	 et	 al.,	 2002).	
While	strides	have	been	made	with	pancreatic	transplantation,	this	intervention	is	not	
favoured	(Demartinesa	et	al.,	2005).	
	 	 	16	
1.5	 Biomarkers	of	acute	pancreatitis	
	
Several	definitions	have	been	proposed	in	relation	to	the	term	“biomarker”.	The	most	
applicable	 interpretation	with	 respect	 to	 AP	 is	 “any	 substance,	 structure	 or	 process	
that	 can	 be	 measured	 in	 the	 body	 or	 its	 products	 and	 influence	 or	 predict	 the	
incidence	of	outcome	or	disease”	 (Strimbu	&	Tavel,	 2010).	 The	 two	main	 challenges	
facing	 prospective	 biomarkers	 of	 AP	 is	 the	 length	 of	 time	 between	 the	 onset	 of	 a	
patient’s	 symptoms	 and	 admission	 to	 hospital,	 and	 the	 small	 window	 period	
(approximately	 48h	 following	 the	 onset	 of	 symptoms)	 in	 which	 differentiation	 of	
disease	severity	can	be	made.	Consequently,	the	idea	of	a	single	biomarker	capable	of	
diagnosis	 of	 AP	 and	 early	 prediction	 of	 severity	 is	 appealing.	 Many	 diagnostic	 and	
prognostic	biomarkers	of	AP	have	been	reported,	from	inflammatory	markers	such	as	
CRP	and	IL-6,	to	digestive	enzymes	such	as	amylase,	lipase	and	trypsinogen-2,	and	the	
by-product	 of	 trypsinogen	 activation	 -	 trypsinogen	 activation	 peptide	 (TAP).	 All	 of	
these	biomarkers	 have	 enjoyed	 some	 recognition;	with	 amylase	 and	 lipase	 routinely	
employed	internationally	 in	a	diagnostic	capacity	(Hofmeyr	et	al.,	2014),	and	CRP	the	
most	 frequently	 used	 predictor	 of	 severity	 (Staubli	 et	 al.,	 2015).	 Despite	 this,	 novel	
biomarkers	of	AP	continue	 to	be	 reported	 in	 the	 literature	with	 specific	 focus	areas,	
namely	 prediction	 of	 severity	 (cytokeratin	 18,	 copeptin,	 neutrophil	 gelatinase-
associated	 lipocalin	 (NGAL)-1);	 prediction	 of	 pancreatic	 necrosis	 (adipocytokines,	
matrix	 metalloproteinase	 (MM)-9,	 fibrogen-like	 protein	 (fgl)-2);	 and	 prediction	 of	
persistent	organ	failure	 (angiopoietin	2,	D-dimer,	soluble	CD73)	 (Meher	et	al.,	2015).	
However,	the	performance	of	these	biomarkers	has	yet	to	be	fully	evaluated	in	 large	
clinical	studies.	While	there	is	obviously	an	underlying	dissatisfaction	driving	continued	
exploration	for	novel	biomarkers	of	AP,	the	recent	reclassification	of	the	disease	and	
the	 advent	 of	 point-of-care	 (POC)	 technology	 provide	 ample	 scope	 to	 revisit	 and	
reassess	some	of	the	more	promising	biomarkers,	such	as	TAP.	
	 	 	17	
1.5.1	 Amylase	and	lipase	
	
The	pancreas	is	one	of	two	major	sources	of	amylase	in	humans,	the	salivary	glands	being	
the	 other.	 Pancreatic	 amylase	 degrades	 starch	 into	 smaller	 carbohydrate	 molecules	 as	
part	of	normal	digestion.	Amylase	has	also	been	found	in	other	body	tissues	such	as	the	
lung,	 ovary	 and	 testis	 (Vissers	 et	 al.,	 1999).	 Consequently,	 amylase	 is	 not	 pancreas-
specific.	Serum	amylase	levels	also	quickly	revert	to	normal.	Furthermore,	normal	amylase	
levels	have	 frequently	been	reported	 in	patients	with	AP	 (Vissers	et	al.,	1999)	and	most	
importantly	in	patients	with	severe	AP	(Lankisch	et	al.,	1999).	Amylase	is	also	ineffective	
with	measurement	of	alcohol-induced	pancreatitis	 (Hofmeyr	et	al.,	2014).	Despite	 these	
facts,	amylase	is	still	the	most	commonly	measured	biomarker	of	AP	and	a	cut-off	of	three	
times	the	upper	 limit	of	normal	 (>3	ULN)	 is	generally	recommended	for	the	diagnosis	of	
AP	by	amylase	(Hofmeyr	et	al.,	2014).		
	
Lipase	is	synthesised	by	pancreatic	acinar	cells	and	is	involved	in	digestion	of	fats.	Elevated	
levels	of	lipase	can	be	observed	from	4-8h	after	the	onset	of	AP,	with	a	subsequent	peak	
at	24h	and	a	return	to	normal	 levels	over	a	period	of	up	to	14	days	(Yadav	et	al.,	2002).	
Therefore,	lipase	is	beneficial	for	diagnosis	of	AP	in	late	patient	presentation	(Hofmeyr	et	
al.,	 2014).	 Initial	 laboratory	methods	 for	 lipase	measurement	were	 labour-intensive	and	
cumbersome	 due	 to	 insolubility	 issues	 in	 aqueous	 solutions	 (Vissers	 et	 al.,	 1999).	
Consequently,	adoption	of	this	biomarker	for	clinical	application	was	slow	until	the	arrival	
of	 more	 reproducible	 assay	 methods,	 as	 with	 the	 Roche	 COBAS	 INTEGRA	 (Moridani	 &	
Bromberg,	2003)	or	Siemens	Advia	1800	system	(Hofmeyr	et	al.,	2014).	Since	then,	lipase	
was	shown	to	be	a	superior	to	amylase	for	diagnosis	of	AP,	particularly	in	alcohol-induced	
pancreatitis	 (Hofmeyr	 et	 al.,	 2014).	 However,	 lipase	 can	 also	 be	 elevated	 in	 other	
conditions	 such	 as	 peptic	 ulcer,	 intestinal	 obstruction,	 liver	 disease,	 kidney	 failure,	
inflammatory	bowel	disease,	acute	cholecystitis	and	mumps (Yadav	et	al.,	2002;	Hofmeyr	
et	al.,	2014).	A	‘cut-off’	of	(>3	ULN)	is	also	recommended	for	the	diagnosis	of	AP	by	lipase	
(Hofmeyr	et	al.,	2014).	However,	while	normal	 lipase	values	are	rare	 in	patients	with	AP	
(Lippi	et	al.,	2012),	similar	 lipase	 increases	 (>3	ULN)	have	also	been	reported	 in	patients	
with	kidney	 failure	 (Vissers	et	al.,	1999)	and	there	 is	no	ability	 to	predict	severity	of	AP.	
Lipase	and	amylase	are	clearly	biomarkers	for	diagnostic	purposes	only.	
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1.5.2	 C-reactive	protein	
	
An	acute	phase	protein	that	 is	produced	by	the	 liver	 in	response	to	cytokine	stimulation	
(Jain	et	al.,	2011),	CRP	has	gained	popularity	as	the	biomarker	of	choice	for	the	prediction	
of	 AP	 severity	 (Staubli	 et	 al.,	 2015).	 It	 has	 been	 demonstrated	 to	 predict	 pancreatic	
necrosis	 (Schütte	 &	Malfertheiner,	 2008).	 However,	 it	 cannot	 predict	 infected	 necrosis	
(Staubli	 et	 al.,	 2015).	 A	 ‘cut-off’	 value	 of	 150	 mg/L	 by	 48h	 after	 hospital	 admission	 is	
generally	applied	for	the	prediction	of	severe	AP.	However,	CRP	can	take	at	least	48-72h	
before	 a	 clear	 level	 peak	 can	 be	 distinguished	 (Staubli	 et	 al.,	 2015).	 It	 was	 also	
demonstrated	to	be	superior	to	other	potential	inflammatory	biomarkers	such	as	IL-8,	and	
TNF-α	 (Yadav	 et	 al.,	 2002).	 Numerous	 cytokines	 have	 been	 studied	 with	 respect	 to	
prediction	 of	 severity	 in	 AP.	 However,	 most	 of	 them	 have	 proven	 to	 be	 of	
pathophysiological	 interest	rather	than	of	clinical	utility.	While	some	studies	of	IL-6	have	
shown equivalent	ability	to	stratify	severity	of	AP	(Yadav	et	al.,	2002),	a	simple,	cheap	and	
widely	available	method	of	determination	does	not	currently	exist	(Meher	et	al.,	2015).	It	
is	important	to	note	that	CRP	is	not	‘disease-specific’	but	is	instead	a	general	inflammatory	
biomarker.	 For	 instance,	 other	 inflammatory	 conditions	 such	 as	 cholangitis	 and	
pneumonia	must	be	eliminated	when	using	CRP	for	diagnosis	of	AP.	Tellingly;	CRP	 is	not	
included	in	any	of	the	current	guidelines	for	the	management	of	AP	(Meher	et	al.,	2015). 
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1.5.3	 Trypsinogen-2	
	
The	inactive	zymogen	trypsinogen	is	stored	in	the	pancreatic	acinar	cells	prior	to	release	
and	 activation	 by	 enterokinase	 in	 the	 small	 intestine,	 as	 discussed	 previously	 in	 section	
(1.1).	In	addition	to	inappropriate	zymogen	cleavage	and	activation	within	the	acinar	cells	
during	 the	 early	 stages	 of	 AP,	 it	 was	 demonstrated	 that	 a	 large	 amount	 of	 uncleaved	
trypsinogen	leaves	the	acinar	cell	and	moves	from	the	interstitium	through	the	lymphatic	
and	portal	circulation.	Activation	of	this	extracellular	trypsinogen	can	cause	necrosis,	even	
in	mild	AP,	is	believed	to	be	lead	to	the	progression	from	mild	to	severe	AP,	and	possibly	
contributes	 to	 extra-pancreatic	 injury	 such	 as	 in	 the	 lungs	 (Hartwig	 et	 al.,	 1999).	
Trypsinogen	exists	 in	 two	major	 isoforms,	namely	 trypsinogen-1	and	 -2.	Both	have	been	
found	 at	 increased	 levels	 in	 the	 blood	 and	 urine	 of	 patients	 with	 AP,	 however,	
trypsinogen-2	may	 auto-activate	 faster	 than	 trypsinogen-1	 due	 to	 Ca2+	 and	 pH	 changes	
during	 AP	 (Paju	 &	 Stenman,	 2006)	 and	 thus	 50-	 versus	 15-fold	 increases	 in	 serum	
concentration	 have	 been	 observed	 (Kylänpää	 et	 al.,	 2002).	 Urinary	 tyrpsinogen-2	
concentration	is	also	elevated	at	the	onset	of	AP,	with	trypsinogen-1	either	reabsorbed	by	
the	kidneys	or	degraded	prior	to	excretion	in	urine.	Like	any	urinary	biomarker,	its	levels	
can	be	affected	by	dehydration	or	 reduction	 in	kidney	 function	 (Hedström	et	al.,	 1996).	
Urinary	 trypsinogen-2	 levels	 are	more	 increased	 in	 alcohol-induced	 pancreatitis	 than	 in	
gallstone-related	disease	(Lempinen	et	al.,	2003).	
A	 commercially	 available	 (Medix	 Biochemica,	 Finland)	 dipstick	 test	 for	 the	 rapid	
determination	 of	 urinary	 trypsinogen-2	 has	 been	 studied	 in	 great	 detail.	 This	 dipstick	 is	
immersed	 into	 the	 urine	 sample	 where	 blue	 latex	 particles	 labeled	 with	 monoclonal	
antibody	bind	to	trypsinogen-2	present	in	the	sample	and	migrate	across	a	nitrocellulose	
membrane	to	a	region	containing	another	antibody	specific	for	a	separate	distinct	epitope	
of	 trypsinogen-2.	 A	 trypsinogen-2	 concentration	 greater	 than	 50	 μg/L	 results	 in	 the	
development	of	a	blue	line	at	this	region,	and	the	result	is	considered	positive	if	this	clear	
blue	line	is	observed	within	5	minutes	(Abraham,	2011).	Antibodies	and	this	test	approach	
are	discussed	further	in	sections	1.6	and	1.8.	Measurement	of	trypsinogen-2	was	shown	to	
compare	 favourably	 with	 serum	 amylase	 and	 lipase	 for	 the	 diagnosis	 of	 AP,	 albeit	 at	
conflicting	 time	measurement	 intervals	 (Jang	et	 al.,	 2007).	 Still,	 there	 are	 other	 studies	
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showing	that	its	diagnostic	ability	is	secondary	to	lipase	(Jin	et	al.,	2013).	Moreover,	while	
trypsinogen-2	is	useful	for	the	diagnosis	of	ERCP-induced	pancreatitis	(Meher	et	al.,	2015),	
lipase	 is	 still	 superior	 (El-Garem	et	al.,	 2013).	With	 trypsinogen-2	 levels	peaking	by	24h,	
diagnostic	ability	of	 this	biomarker	declines	rapidly	and	 is	 therefore	 less	accurate	 in	 late	
hospital	admissions	 (Çevik	et	al.,	2010).	All	of	 this	 is	 indicative	 that	 trypsinogen-2	would	
require	 the	 support	 of	 additional	 tests	 for	 the	 successful	 diagnosis	 of	 AP.	 Conflicting	
results	exist	on	the	assessment	of	trypsinogen-2	as	a	biomarker	for	prediction	of	disease	
severity,	with	 superior	 results	 observed	 at	 24h	 after	 hospital	 admission	 compared	with	
CRP	(Lempinen	et	al.,	2003)	but	not	in	the	case	of	work	reported	by	Kamer	et	al.	(2007).	
Accordingly,	 interest	 in	 this	 function	 has	 diminished.	 The	 short	 test	 time,	 low	 cost	 and	
ease-of-use	provided	by	 this	dipstick	 technology	 still	means	 that	 trypsinogen-2	could	be	
used	 to	eliminate	a	diagnosis	of	AP,	with	an	emphasis	on	differentiation	between	acute	
abdominal	 diseases	 of	 pancreatic	 and	 extra-pancreatic	 origin	 (Çevik	 et	 al.,	 2010).	
Furthermore,	these	virtues	highlight	the	applicability	of	such	a	technology	in	this	sphere.	
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1.5.4	 Trypsinogen	activation	peptide 	
The	cleavage	of	 trypsinogen	by	enterokinase	 results	 in	 the	activation	of	 trypsin	and	 the	
release	of	the	carboxy	(C)-terminal	peptide	known	as	trypsinogen	activation	peptide	(TAP)	
in	 the	 small	 intestine	 (Mayer	 et	 al.,	 1999).	 As	 this	 activation	 peptide	 is	 proportionally	
produced	 to	 trypsinogen	 activation	 (Lempinen	 et	 al.,	 2003)	 and	 is	 highly	 conserved	 in	
vertebrates	(Hurley	et	al.,	1988),	antibodies	directed	against	TAP	have	been	widely	used	in	
experimental	model	studies	relating	to	trypsinogen	activation	(Frick	et	al.,	1997;	Grady	et	
al.,	1998;	Matsukura	et	al.,	2006).	During	normal	digestion	(see	Figure	1.1.1),	the	release	
of	 TAP	 should	 be	 difficult	 to	 detect	 as	 the	 peptide	 is	 likely	 degraded	 by	 intestinal	
oligopeptidases,	 however,	 during	 the	 onset	 of	 AP,	 the	 intra-pancreatic	 activation	 of	
trypsinogen	results	 in	the	rapid	release	of	TAP	 into	the	peritoneal	 fluid,	blood	and	urine	
(Tenner	 et	 al.,	 1997).	 Characterisation	 of	 TAP	 has	 shown	 that	 this	 peptide	 is	 largely	
detected	 as	 a	 penta-peptide	 molecule	 with	 a	 tetra-L-aspartyl-L-lysine	 structure.	 The	
existence	 and	 detection	 of	 both	 smaller	 (Hurley	 et	 al.,	 1988)	 and	 larger	 (Petersson	 &	
Borgström,	2006)	activation	peptide	molecules	has	also	been	shown,	but	it	is	believed	that	
the	 penta-peptide	 is	 the	 more	 stable	 molecule	 due	 to	 rapid	 degradation	 of	 larger	
molecules	 in	pancreatic	 juice	and	 in	blood.	The	serum	concentrations	of	TAP	have	been	
shown	to	decrease	after	6-24h	(Petersson	&	Borgström,	2006)	and	plasma	concentrations	
can	 show	no	 significant	 difference	 between	 normal	 and	 diseased	 patients	 (Vogel	et	 al.,	
1997).	 Contrastingly,	 urinary	 concentrations	 of	 TAP	 are	 observed	 at	 elevated	
concentrations	up	to	48h	after	the	onset	of	AP/admission.	Higher	urinary	concentrations	
of	 TAP	have	been	 found	 in	patients	with	 alcohol-induced	pancreatitis	 than	 in	 gallstone-
related	disease	(Lempinen	et	al.,	2003).	However,	no	particular	etiology	is	associated	with	
this	biomarker	(Huang	et	al.,	2013).	Consequently,	the	penta-peptide	is	detected	in	large	
amounts	 in	urine	(Petersson	&	Borgström,	2006).	Antibodies	directed	against	TAP	are	C-
terminal	binding	and	do	not	bind	trypsinogen	(Hurley	et	al.,	1988).	Trypsinogen	activation	
peptide	has	been	 shown	 to	bind	 calcium	 in	 some	 instances,	 leading	 to	 the	discovery	of	
calcium-dependent	and	independent	antibodies	that	may	bind	two	individual	epitopes.	It	
is	 also	 suggested	 that	 calcium	 may	 directly	 bind	 to	 anti-TAP	 antibodies,	 leading	 to	 a	
conformation	 change	 and	 enhancing	 the	 binding	 affinity	 for	 TAP	 (Hurley	 et	 al.,	 1988).	
Antibodies	are	discussed	further	in	section	1.6.	
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Numerous	studies	have	detailed	the	ability	of	TAP	as	a	biomarker	for	the	early	prediction	
of	disease	severity	in	AP.	In	addition,	significantly	elevated	urinary	TAP	levels	for	patients	
with	severe	AP	when	compared	to	those	with	mild	AP	have	been	demonstrated	from	early	
onset	of	AP,	clearly	demonstrating	the	stratification	potential	of	this	biomarker	(Huang	et	
al.,	2013).	Studies	have	shown	that	TAP	is	superior	to	CRP	for	the	prediction	of	severe	AP	
when	 the	 measurement	 is	 performed	 within	 48h	 after	 the	 onset	 of	 symptoms	 of	 AP	
(Tenner	 et	 al.,	 1997;	 Neoptolemos	 et	 al.,	 2001;	 Liu	 et	 al.,	 2002).	 Additionally,	 the	
superiority	of	TAP	to	scoring	systems	such	as	APACHE-II	(Neoptolemos	et	al.,	2001;	Liu	et	
al.,	2002),	Ranson	(Khan	et	al.,	2002)	and	Glasgow-Imrie	(Gudgeon	et	al.,	1990)	has	also	
been	 proven.	 The	 particularly	 high	 negative	 predictive	 value	 of	 TAP,	 i.e.	 the	 ability	 to	
distinguish	those	patients	who	do	not	have	severe	AP,	allows	for	the	exclusion	of	patients	
from	admission	to	the	ICU,	requirement	of	CECT	analysis	and	specialist	care	resulting	in	a	
reduction	of	patient	management	costs	(Al-Bahrani	&	Ammori,	2005).	The	outcomes	from	
these	studies	 initially	 lead	to	some	making	the	claim	that	TAP	should	be	used	 in	routine	
clinical	practice	(Neoptolemos	et	al.,	2001).	However,	there	is	an	obvious	disadvantage	in	
that	 TAP	 levels	 decrease	 after	 two	 days	 and	 thus	 cannot	 be	 used	 for	 late	 hospital	
admissions	(Gudgeon	et	al.,	1990).	Despite	the	positive	perception	of	TAP	as	a	biomarker,	
it	has	all	but	disappeared	from	the	literature	in	the	last	decade.	This	has	largely	been	due	
to	 reproducibility	 issues	experienced	with	 the	polyclonal	 antibody	 technology	employed	
by	the	enzyme-linked	 immunosorbent	assay	(ELISA)	produced	by	EKF	Diagnostics.	ELISAs	
are	further	discussed	in	chapter	3.	Even	so,	TAP	has	also	been	shown	to	surpass	one	of	the	
more	promising	biomarkers	of	 recent	years,	namely	 trypsinogen-2,	 for	 the	prediction	of	
severe	 AP	 (Lempinen	 et	 al.,	 2003).	 Despite	 the	 shortcomings	 of	 trypsinogen-2	 as	 a	
prognostic	biomarker,	great	 interest	was	shown	due	to	 its	application	as	a	point-of-care	
(POC)	device	in	a	rapid	dipstick	test	format.	The	recent	evolution	of	POC	testing	methods	
has	the	potential	to	translate	into	improvements	for	clinical	assessment	by	re-evaluating	
biomarkers	that	were	studied	previously	(Staubli	et	al.,	2015).	Therefore,	overcoming	the	
antibody	 reproducibility	 issues	 for	 the	 TAP	 ELISA	 through	 the	 use	 of	 a	 monoclonal	
antibody,	 and	 investigating	 the	 application	 of	 the	 TAP	 biomarker	 in	 a	 rapid	 test	 format	
could	potentially	renew	the	interest	in	this	once	promising	biomarker.	Moreover,	with	the	
inclusion	 of	 an	 additional	 moderately	 severe	 category	 in	 the	 revised	 Atlanta	
reclassification	 (Banks	et	al.,	 2012)	and	 the	ability	of	TAP	 to	 clearly	distinguish	between	
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mild	 and	 severe	 patients,	 there	 is	 also	 scope	 to	 evaluate	 the	 potential	 of	 the	 TAP	
biomarker	to	stratify	patients	across	these	three	categories.			
1.6	 Antibodies	–	polyclonal	versus	monoclonal			
Antibodies	or	immunoglobulins	(Ig)	are	soluble	glycoproteins	produced	by	B-lymphocyte	–
derived	 plasma	 cells	 in	 response	 to	 foreign/toxic	 organisms	 and/or	 products	 during	 the	
adaptive	 immune	 response	 of	 a	 host.	 Antibodies	 have	 two	 functions	 –	 binding	 and	
deactivation	of	a	target	antigen	such	as	a	bacterial	toxin	or	viral	receptor,	or	binding	and	
activation	 of	 immune	 signalling.	 This	 basic	 but	 powerful	 utility	 has	 resulted	 in	 their	
widespread	 application	 as	 diagnostic	 reagents.	 Antibodies	 are	 composed	 of	 four	
polypeptides	consisting	of	two	identical	heavy	chains	(with	a	molecular	weight	of	~50	kDa)	
and	two	identical	light	chains	(~25	kDa)	that	are	held	together	by	disuphide	bonds.	Both	of	
these	chains	contain	constant	(C)	and	variable	(V)	regions.	The	fragment	antigen-binding	
(Fab)	 region	of	 the	antibody	 is	composed	of	 two	 identical	 fragments	with	 the	VH	and	VL	
regions.	The	fragment	crystallisable	(Fc)	region	is	composed	of	the	constant	heavy	regions	
(CH1,	CH2	and	CH3),	which	are	important	in	immune	signaling	and	effector	functions.	There	
are	five	different	classes	of	Ig	found	in	mammals	(IgA,	IgD,	IgE,	IgG	and	IgM),	with	IgG	and	
IgA	also	being	 further	 subdivided	 into	different	 isotypes.	 IgG	 is	 the	most	abundant	class	
found	 in	 serum	 and	 the	 most	 widely	 used	 in	 diagnostic	 applications.	 Its	 structure	 is	
outlined	in	Figure	1.6.1.	The	diversity	of	presenting	antigens	can	lead	to	the	generation	of	
distinctive	 antibodies.	 Polyclonal	 antibodies	 (pAb)	 are	 derived	 from	 a	 collection	 of	
different	 plasma	 cells	 whereas	 monoclonal	 antibodies	 are	 derived	 from	 a	 single	 clone.	
PAbs	recognise	and	bind	to	multiple	epitopes	of	a	target	antigen,	ensuring	greater	binding	
of	the	antigen	on	a	larger	scale,	but	with	a	lower	affinity	and	specificity.	PAbs	can	also	be	
generated	 rapidly	 at	 lower	 costs.	Monoclonal	 antibodies	 (mAb)	 recognize	 and	bind	 to	 a	
single	 individual	 epitope	of	 a	 target	 antigen,	 resulting	 in	 a	 highly	 specific	 interaction.	 In	
addition,	 the	use	of	hybridoma	technology	provides	homogenous	and	reproducible	mAb	
performance.	However,	structural	changes	such	as	antigen	denaturation	can	prevent	mAb	
binding	(Lipman	et	al.,	2005).	Antibodies	have	played	a	crucial	and	successful	role	in	many	
research	 applications	 such	 as	 purification	 and	 enrichment	 of	 antigens	 and	 ELISAs,	 and	
continue	to	play	an	essential	role	in	the	growing	POC	industry	for	medical	diagnostics.	
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Figure	1.6.1	Basic	structure	of	an	 IgG	molecule,	showing	the	heavy	chain	consisting	of	a	
variable	 (VH)	 region	 linked	 to	 tree	 constant	 regions	 (CH1,	 CH2	 and	 CH3).	 The	 light	 chain	
consists	of	a	single	variable	(VL)	and	constant	region	(CL).		
	
1.7	 Point-of-Care	tests		
The	 growing	 trend	 of	 POC	 diagnostics	 in	 the	 developed	 world	 has	 emerged	 from	 the	
increasing	 pressure	 to	 limit	 healthcare	 budgets	 and	 the	 realisation	 that	 the	 current	
healthcare	model	 is	 neither	 sustainable	 nor	 fit-for-purpose.	With	 the	 increasing	 burden	
placed	 on	 hospital	 resources	 due	 to	 budgetary	 constraints	 and	 increasing	 incidence	 of	
illnesses	such	as	cardiac	diseases,	patient	care	has	become	less	patient-focused	and	more	
fragmented	with	the	need	for	follow-up	visits	or	consultations	required	after	assessment	
or	hospital	discharge.	This	challenge	can	be	met	head-on	through	the	use	of	POC	devices	
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that	 will	 offer	 the	 opportunity	 to	 decentralise	 patient	 care	 to	 a	 community	 level.	 POC	
devices	can	and	are	playing	a	front-line	role	in	hospitals	worldwide	(St	John	&	Price,	2014).	
Biomarker	POC	tests,	such	as	the	use	of	cardiac	troponin	I	(cTnI)	for	the	analysis	of	acute	
coronary	syndrome,	have	been	demonstrated	to	reduce	the	length	of	stay	in	the	hospital	
Emergency	Department	 (ED)	when	compared	 to	central	 laboratory	 testing	 (Singer	et	al.,	
2005;	 McDonnell	 et	 al.,	 2009). The	 cost	 of	 these	 tests	 may	 be	 higher	 than	 central	
laboratory	 testing,	 but	 this	 is	 offset	 by	 the	 reduction	 in	 length	 of	 stay	 and	 the	 overall	
impact	 to	 patient	 management	 costs	 (St	 John	 &	 Price,	 2014).	 In	 addition,	 POC	 tests	
provide	rapid	and	time-saving	 results	without	 the	requirement	of	a	skilled	 test	operator	
and	 can	 contribute	 to	 avoidance	 of	 sample	 mislabeling	 and	 incorrect	 interpretation	 of	
results	(Gubala	et	al.,	2012;	Sharma	et	al.,	2015). Taking	all	of	this	into	account, the	POC	
market	was	projected	to	reach	a	value	of	US$18	billion	by	this	year	(St	John	&	Price,	2014). 
The	 key	 requirements	 of	 POC	 devices	 include	 simplicity	 of	 use,	 robust	 storage	 and	
operation	across	varying	 temperatures,	an	established	 reference	method	 for	monitoring	
accuracy	 of	 results,	 and	 safety	 of	 use,	 i.e.	 no	 harmful	 elements	 or	 reagents.	 These	
principles	 have	 been	 extended	 through	 guidelines	 provided	 by	 the	 WHO	 under	 the	
acronym	of	ASSURED	 for	 the	 development	 of	 POC	devices	 for	 the	 detection	of	 sexually	
transmitted	diseases	(Table	1.7.1).		
	
Table	1.7.1	The	ASSURED	guidelines	for	features	that	should	be	included	in	POC	devices:	
•	Affordable	–	for	those	at	risk	of	infection	
•	Sensitive	–	minimal	false	negatives	
•	Specific	–	minimal	false	positives	
•	User-friendly	–	minimal	steps	to	carry	out	test	
•	Rapid	&	Robust	–	short	turnaround	time	and	no	need	for	refrigerated	storage	
•	Equipment-free	–	no	complex	equipment		
•	Delivered	–	to	end-users	
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Current	 POC	 devices	 can	 be	 divided	 into	 “over-the-counter”	 products	 such	 as	 glucose	
monitoring	 devices	 for	 diabetes	 and	 pregnancy	 tests	 that	 are	 aimed	 at	 the	 non-
professional	 market,	 and	 devices	 for	 the	 analysis	 of	 infectious	 diseases,	 cardiac	
biomarkers	and	haemotology	which	are	utilised	 in	professional	 testing.	The	professional	
market	 mainly	 comprises	 larger	 bench-top	 analysers	 in	 critical	 care,	 representing	 an	
evolution	away	 from	central	 laboratory	 testing	whereby	operation	can	be	performed	by	
non-laboratory	trained	staff	such	as	nurses.	This	is	facilitated	by	ease	of	use	with	limited	
sample	handling,	simple	touchscreen	interface	integration,	barcode	scanner	cataloging	of	
test	and	patient	 information,	connection	 to	central	 information	systems	 for	 storage	and	
analysis	of	patient	data	and	room	temperature	storage	of	test	reagents.	Small	hand-held	
POC	devices	 comprise	portable	 tests	 that	 can	 transcend	both	 the	professional	 and	non-
professional	markets	due	to	built	in	quality	control	checks	that	ensure	accuracy	of	results,	
including	at	home	(St	John	&	Price,	2014;	Sharma	et	al.,	2015).	The	single	most	successful	
home	 POC	 device	 is	 the	 pregnancy	 test	 kit	 measuring	 the	 pregnancy	 hormone	 human	
chorionic	gonadotropin	(hCG)	utilising	antibody-antigen	binding	in	the	format	of	a	lateral	
flow	 test	 strip.	 In	 fact,	 the	 majority	 of	 POC	 devices	 use	 this	 immunoassay	 technology	
(Gubala	 et	 al.,	 2012).	 Lateral	 flow	 immunoassay	 (LFIA)	 technology	 has	 also	 been	 used	
extensively	 in	 the	 modern	 success	 of	 POC	 cardiac	 biomarkers,	 demonstrating	 its	
considered	value	(Chan	et	al.,	2013).	
	
1.8	 Lateral	flow	immunoassays	and	superparamagnetic	particles	in	point-of-care		
The	 lateral	 flow	 immunoassay	 (LFIA)	 has	 been	 adapted	 for	 use	 in	 a	multitude	 of	 fields	
including	 medical,	 veterinary,	 food,	 agricultural	 and	 environmental	 	settings.	 LFIAs	 are	
primarily	used	for	the	detection	of	small	antigens	or	analytes	such	as	peptides,	proteins,	
haptens	and	nucleic	acids.	In	LFIAs,	a	liquid	sample	carrying	an	analyte	of	interest	migrates	
though	a	polymeric	strip	coated	with	immobilised	molecules	that	interact	with	the	analyte	
and	 produce	 a	 signal	 that	 can	 be	 visually	 detected	 through	 coloured	 nanoparticles,	
including	 gold	 or	 latex	 (Koczula	&	Gallotta,	 2016).	 In	 addition	 to	 this	 test	 region	where	
binding	 and	 visualisation	 occurs,	 an	 independent	 control	 region	 using	 non-specific	
antibodies	 is	also	 included	 to	ensure	correct	 functionality.	The	simplicity	of	LFIA	devices	
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hides	 the	 complex	 assembly	 of	many	 vital	 components	which	must	 be	 fully	 considered	
from	an	early	 stage.	Obviously,	 the	biological	 reagents	 such	as	antibodies	are	of	utmost	
importance,	 however,	 the	 selection	 of	 the	 most	 appropriate	 materials	 will	 ensure	 the	
consistency	 of	 the	 device.	 LFIAs	 are	 generally	 composed	 of	 a	 nitrocellulose	membrane,	
sample	pad,	conjugate	pad	and	absorbent	pad	which	are	assembled	onto	a	backing	card	
for	 support	 before	 housing	 in	 a	 plastic	 test	 cassette.	 An	 example	 of	 this	 assembled	
architecture	is	shown	in	Figure	1.8.1.	Nitrocellulose	(NC)	membranes	are	porous	polymers	
that	are	available	with	a	variety	of	pore	sizes	to	facilitate	the	capillary	flow	of	the	sample	
to	the	analytical	region.	The	capillary	flow	rate	controls	the	time	taken	for	the	sample	to	
fill	and	travel	across	the	test	strip.	The	NC	membrane	material	also	effects	the	binding	and	
immobilisation	 of	 antibodies/antigens	 used	 in	 the	 assay.	 The	 sample	 pad	 is	 commonly	
composed	of	cellulose	and	is	the	loading	point	for	the	test	sample	and	can	act	as	a	filter	
for	undesired	materials	such	as	red	blood	cells	from	a	plasma	sample.	This	pad	can	also	be	
pretreated	for	neutralisation	of	sample	pH	when	testing	with	urine.	The	conjugate	pad	is	
generally	 composed	 of	 glass	 fibre	 and	 can	 be	 pretreated	 with	 dried	 conjugate	 such	 as	
antibody	labeled	with	nanoparticles.	The	integrity	of	the	conjugate	is	maintained	through	
the	 use	 of	 a	 concentrated	 sugar	 buffer	 that	 protects	 the	 conjugate	 activity	 until	 the	
sample	enters	 the	pad.	The	absorbent	pad,	often	composed	of	high-density	 cellulose,	 is	
located	at	 the	end	of	 the	 test	 strip	 and	wicks	up	any	excess	 sample	 reaching	 this	 point	
(Sharma	et	al.,	2015).	Advantages	of	LFIAs	include	that	it	 is	a	simple,	versatile,	rapid	and	
low-cost	test	method	that	can	be	used	for	both	qualitative	and	quantitative	purposes	and	
without	 the	 need	 for	 sample	 pretreatment	 (Posthuma-Trumpie	 et	 al.,	 2009).	
Disadvantages	 of	 LFIAs	 include	 that	 obstruction	 of	 membrane	 pores	 by	 sample	 matrix	
components,	 inaccurate	 loading	 volumes	 including	 over-loading	 of	 the	 sample	 port	 can	
reduce	the	precision	and	reliability	of	the	test	result,	the	viscosity	of	the	sample	can	affect	
the	 test	 development	 time,	 inconsistent	 binding	 and	 release	 of	 conjugate	 can	 occur,	
protein	incompatibility	can	lead	to	binding	with	the	NC	membrane,	and	sensitivity	can	be	
limited	due	 to	a	 lack	of	possibility	 for	 signal	enhancement	using	enzyme	conjugates	 like	
ELISAs	(Posthuma-Trumpie	et	al.,	2009;	St	John	&	Price,	2014).	LFIAs	are	discussed	again	in	
chapter	4.	
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Figure	1.8.1	 Typical	 LFIA	 test	 strip	construction	 (taken	 from	Koczula	&	Gallotta,	2016),	
showing	 backing	 card,	 sample	 pad,	 conjugate	 pad,	 strip	 membrane	 where	 immobilised	
antibodies	are	located	at	test	and	control	regions	and	absorbent	wicking	pad.	
The	 use	 of	 LFIAs	 for	 quantitative	 applications	 has	 been	 facilitated	 through	 the	 use	 of	
instruments	 and	 devices	 that	 are	 capable	 of	 detection	 methods	 such	 as	 fluorescence	
(Posthuma-Trumpie	et	al.,	2009)	and	magnetic	excitation	(LaBorde	&	O’Farrell,	2002).	The	
ease	of	use	for	gold	and	latex	particles	in	qualitative	LFIAs	has	influenced	the	adoption	of	
magnetic	 particles	 in	 this	 assay	 format	 (LaBorde	&	O’Farrell,	 2002).	 Superparamagnetic	
particles	(SPMPs)	are	magnetic	 iron	oxide	nanoparticles	with	production	techniques	that	
allow	for	controllable	sizes	ranging	from	10-100	nm	(comparable	with	a	cell)	to	10-450	nm	
(comparable	with	a	virus)	and	beyond.	These	particles	can	be	coated	using	biocompatible	
polymers	such	as	polyethelene	glycols	(PEG)	and	poly	vinyl-alcohol	(PVA)	for	stabilisation	
and	facilitating	conjugation	to	biological	molecules	such	as	antibodies	(Nor	et	al.,	2012).	In	
addition,	magnetic	particles	can	be	non-invasively	detected	by	a	wide	range	of	methods,	
are	physically	and	chemically	stable	and	relatively	 inexpensive	 to	produce	 (Tamanaha	et	
al.,	2008).	They	are	also	of	low	toxicity	compared	to	alternative	substances	such	as	nickel	
(Nor	et	al.,	2012).	 The	 fact	 that	SPMPs	are	only	magnetic	when	placed	 in	a	very	strong	
magnetic	field,	gives	these	particles	a	major	advantage	as	labels	for	separation	or	analyte	
detection	 (LaBorde	 &	 O’Farrell,	 2002). The	 ability	 of	 magnetic	 fields	 to	 penetrate	 into	
human	 tissue	 has	 resulted	 in	 the	medical	 application	 of	 these	 particles	 in	 drug	 delivery	
and	MRI	 imaging	 (Pankhurst	et	al.,	2003).	SPMPs	possess	a	single	magnetic	domain	that	
can	be	manipulated	by	an	external	magnetic	field	to	produce	uniform	magnetic	excitation	
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that	 can	 be	 quantified	using	 a	 magnetic	 detection	 sensor	 (Tartaj	 et	 al.,	 2003).	 Several	
groups	have	developed	sensors	for	the	detection	and	quantification	of	magnetic	particles	
including	MagnaBioSciences,	 LLC,	 Quantum	 Design,	 San	 Diego,	 CA,	 USA,	 LifeAssays	 AB,	
Lund,	 Sweden,	 Senova	 Immunoassay	 Systems,	 Jena,	 Germany,	 Magnotech,	 Philips,	
Amsterdam,	 The	Netherlands,	Magnisense,	 Paris,	 France	 and	MagArray	 Inc.,	 Sunnyvale,	
CA,	USA	(Barnett	et	al.,	2014)	and	Magnasense,	Vantaa,	Finland	(Magnasense.com).	The	
magnetic	 immunochromatographic	 test	 (MICT)	 system	 from	MagnaBioSciences,	 LLC	 has	
been	evaluated	 for	 the	development	of	magnetic	LFIAs	 in	an	extensive	number	of	 fields	
including	parasitic	infection	(Handali	et	al.,	2010),	viral	infection	leading	to	cervical	cancer	
(Peck	et	al.,	2006),	bacterial	infection	(Shi	et	al.,	2015),	detection	of	fish	allergens	(Zheng	
et	 al.,	 2012)	 and	 acute	 myocardial	 infarction	 (Xu	 et	 al.,	 2009).	 Additionally,	 the	 MICT	
instrument	and	a	commercial	thyrotropin-releasing	hormone	(TSH)	test	received	clearance	
from	 the	 US	 Food	 and	 Drug	 Administration	 (FDA)	 governing	 body	 in	 March	 2012,	
confirming	the	safety	and	efficacy	of	the	MICT	system	(MagnaBioSciences	News	Release,	
2012).	With	 the	MICT	 platform,	 the	 LFIA	 test	 strip	 is	 placed	 inside	 a	 C-shaped	 electro-
magnet	 that	houses	 several	 coils	between	 its	poles.	A	 voltage	 is	 applied	 from	a	parallel	
capacitor	 to	 activate	 the	 coils	 and	 generate	 a	 magnetic	 field.	 The	 subsequent	
magnetisation	 of	 the	 SPMPs	 is	 detected	 by	 magnetic	 field	 sensors	 and	 the	 signal	 is	
amplified	and	processed	to	quantify	the	number	of	magnetic	particles	at	both	the	test	and	
control	 line	 locations	 only.	 This	 signal	 is	 quantified	 as	magnetic	 assay	 reading	 (MAR),	 a	
unitless	number.	 When	using	 the	MICT	 instrument,	 the	magnetic	 field	excites	all	of	 the	
SPMPs,	 throughout	 the	 NC	 membrane,	 allowing	 for	 sensitive	 and	 quantitative	
measurement	of	 the	 test	analyte	 (MagnaBioSciences,	2011).	 The	MICT	 system	has	been	
demonstrated	to	have	almost	10	to	1000-times	higher	sensitivity	over	conventional	LFIA	
methods. The	magnetic	 signal	 does	 not	 degrade	 over	 a	 long	 time	 period,	 and	 thus	 the	
MICT	LFIA	strips	can	be	stored	for	rechecking	of	results	 if	necessary	(Wang	et	al.,	2009).	
The	sensitivity	of	this	platform	also	allows	for	the	multiplexing	of	several	analyte	regions	
along	the	NC	membrane.	Consequently,	this	platform	is	capable	of	measuring	a	panel	of	
biomarkers,	holding	major	potential	 for	 future	POC	applications.	This	concept	also	holds	
potential	in	AP	assessment	and	has	been	alluded	to	by	others	(Staubli	et	al.,	2015).	SPMPs	
and	the	MICT	instrument	are	discussed	again	in	chapter	4.	
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Once	 again,	 the	 aim	 of	 this	 body	 of	 work	 is	 to	 develop	 a	 competitive	 enzyme-linked	
immunosorbent	assay	(ELISA)	and	rapid	lateral	flow	immunoassay	(LFIA)	for	the	detection	
of	 trypsinogen	 activation	 peptide	 (TAP),	 and	 to	 utilise	 these	 prototypes	 to	 reopen	 the	
discussion	 of	 the	 clinical	 utility	 of	 the	 TAP	 biomarker	 at	 a	 time	 when	 the	 definition	 of	
acute	pancreatitis	disease	severity	has	been	revised	under	the	internationally	recognised	
Atlanta	classification.			
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2.1	 MATERIALS	
	
2.1.1	 Equipment	list	
	
Equipment	 Supplier	
XCell	SureLockTM	Mini-Cell						
Electrophoresis	System	
Invitrogen	Life	Technologies,	5791	Van	
Allen	Way,	Carlsbad,	CA	92008,	USA.	
PowerEase®	500	Power	Supply	Pack	
Gel	Doc	EZ	Imager	 Bio-Rad	Laboratories	Ltd.,	Bio-Rad	House,	
Maxted	Road,	Hemel	Hempstead,	
Hertfordshire,	HP2	7DX,	UK.	
NanoDropTM	ND1000	 NanoDrop	Technologies	Inc.,	3411	
Silverside	Road,	Willmington,	DE	19810,	
USA.	
MTS	2/4	Digital	Microtitre	Plate	Shaker	 IKA,	Janke	&	Kunkel-Str.	10,	79219,	
Staufen,	Germany.	
SunriseTM	Microplate	Absorbance	Reader	 TECAN	Group	Ltd.,	Seestrasse	103,	8708	
Männedorf,	Switzerland.	
Stuart	Gyro-Rocker	SSL3	 Lennox	Laboratory	Supplies	Ltd.,	John	F.	
Kennedy	Drive,	Naas	Road,	Dublin	12,	
Ireland.	
Stuart	SRT6D	Tube	Rotator	
Stuart	SB3	Tube	Rotator	
Stuart	Magnetic	Stirrer	CB161	
Techne	Dri-Block	DB2A	Heating	Block	
Sonicator	Bath	U95	 Ultrawave	Ltd.,	Eastgate	Business	Park,	
Wentloog	Avenue,	Cardiff,	South	
Glamorgan	CF3	2EY,	UK.	
Magnetic	Immunochromatographic	Test	
(MICT®)	Reader	System	
MagnaBioSciences	LLC.,	6325	Lusk	
Boulevard,	San	Diego,	CA	92121-3733,	
USA.	MICT®	Cassette	Assembly	Clamp	
CAMAG	Linomat	5	Semi-Automatic	
Application	System	
Mason	Technology	Ltd.,	228	South	Circular	
Road,	Dublin	8,	Ireland.	
Eppendorf	Centrifuge	5810R																		
Rotors	-	F45-30-11	(14,000	rpm),																				
A-4-62	(4,000	rpm)		
Unitech	Ireland	Ltd.,	Unit	2,	Airton	Business	
Park,	Airton	Road,	Dublin	24,	Ireland.	
OHAUS	Enclosed	Analytical	Balance	 VWR	International,	LLC.,	1310	Goshen	
Parkway,	West	Chester,	PA	19380,	USA.	KERN	Top	Pan	Balance	440-53N	
ThermoOrion	model420	pH	Meter	 Fisher	Thermo	Scientific,	47341	Bayside	
Pkwy.,	Fremont,	CA	94538,	USA.	
SANYO	Incubator	MIR-162	 AGB	Scientific	Ltd.,	Dublin	Industrial	Estate,	
Dublin	11,	Ireland.	
Autoclave	 Priorclave	Ltd.,	129-131	Nathan	Way,	West	
Thamesmead	Business	Park,	London,	SE28	
OAB,	UK.	
Pipettes	(Various)	 Eppendorf	UK	Ltd.,	Eppendorf	House,	
Gateway	1000	Whittle	Way,	Arlington	
Business	Park,	Stevenage,	SG1	2FP,	UK.	
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2.1.2	 Consumables		
Consumable	 Supplier	
Plastic	Labware,	including	microtubes,								
syringes,	sterilin	tubes	and	pipette	tips	
Fisher	Thermo	Scientific,	47341	Bayside	
Pkwy.,	Fremont,	CA	94538,	USA.	
Whatmann	PURADISC	Disposable	Filter	Device	
GE	Healthcare	Disposable	PD-10	Desalting	and	
Buffer	Exchange	Pre-packed	Columns	
Pierce®	Streptavidin	Coated	High-Binding		
Capacity	8-Well	Clear	Strip	Microplates	
NUNC	Lockwell	C8	MaxisorpTM	Clear-Well	
Microplates	
Scharlau	pH	Calibration	Buffers	(pH	4.0,	7.0,	
10.0)	
Sterile	Screw-Cap	Micro	tubes	(0.5mL)	 Sarstedt	AG	&	Co.,	Sarstedtstraße	1,	
51588	Nümbrecht,	Germany.	
Novex	4-12%	Bis-Tris	Gels,	1.0mm	 Bio-Sciences	Ireland,	3	Charlemont	
Terrace,	Crofton	Road,	Dun	Laoghaire,	
Co	Dublin,	Ireland.	
MiniPax®	Compact	Desiccant	Packets	 Multisorb	Technologies,	325	Harlem	
Road,	Buffalo,	New	York	14224,	USA.	
Vivaspin®	6,	10,000	MWCO	PES	 Sartorius	Stedim	Ireland	Ltd.,	Unit	41,	
The	Business	Centre,	Stadium	Business	
Park,	Ballycoolin	Road,	Dublin	11,	
Ireland.	
Vivaspin®	500,	30,000	MWCO	PES	
UniSart	CN	140	Cellulose	Nitrate	Membrane									
on	100μm	polyester	film	
Sample	Pad,	Grade	205	(27mm	width)	 Ahlstrom	Filtration,	LLC.,	122	West	
Butler	Street,	Mt	Holly	Springs,	PA	
17065,	USA.	
Upper	Wick	Cellulose	Fibre	Pad,	Grade	A222	
(21mm	width)	
Conjugate	Glass	Fibre	Pad,	Grade	8964											
(10mm	width)	
ARcare®	7759	Clear	Polyester	Single-Sided	
Adhesive	Tape	
Adhesives	Research	Ireland	Ltd.,	
Raheen	Business	Park,	Raheen,	
Limerick,	V94	VH22,	Ireland.	
MICT®	Disposable	Cleaning	Cassettes	 MagnaBioSciences	LLC.,	6325	Lusk	
Boulevard,	San	Diego,	CA	92121-3733,	
USA.	
MICT®	Test	Cassettes	for	5.0mm	Strips	
Die-cut	Base	Card	for	5.0mm	Strips									
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2.1.3	 Reagents		
Reagent	 Supplier	
Novex®	SeeBlue®	Plus2	Prestained	Protein	
Standard	
Bio-Sciences	Ireland,	3	Charlemont	
Terrace,	Crofton	Road,	Dun	Laoghaire,	Co.	
Dublin,	Ireland.	InvitrogenTM	SimplyBlueTM	Safe	Stain		
Novex®	NuPage	MES	SDS	Running	Buffer	
Trizma®	base	 Sigma	Aldrich	Ireland	Ltd.,	Vale	Rd,	
Arklow,	Co.	Wicklow.	Aprotinin	from	bovine	lung	
Sodium	Hydroxide	(NaOH)	
Calcium	Chloride	
Sodium	Dodecyl	Sulphate	(SDS)	
2-mercaptoethanol	
2-Propanol	
5-bromo-5-nitro-1,3-dioxane	(Bronidox-L)	
Oxoid	Phosphate	Buffered	Saline	(PBS)			
Tablets	
Fisher	Thermo	Scientific,	47341	Bayside	
Pkwy.,	Fremont,	CA	94538,	USA.	
Bromophenol	blue	
Glycerol	
Casein	
Hydrochloric	Acid,	37%	(v/v)	in	water	(HCl)	
EDC	(1-ethyl-3-(3-dimethylaminopropyl)	
carbodiimide	hydrochloride)	
NHS	(N-Hydroxysuccinimide)	
BupHTM	0.05M	Borate,	0.1M	2-(N-
morpholino)	ethanesulfonic	acid	(MES),	
0.9%	NaCl	Buffer	Packs,	pH	4.7	
BupHTM	Borate	Buffer	Packs,	0.05M	Sodium	
borate,	pH	8.5	
Sodium	Chloride	 Millipore	Ireland	B.V.,	Tullagreen,	
Carrigtwohill,	Co.	Cork,	Ireland.	Tween®	20	
Sodium	Azide	
Bovine	Serum	Albumin	(BSA)	
ProClin	950	 Supelco,	595	North	Harrison	Road,	
Bellefonte,	PA	16823-0048,	USA.	
Prestained	3,3',5,5'-Tetramethylbenzidine	
(TMB)	X-tra	
Kem-En-Tec	Diagnostics	A/S,	Kuldyssen	10,	
2630	Taastrup,	Denmark.	
Estapor®	Carboxyl-Modified					
Superparamagnetic	Microspheres																					
(MH1-020/50,	200nm)	
Merck	Chimie	SAS,	201	rue	Carnot,	F-
94126	Fontenay	sous	Bois	Cedex,	France.			
Ademtech	Storage	Buffer	(10X)	 Ademtech,	BioParc	Biogalien	Bat	C	1	
étage,	27	allée	Charles	Darwin,	33600	
Pessac,	France.	
Siemens	Multistix®	10	SG,	Reagent	Strips								
for	Urinalysis	
Promed,	Tulligmore,	Killorglin,	Co.	Kerry,	
Ireland.	
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2.1.4	 Proprietary	antibodies	used	in	this	research		
Antibody/Peptide	 Catalogue	Number	 Supplier	
Anti-Trypsinogen	Activation	Peptide,	
Rabbit	Monoclonal	IgG	Antibody	
BTR-1-14-8	 AbCam	Burlingame,	863	
Mitten	Road,	Suite	103,	
Burlingame,	CA	94010-
1303,	USA.	
Trypsinogen	Activation	Peptide																
(Custom	Synthesis)	
4055133	 Bachem	AG,	Hauptstrasse	
144,	4416	Bubendorf,	
Switzerland.		
	
	
	
2.1.5	 Commercial	antibodies	used	in	this	research		
Commercial	Antibody/Protein	 Catalogue	Number	 Supplier	
AffinPure	Goat	Anti-Rabbit	IgG	(H+L)	
(minimal	cross-reaction	to	Human	
Serum	Proteins)	
111-005-045	 Jackson	Immunoresearch	
Laboratories,	Inc.,	872	W.	
Baltimore	Pike,	West	
Grove,	PA	19390,	USA.	AffinPure	Goat	Anti-Chicken	IgY	
(H+L)	(minimal	cross-reaction	to	
Human	Serum	Proteins)	
111-005-046	
IgG	from	Rabbit	Serum	 I5006	 Sigma-Aldrich,	3050	Spruce	
Street,	St.	Louis,	MO	
63103,	USA.	
Chicken	IgY	 IgY-100	 Gallus	Immunotech	Inc.,	
120	Brookbank	Hill,	Pl	Cary,	
NC	27519,	USA.	
ImmunoPure	Streptavidin	
(Lyophilised)	
2122	 Fisher	Thermo	Scientific,	
47341	Bayside	Pkwy.,	
Fremont,	CA	94538,	USA.															
	
	
		 36	
2.1.6	 Buffers		
Buffer	 Composition	
Phosphate	Buffered	Saline	(PBS)	(0.01M)	
PBS	Tablet	 1	tablet	
dH2O	 up	to	100	mL	
Final	pH	7.3	 		
Bromophenol	Blue	Solution	(0.5%	w/v)	
Bromophenol	blue	 0.1	g	
dH2O	 20	mL	
Sodium	Dodecyl	Sulphate	(SDS)	(10%	w/v)	
SDS	 1.0	g	
dH2O	 up	to	10	mL	
Tris-HCl	Buffer	(0.5M)	
Tris	 6.05	g	
dH2O	 up	to	100	mL	
Final	pH	6.8	 		
5X	Solubilisation	Buffer	
Glycerol	 10	g	
SDS	(10%	w/v)	 1.6	mL	
Tris	HCl	(0.5M,	pH	6.8)	 1.0	mL	
2-mercaptoethanol	 0.4	mL	
Bromophenol	blue	 0.2	mL	
dH2O	 4	mL	
Concentrated	Coating	Buffer	
Proprietary	composition	
PBS	Tween	(PBST)	
Blocking	Buffer	
Tris	Buffered	Saline	Tween	(TBST)	
Tris	Buffered	Saline	Tween,	1%	(w/v)	BSA	
Sample	Diluent	
Calibrator	Diluent	
Conjugate	Diluent	Buffer	
Positive	Control	Diluent	
Stop	Solution	(1M)	
Concentrated	H2SO4	 28.0	mL	/L	
dH2O	 972.0	mL	/L	
Activation	Buffer	 BupHTM	0.05M	Borate,	0.1M	2-
(N-morpholino)	ethanesulfonic	
acid	(MES),	0.9%	NaCl	Buffer	
Pack,	pH	4.7	
1	pack	
Tween20	(0.55%	w/v)	 0.275g	
dH2O	 up	to	500	mL	
Cross-Linking	Buffer	 BupHTM	Borate	Buffer	Packs,	
0.05M	Sodium	borate,	pH	8.5	 1	pack	
Tween20	(0.55%	w/v)	 0.275g	
NaCl	(0.15M)	 4.383g	
dH2O	 up	to	500	mL	
Sample	Pad	Buffer	 Proprietary	composition	
		 37	
2.1.7	 Commercial	kits		
Commercial	Kit	 Catalogue	Number	 Supplier	
Lightning-LinkTM	HRP	Conjugation	Kit	
(LL-HRP	3	reactions	of	100	μg)	
701-0000	 Innova	Biosciences	Ltd.,	
Babraham	Research	
Campus,	Cambridge,	
Cambridgeshire,	CB22	
3AT,	UK.	
Lightning-LinkTM	Biotin	Conjugation	Kit	
(Type	B	-	3	reactions	of	100-200	μg)	
715-0010	
				
2.1.8	 Software		
	
List	of	software	used	for	data	analysis	in	this	research:			
Software	 Supplier	
GEN5	MicroPlate	Reader	Software		
(Version	1.06)	
Biotek	Instruments,	Inc.,		
100	Tigan	Street,	Winooski,	
VT05404,	USA.	
		 		
Analyse-it	-	Statistical	Analysis	and		
Data	Visualisation	Software				
Analyse-it	Software	Ltd.,		
The	Tannery,	91	Kirkstall	Road,	Leeds,	
LS3	1HS,	UK.	
		 		
Graphpad	Prism	Statistical	Software	
(Version	7)	
GraphPad	Software,	Inc.			
7825	Fay	Avenue,	Suite	230	La	Jolla,	CA	
92037	USA	
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2.2	 METHODS	
	
2.2.1	 Characterisation	of	monoclonal	14-8	anti-TAP	antibody		
	
2.2.1.1	SDS-PAGE	analysis	of	monoclonal	14-8	anti-TAP	antibody	purity	
	
Purified	monoclonal	antibody	(Lot#	B_4168,	B_4346	and	B_37042)	was	prepared	at	
250	and	500	μg/mL	concentrations	with	PBS	(0.01M).	The	samples	were	mixed	with	
10	 μL	 of	 5X	 solubilisation	 buffer	 and	 heated	 at	 95°C	 for	 10	 minutes.	 The	 heated	
samples	 (20	μL)	were	 loaded	 into	the	wells	of	a	4-12%	(w/v)	Novex®	Bis-Tris	gel	at	
final	concentrations	of	5	and	10	μg/well.	The	gel	was	resolved	at	250	volts	until	the	
prestained	protein	standard	and	bromophenol	blue	dye	reached	the	bottom	of	the	
gel	(approximately	35	minutes).	The	gel	was	removed	and	washed	three	times	with	
dH20	before	staining	with	SimplyBlueTM	safe	stain	 for	one	hour.	Finally,	 the	stained	
gel	was	destained	three	times,	each	of	1	hour	duration,	with	dH20.	
	
2.2.2	 Microtitre	plate	coating	
	
Purified	 monoclonal	 anti-TAP	 antibody	 was	 coated	 in	 a	 96-well	 plate	 (Nunc,	
MaxisorpTM)	 at	 various	 concentrations	 (2,	 3,	 4,	 6	 and	 8	 μg/mL).	 The	 antibody	was	
diluted	with	 1X	 coating	 buffer	 as	 required	 and	mixed	 for	 60	minutes	 by	magnetic	
stirrer	prior	to	commencing	plate	coating.	The	coating	solution	was	dispensed	at	100	
μL/well	and	the	plate	was	covered	with	a	plate	sealer	and	incubated	at	4°C	for	16-24	
hours.	 The	 coated	 plate	 was	 removed	 and	 washed	 four	 times	 with	 1X	 PBST	 (300	
μL/well)	 before	 firmly	 tapping	 on	 absorbent	 paper	 to	 ensure	 no	 residual	 coating	
solution	remained	in	the	wells.	Blocking	buffer	was	dispensed	at	200	μL/well	and	the	
plate	was	covered	with	a	plate	sealer	and	incubated	at	room	temperature	(20-25°C)	
for	2	hours.	The	blocked	plate	was	removed	and	aspirated	before	firmly	tapping	on	
absorbent	paper	to	ensure	no	residual	blocking	solution	remained	in	the	wells.	The	
plate	was	dried	for	18-22	hours	at	37°C	 in	the	presence	of	1kg	of	calcium	chloride.	
The	dried	plate	was	sealed	in	a	foil	pouch	with	2	desiccants	and	stored	at	4°C	until	
required	for	use.	
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2.2.3	 Conjugation	of	TAP	antigen	to	HRP	
	
Lightning-LinkTM	HRP	conjugation	kit	(Innova	Biosciences)	was	supplied	with	100	μg	
lyophilised	HRP	(40	kDa)	per	vial,	equivalent	to	2.5	nanomoles	of	HRP.	A	4-fold	molar	
excess	of	protein	to	HRP	was	recommended	for	use	with	this	kit.	The	lyophilised	TAP	
antigen	(769.72	g/L,	5	mg	–	as	indicated	by	supplier,	Bachem)	was	reconstituted	to	1	
mM	concentration	using	6.5	mL	of	dH20.	The	reconstituted	stock	was	then	diluted	to	
a	final	volume	of	100	μL	(minimum	required	for	use	with	this	kit)	by	addition	of	1	μL	
(1	mM	TAP)	to	99	μL	of	PBS	to	give	10	nanomoles	of	TAP	antigen.	The	conjugate	was	
prepared	as	per	product	insert	and	an	equal	volume	(120	μL)	of	80%	(w/v)	glycerol	
was	added	to	the	stock	solution,	which	was	stored	at	4°C	until	required.	
	
2.2.4	 Competitive	monoclonal	14-8	anti-TAP	ELISA	
	
All	 assay	 components	 were	 removed	 from	 storage	 (-20	 or	 4°C)	 and	 allowed	 to	
equilibrate	 to	 room	 temperature	 (20-25°C)	 prior	 to	 use.	 Calibrators	 and	 samples	
were	prepared	and	loaded	to	the	assay	plate	(50	μL/well)	before	addition	of	diluted	
conjugate	 (50	μL/well),	as	 required.	The	plate	was	covered	with	a	plate	sealer	and	
incubated	 at	 room	 temperature	 with	 uniform	 shaking	 (350	 ±	 10	 rpm)	 for	 1	 hour.	
Following	 incubation,	 the	 plate	 was	 washed	 six	 times	 with	 1X	 TBST	 (300	 μL/well)	
before	firmly	tapping	the	plate	on	absorbent	paper	to	ensure	complete	removal	of	
wash	 solution.	 TMB	 substrate	 was	 added	 (100	 μL/well)	 with	 no	 shaking	 at	 room	
temperature	 in	 the	 dark	 for	 15	 minutes.	 Colour	 development	 was	 quenched	 by	
addition	of	 Stop	 Solution	 (100	μL/well).	 The	plate	was	 read	 immediately	using	 the	
TecanTM	 Sunrise	microplate	 absorbance	 reader	 (450nm	with	 a	 reference	 of	 620nm).	
The	reference	wavelength	absorbance	(620nm)	value	was	subtracted	from	the	450nm	
absorbance	value	for	all	assays	performed	in	this	project.	
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2.2.5	 Biotinylation	of	monoclonal	14-8	anti-TAP	antibody	
	
Lightning-LinkTM	Biotin	conjugation	kit	(Innova	Biosciences)	was	supplied	with	100	μg	
lyophilised	 biotin	 per	 vial.	 An	 antibody	 concentration	 of	 1	 –	 2.5	 mg/mL	 was	
recommended	 for	 use	 with	 this	 kit.	 The	 purified	 monoclonal	 anti-TAP	 antibodies	
(Lot#	 B_4168,	 B_4346	 and	 B_37042)	 were	 concentrated,	 where	 required,	 as	 per	
section	2.2.6.1,	prior	to	use	with	this	kit.	Lightning	LinkTM	rapid	modifier	solution	(10	
μL)	 was	 added	 to	 the	 anti-TAP	 antibody	 before	 this	 mixture	 was	 added	 to	 the	
lyophilised	biotin	material.	 The	 reaction	mixture	was	 incubated	 for	3	hours	before	
Lightning	 LinkTM	 rapid	 quencher	 solution	 (10	 μL)	 was	 added.	 The	 biotinylated	
antibody	was	stored	at	4°C	until	required	for	further	use.	
	
2.2.6	 Competitive	ELISA	with	streptavidin-coated	plate	/	biotinylated	monoclonal	
14-8	anti-TAP	antibody		
	
All	 assay	 components	 were	 removed	 from	 storage	 (-20	 or	 4°C)	 and	 allowed	 to	
equilibrate	 to	 room	 temperature	 prior	 to	 use.	 The	 streptavidin-coated	 plate	 was	
washed	 three	 times	 (200	 μL/well)	 with	 1X	 TBST,	 containing	 0.1%	 (w/v)	 BSA.	
Biotinylated	anti-TAP	monoclonal	antibody	was	loaded	(100	μL/well)	onto	the	plate,	
covered	 with	 a	 plate	 sealer	 and	 incubated	 at	 room	 temperature	 with	 uniform	
shaking	(350	±	10	rpm)	for	2	hours.	The	plate	was	washed	three	times	(200	μL/well)	
with	1X	TBST,	0.1%	(w/v)	BSA	before	firmly	tapping	the	plate	on	absorbent	paper	to	
ensure	 complete	 removal	 of	 wash	 solution.	 The	 remainder	 of	 the	 assay	 was	
completed,	as	described	 for	 the	monoclonal	14-8	anti-TAP	antibody	ELISA	method,	
section	2.2.3.	
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2.2.7	 Buffer	exchange	and	protein	concentration	of	monoclonal	14-8	anti-TAP	
antibody	
	
2.2.7.1	Protein	concentration	by	ultrafiltration	
	
Antibodies	 were	 concentrated	 using	 Vivaspin	 columns	 (GE	 Healthcare)	 with	 an	
appropriate	molecular	weight	cut-off	(MWCO:	10	-	30	kDa).	The	Vivaspin	column	was	
pre-rinsed	by	addition	of	PBS	to	half	the	maximum	volume	of	the	Vivaspin	unit	and	
centrifuged	 (4,000	 x	 g)	 using	 Eppendorf	 Centrifuge	 5810R	 rotor	 A-4-62	 at	 a	
temperature	of	4⁰C	for	5	minutes.	The	PBS	was	discarded	from	the	upper	and	lower	
chambers.	 Antibody	 solution	 was	 added	 to	 the	 upper	 chamber	 and	 centrifuged	
(2,500	x	g)	at	a	temperature	of	4⁰C	for	5	minutes.	The	process	was	repeated	until	the	
sample	was	 concentrated	 sufficiently.	On	 reaching	 the	 required	 concentration,	 the	
concentrated	sample	was	mixed	by	pipetting	and	removed.	 	A	small	volume	of	PBS	
was	 subsequently	 added	 to	 the	upper	 chamber	and	mixed	by	pipetting	 to	 capture	
any	 residual	 antibody	 remaining.	 This	 solution	 was	 pooled	 with	 the	 concentrated	
sample.	 Antibody	 concentration	 was	 measured	 using	 a	 Nanodrop	
spectrophotometer	(A280nm). 
	
2.2.7.2	Buffer	exchange	by	desalting	column	
	
PD-10	 columns	 (GE	 healthcare)	 provide	 a	 rapid	 means	 to	 buffer	 exchange	 small	
volumes	of	protein	solutions	with	a	maximum	sample	volume	of	2.5	mL	per	column.		
The	top	cap	of	the	PD-10	column	was	removed	and	the	column	storage	solution	was	
discarded.	The	sealed	end	of	the	column	was	cut	at	the	notch	using	a	scissors.	The	
column	was	equilibrated	with	25	mL	of	PBS.	The	antibody	solution	was	added	to	the	
column	and	allowed	to	completely	enter	the	packed	bed	by	gravity	 flow.	 If	sample	
volume	was	<2.5	mL,	additional	PBS	was	added	to	adjust	 the	volume	up	to	2.5	mL	
after	the	sample	had	entered	the	packed	bed	completely.	The	flow-through	solution	
was	discarded	before	the	antibody	was	eluted	with	3.5	mL	of	0.05M	borate,	0.55%	
Tween20	(w/v),	0.15M	NaCl,	pH	8.5	(cross-linking	buffer,	see	section	2.2.8	also)	and	
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collected	 into	 a	 test	 tube.	 Antibody	 concentration	 was	 measured	 using	 the	
Nanodrop	 spectrophotometer	 (A280nm)	 and	 stored	 at	 2-8°C	 or	 -20°C	 for	 short	 and	
long-term	storage,	respectively.	
	
2.2.8	 Lateral	flow	test	strip	–	superparamagnetic	particle	(SPMP)	conjugation	
	
The	rabbit	 IgG	and	chicken	 IgY	antibodies	were	buffer	exchanged	 into	cross-linking	
buffer,	as	per	section	2.2.6.2.	The	lyophilised	TAP	peptide	was	reconstituted	directly	
into	 cross-linking	 buffer	 due	 to	 the	 limited	 availability	 of	 material.	 All	 stock	
concentrations	 were	 confirmed	 by	 NanodropTM	 prior	 to	 use.	 A	 concentration	 >2	
mg/mL	was	required	for	this	protocol.	Magnetic	particles	were	diluted	to	a	3%	(w/v)	
solid	 content	 solution	 by	 addition	 of	 activation	 buffer	 (0.1M	 2-(N-morpholino)	
ethanesulfonic	acid	(MES),	0.9%	NaCl	(w/v),	pH	4.7,	100	μL	total	volume)	in	a	1.5	mL	
tube.	 The	 particle	 solution	 was	 pulled	 down	 by	 a	 magnetic	 separator	 and	 the	
supernatant	removed.	The	particle	pellet	was	fully	suspended	by	pipetting	with	200	
μL	of	activation	buffer	before	‘pull-down’	and	removal	of	supernatant	was	repeated.	
The	 particles	were	 re-suspended	 in	 250	 μL	 of	 activation	 buffer	 and	 sonicated	 in	 a	
water	bath	for	2	minutes	(1	minute	on,	1	minute	off,	1	minute	on)	at	a	power	output	
of	 35W	 at	 44kHz	 to	 ensure	 even	 dispersion.	 1-Ethyl-3-(3-dimethylaminopropyl)	
carbodiimide	hydrochloride	and	N-hydroxysuccinimide	were	weighed	and	dissolved	
into	50	μL	of	activation	buffer	before	quickly	transferring	to	the	sonicated	particles.	
The	reaction	mixture	was	placed	in	a	tube	rotator	at	a	90°	angle	with	slow	mixing	(20	
rpm)	at	37°C	for	1	hour.	The	activated	particles	were	pelleted	and	suspended	twice	
in	300	μL	of	activation	buffer,	removing	the	reaction	supernatant	on	each	occasion.	
The	 particle	 pellet	 was	 fully	 suspended	 in	 300	 μL	 of	 cross-linking	 buffer	 before	
transfer	 to	 a	 clean	 1.5	 mL	 tube,	 followed	 by	 particle	 pull-down	 and	 removal	 of	
supernatant.	The	particle	pellet	was	 re-suspended	 in	200	μL	of	 cross-linking	buffer	
and	sonicated	as	above.	The	required	amount	of	antibody	or	peptide	was	added	to	
the	 sonicated	particles	 and	 additional	 cross-linking	buffer	was	 added	 to	bring	 to	 a	
final	 volume	of	 350	μL,	 if	 needed.	 If	 this	 final	 volume	was	 exceeded	 following	 the	
addition	of	a	large	amount	of	antibody	or	peptide,	no	additional	cross-linking	buffer	
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was	 added.	 The	 reaction	mixture	was	placed	 in	 a	 tube	 rotator	 at	 a	 90°	 angle	with	
slow	mixing	(20	rpm)	at	37°C	for	3	hours.	The	residual	activated	COOH	groups	of	the	
conjugated	particles	were	blocked	by	addition	of	40	μL	of	cross-linking	buffer	with	
5%	 (w/v)	 BSA.	 This	 solution	was	 incubated	 at	 37°C	 for	 30	minutes	without	mixing	
before	washing	three	times	with	400	μL	of	cross-linking	buffer	by	particle	pelleting,	
supernatant	 removal	 and	 particle	 resuspension.	 On	 the	 third	 wash,	 the	 particles	
were	transferred	to	a	new	1.5	mL	tube	and	the	supernatant	removed.	The	washed	
particles	were	fully	suspended	in	300	μL	of	1X	Ademtech	storage	buffer	and	stored	
at	4°C	until	use.	
	
2.2.9	 Lateral	flow	test	strip	–	antibody	spotting	
	
A	 base	 card	 (MagnaBioSciences)	 was	 divided	 into	 5	 mm	 strips	 using	 a	 Lumicolor	
permanent	 marker	 and	 ruler.	 The	 nitrocellulose	 membrane	 was	 attached	 to	 the	
backing	 card	 at	 1	 mm	 from	 both	 sides	 of	 the	 indicated	 central	 position	 (Figure	
2.2.8.1.)	Goat	anti-rabbit	IgG	or	goat	anti-chicken	IgY	capture	antibody	was	diluted	to	
1	mg/mL	in	PBS	and	dispensed	by	pipette	(0.5	μL/strip)	onto	the	nitrocellulose	at	the	
required	 line	position	 (Control	Line	=	43.8	mm	from	upper	wick	end	of	base	card).	
Streptavidin	was	diluted	to	1	mg/mL	in	PBS,	0.5%	(v/v)	green	dye	and	dispensed	(0.5	
μL/strip)	 onto	 the	 nitrocellulose	 at	 the	 required	 line	 position	 as	 shown	 in	 Figure	
2.2.8.1	(Test	Line	=	54.2	mm,	from	upper	wick	end	of	base	card).	Both	line	positions	
were	 marked	 by	 pencil	 for	 guidance,	 ensuring	 minimal	 pressure	 on	 the	
nitrocellulose.	 Following	 air-drying	 for	 ~5	 minutes,	 the	 biotinylated	 antibody	 was	
diluted	to	0.8	mg/mL	in	PBS	and	dispensed	(0.5	μL/strip)	onto	the	green	streptavidin	
spot.	 The	 spotted	 strips	were	 stored	overnight	 at	 room	 temperature	 in	 sealed	 foil	
pouches	with	2	MiniPax®	compact	desiccant	packets	 before	 final	assembly,	cutting	
and	housing	in	MICT®	cassette	casings	(see	Figure	2.2.11.2).		
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Figure	2.2.8.1:	Streptavidin	solution	spotted	on	nitrocellulose	at	the	test	line	
position.	
	
	
	
	
2.2.10	 Lateral	flow	test	strip	–	antibody	striping	
	
The	base	card,	nitrocellulose	membrane,	streptavidin	and	antibodies	were	prepared	
as	described	for	section	2.2.7.	A	Linomat	5	(CAMAG)	instrument	was	used	to	stripe	
the	Control	and	Test	Line	at	the	required	positions.	The	Linomat	5	was	programmed	
to	 dispense	 0.1	 μL	 antibody	 solution	 per	 1	 mm	 at	 a	 rate	 of	 500	 nL/second.	 The	
dispensed	volume	was	equivalent	to	spotting	0.5	μL	per	5	mm	strip.	The	strips	were	
stored	 overnight	 at	 room	 temperature	 in	 sealed	 foil	 pouches	 with	 2	 desiccants	
before	final	assembly,	cutting	and	housing	in	MICT	cassette	casings.		
	
	
	
	
	
	
Base	card	
	Streptavidin	solution	spot	
Nitrocellulose	membrane	
Test	line	location	(pencil	line)	
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2.2.11	 Lateral	flow	test	strip	–	device	assembly	
	
Sample,	conjugate	and	upper	wick	pads	(Ahlstrom)	were	supplied	in	standard	sheets	
of	 300	 mm	 width.	 The	 desired	 length	 of	 each	 component	 (Table	 2.2.10.1)	 was	
measured	and	cut	using	a	scissors.	Sample	pad	strips	were	treated	with	sample	pad	
buffer	by	soaking	in	solution,	turning	once	after	2-3	minutes.	The	sample	pad	buffer	
was	 formulated	 to	 aid	 in	 neutralisation	 of	 sample	 pH	 upon	 loading	 onto	 the	
assembled	test	strip.	The	wetted	strips	were	left	to	air-dry	overnight	before	storing	
at	 room	 temperature	 in	 a	 sealed	 plastic	 bag	 with	 2	 desiccants.	 The	 test	 strip	
assembly	was	completed	as	shown	in	Figures	2.2.11.1	and	2.2.11.2.		
	
	
Table	2.2.11.1:	Standard	test	strip	component	measurements:	
	
Component	 Length	[mm]	
Sample	Pad	(SP)	 25.0	
Conjugate	Pad	(CP)	 10.0	
Upper	Wick	(UW)	 25.0	
Nitrocellulose	(NC)	 39.5	
Lamination	Tape	 45	.0	
	
	
	
	
	
	
	
	
Figure	2.2.11.1:	Lateral	flow	test	strip	component	measurements	for	assembly.	
			
		 46	
	
	
Figure	 2.2.11.2:	 Lateral	 flow	 test	 strip	 assembly.	1:	Overlay	position	of	upper	wick	
and	sample	pad	is	measured	on	NC.	2:	Sample,	conjugate	and	upper	wick	pads	fixed	
into	position.	3:	Lamination	of	test	strips	and	removal	of	air	bubbles	by	hand	rolling.	
4:	Cutting	of	test	card	into	5	mm	strips.	5:	Closure	of	test	strips	into	MICT	cassettes.	
	
	
2.2.12	 Lateral	flow	test	strip	–	test	procedure	
	
All	 assay	 components	 were	 removed	 from	 storage	 (-20	 or	 4°C)	 and	 allowed	 to	
equilibrate	 to	 room	 temperature	 prior	 to	 use.	 The	 TAP-SPMP	 test	 conjugate	 and	
rabbit	 IgG	 or	 chicken	 IgY-SPMP	 control	 conjugates	 were	 sonicated	 and	 diluted	
separately	 in	conjugate	dilution	buffer	before	pooling	and	addition	of	PBS	or	urine	
sample	to	a	1/9	final	dilution.	For	example,	to	analyse	5	test	strips,	480	μL	of	PBS	or	
urine	sample	was	added	to	60	μL	pooled	SPMP	conjugate.	PBS	was	used	in	place	of	
urine	matrix	throughout	the	test	optimisation.	Pooled	conjugate	stock	consisted	of	1	
1 2 
3 
4 
5 
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part	 control	 conjugate,	 1	 part	 test	 conjugate	 and	 1	 part	 conjugate	 dilution	 buffer.	
The	 sample/conjugate	mixture	was	 loaded	 by	 pipette	 (100	 μL/strip)	 onto	 the	 test	
strip	sample	pad	and	incubated	for	45	minutes	at	room	temperature	before	reading	
in	the	MICT®	instrument.	The	sample	loading	was	staggered	by	~1	minute	intervals	
between	test	replicates	to	allow	for	the	time	taken	to	complete	MICT®	reading.	
	
2.2.13	 Clinical	utility	study	of	TAP	–	sample	collection	protocol	
	
Ethical	approval	was	granted	by	the	research	ethics	committees	of	the	Adelaide	and	
Meath	National	 Children’s	 Hospital	 (AMNCH),	 Tallaght,	 Co.	 Dublin	 and	 by	DCU	 for	
the	collection,	 storage	and	analysis	of	urinary	 samples	at	DCU.	Patients	presenting	
with	 acute	 abdominal	 pain	 as	 a	 result	 of	 suspected	 acute	 pancreatitis	 (AP)	 were	
included	in	this	study.	Diagnosis	of	mild,	moderate	and	severe	AP	was	made	utilising	
three	different	criteria	–	clinical	symptoms	observed,	Imrie	classification	score	and	a	
C-reactive	protein	(CRP)	level	rise	of	>75	mg/L	within	two	days	or	a	CRP	>150	mg/L	
on	Day	2,	following	presentation	to	the	Emergency	Department.	CRP	was	measured	
in	 patient	 plasma.	 The	 course	 of	 patient	 treatment	 was	 altered	 according	 to	
observations	derived	from	all	diagnostic	criteria.	Urine	samples	were	collected	from	
patients	upon	admission	to	the	hospital	ward	and	at	subsequent	time-points	of	12,	
24,	 48	 72,	 96	 and	 120	 hours,	 where	 possible.	 Individual	 identifier	 numbers	 were	
assigned	to	each	patient	with	the	patient’s	sex	and	age	indicated	on	the	label	of	each	
collection	 sample.	 No	 other	 personal	 information	 was	 provided	 to	 protect	 the	
patient’s	 identity.	Patient	outcomes	were	unknown	until	sample	data	was	provided	
to	 AMNCH.	 Patients	 with	 a	 previous	 history	 of	 chronic	 pancreatitis	 and	 aged	 <18	
years	of	age	were	to	be	excluded	from	this	study.	Samples	were	stored	at	-20°C	as	
soon	as	possible	after	collection	and	were	thawed	overnight	at	+4°C	prior	to	analysis	
using	the	competitive	ELISA	and	lateral	flow	prototypes.	
	
	
		 	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Chapter	3	
	
Development	of	a	
Monoclonal	Anti-TAP	ELISA	
	
	
	
	
	
	
	
	
	
	
	
	
	
		 49	
3.1	 INTRODUCTION	
	
The	advent	of	the	radio-immunoassay	(RIA)	for	detection	of	antigens	or	analytes	of	
interest	by	Yalow	and	Berson	in	1960	was	met	with	instant	acclaim	from	researchers	
and	clinicians	alike.	However,	the	safety	and	waste	disposal	concerns	associated	with	
this	detection	method	encouraged	the	development	and	introduction	of	alternative	
immunoassay	 techniques	 that	 utilised	 enzyme-labeled	 antibodies	 or	 antigens	 for	
detection	 of	 other	 antibodies	 or	 antigens.	 	 These	 enzyme	 labels	 interact	 with	
substrates	 to	 generate	 coloured,	 luminescent	 or	 fluorescent	 products	 that	 can	 be	
measured	and	quantified.	From	this	work,	the	enzyme-linked	immunosorbent	assay	
(ELISA)	 was	 spawned	 to	 create	 a	 method	 whose	 unparalleled	 and	 far-reaching	
impact	 on	 scientific	 research	 and	 the	 diagnostics	 and	 medical	 industries	 are	 still	
being	 witnessed	 today	 (Lequin,	 2005).	 ELISAs	 are	 generally	 highly	 sensitive	 and	
specific	for	the	antigen	of	interest	with	wide-ranging	detection	methodologies.	They	
can	 be	 produced	 at	 a	 low-cost	 and	 only	 small	 amounts	 of	 reagents	 are	 required.	
They	are	flexible	and	easy	to	reproduce,	thus	allowing	for	adaption	from	manual	to	
automated	high-throughput	use	(O’Kennedy	et	al.,	1990).	
ELISA	 methods	 include	 multiple	 test	 formats	 with	 two	 main	 classification	
groups	 –	 competitive	 and	 non-competitive.	 Competitive	 immunoassays	 include	
formats	where	enzyme-labeled	antigen	and	unlabeled	‘free’	antigen	in	a	test	sample	
compete	for	binding	to	an	antibody	immobilised	onto	a	solid	phase	i.e.	the	microtitre	
plate	well,	or	enzyme-labeled	antibody	and	unlabeled	antibody	compete	for	binding	
to	 an	 immobilised	 antigen.	 The	 product	 formed	 in	 these	 assays	 is	 inversely	
proportional	to	the	target	antigen/antibody	concentration,	i.e.	the	higher	the	target	
concentration	 within	 the	 test	 sample,	 the	 lower	 the	 amount	 of	 enzyme	 activity	
detected.	In	the	non-competitive	immunoassay	format,	immobilised	antibody	binds	
to	 antigen	 in	 the	 test	 sample	 before	 a	 second	 enzyme-labeled	 antibody	 binds	 the	
captured	antigen	at	an	alternative	site.	This	 is	also	called	a	sandwich	 immunoassay	
and	 uses	 both	 capture	 and	 detection	 antibodies.	 Furthermore,	 binding	 of	
immobilised	 antigen	 by	 an	 antibody	 that	 is	 subsequently	 bound	 by	 an	 enzyme-
labeled	 secondary	 antibody	 specific	 to	 this	 antibody	 is	 also	 possible.	 The	 resulting	
enzyme	activity	of	 these	assays	 is	directly	proportional	 to	 the	 target	concentration	
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(O’Kennedy	 et	 al.,	 1990;	 Wild	 2006).	 Competitive	 assays	 are	 often	 used	 for	 the	
detection	 of	 small	 molecular	 weight	 analytes	 that	 cannot	 be	 detected	 at	 two	
individual	sites	in	a	sandwich	assay	format.	The	TAP	antigen	was	too	small	for	a	non-
competitive	 assay	 and	 consequently,	 a	 competitive	 assay	 format	was	 selected	 for	
development	 of	 an	 ELISA	 prototype	 (Figure	 3.1.1).	 This	 format	 entailed	 the	
conjugation	of	 the	TAP	analyte	 to	a	horseradish	peroxidase	 (HRP)	enzyme	and	 the	
coating	of	the	anti-TAP	capture	antibody	to	the	solid	phase	by	the	passive	adsorption	
method.	This	immobilisation	technique	is	still	not	fully	understood	but	is	thought	to	
involve	 both	 charge	 and	 hydrophobic	 interactions.	 The	 charge	 of	 the	 coating	
antibody	 can	 be	 controlled	 by	 the	 pH	 of	 the	 buffer	 that	 is	 used	 in	 the	 coating	
process.	 A	 carbonate	 buffer	 (0.05M,	 pH	 9.6)	 is	 routinely	 used	 for	 this	 process	
together	 with	 sufficient	 temperature	 control	 and	 incubation	 time	 to	 allow	 for	
saturation	of	the	solid	phase.	Any	remaining	sites	on	the	solid	phase	that	have	not	
been	 coated	 are	 traditionally	 blocked	 with	 inexpensive	 proteins	 such	 as	 bovine	
serum	 albumin	 to	 prevent	 the	 possibility	 of	 non-specific	 binding	 of	 assay	
components	such	as	the	enzyme	conjugate	to	the	plastic	surface	(Deshpande,	1996).	
The	 optimisation	 of	 assay	 conditions	 including	 incubation	 time	 and	 the	
preparation	 and	 selection	 of	 the	 optimal	 buffer	 formulations	 and	 reagents	 is	 an	
essential	 part	 of	 the	 development	 process	 that	must	 also	 be	 carefully	 considered.	
Buffer	solutions	provide	a	controlled	aqueous	environment	(usually	by	maintaining	a	
constant	pH	value)	for	antibody-antigen	binding	to	occur.	Phosphate-buffered	saline	
(PBS)	(0.15M,	pH	7.4)	and	tris-buffered	saline	(TBS)	(0.05M,	pH	7.5)	solutions	contain	
buffer	salts	that	help	maintain	the	pH	range	of	reactions.	Additional	buffer	reagents	
can	 provide	 specific	 functions	 that	 warrant	 their	 inclusion	 in	 the	 formulation.	 For	
example,	Tween20	detergent	in	assay	wash	buffers	can	prevent	non-specific	binding	
and	support	homogeneous	distribution	of	the	protein	 in	conjugate	dilution	buffers.	
Use	of	3,	3’,	5,	5’-tetramethylbenzidene	(TMB)	substrate	is	recommended	for	assays	
using	horseradish	peroxidase	 (HRP)	conjugates	due	 to	 the	 rapid	development	 time	
and	 improved	assay	 sensitivity	versus	other	 substrate	alternatives.	However,	 some	
reagents	 can	 bring	 negative	 effects,	 for	 example,	 sodium	 azide	 used	 as	 a	
preservative	 to	 inhibit	 bacterial	 growth	 can	 also	 impede	HRP	 activity	 (Deshpande,	
1996).	
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Figure	3.1.1	Com
petitive	anti-TAP	m
onoclonal	ELISA	form
at.	Biotinylated	anti-TAP	capture	antibody	is	incubated	w
ith	streptavidin-coated	
m
icrotitre	plate	w
ells.	U
nbound	capture	antibody	is	rem
oved	by	w
ashing.	A	1:1	m
ixture	of	“neat”	(no	dilution)	urine	sam
ple	and	diluted	TAP-
HRP	conjugate	w
ere	loaded	into	the	w
ells.	Both	“free”	and	conjugated	TAP	analyte	com
pete	for	binding	to	the	capture	antibody.	U
nbound	
analyte	and	conjugate	are	rem
oved	by	w
ashing	and	TM
B	substrate	is	added	to	the	assay	w
ells.	The	HRP	conjugate	oxidises	the	TM
B	substrate	
into	a	coloured	product	before	the	reaction	is	quenched	by	addition	of	sulphuric	acid.	The	absorbance	of	the	coloured	product	is	detectable	by	
spectrophotom
etric	m
ethods.		1:	TAP	N
egative	urine	sam
ple	testing	-	TAP-HRP	conjugate	binds	to	capture	antibody	w
hen	no	free	antigen	is	
present.	2:	TAP	Positive	urine	sam
ple	–	TAP	analyte	binds	to	capture	antibody	in	place	of	HRP-conjugated	analyte.	3:	The	colour	developm
ent	
from
	the	binding	reaction	is	inversely	proportional	to	the	analyte	concentration	present	in	the	w
ells,	i.e.	low
er	colour	intensity,	m
ore	analyte	
present	and,	highest	intensity	for	analyte-free	sam
ple.	
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3.2	 AIMS	OF	THIS	CHAPTER	
	
The	development	of	a	competitive	ELISA	prototype	for	the	detection	of	urinary	TAP	
will	be	described.	
	
The	 development	 of	 this	 test	 will	 involve	 the	 characterisation	 of	 the	 monoclonal	
anti-TAP	 antibody,	 conjugation	 of	 the	 TAP	 antigen	 to	 HRP,	 optimisation	 of	 assay	
conditions,	 including	 plate	 coating	 saturation	 and	 selection	 of	 standard	 calibration	
curve	and	the	preparation	of	 internal	control	samples	that	can	be	used	to	monitor	
assay	performance	and	establish	assay	robustness.	
	
	
	
	
3.3	 RESULTS	
	
3.3.1	 Characterisation	of	rabbit	monoclonal	14-8	anti-TAP	antibody	
	
The	 purified	 rabbit	 monoclonal	 anti-TAP	 IgG	 antibody	 was	 produced	 by	 AbCam®	
from	 hybridoma	 supernatant	 using	 protein	 A	 affinity	 chromatography.	 Three	
individual	purified	antibody	stocks	were	obtained	and	assessed	by	sodium	dodecyl-
sulphate	polyacrylamide	gel	electrophoresis	(SDS-PAGE)	analysis	(see	section	2.2.1).	
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Lane:	 	Sample	ID	 	Sample	Type	
1	 MARKER	 	MARKER	
2	 B_4168	(5	μg)	 Capture	mAb,	1.09	mg/mL	
3	 B_4168	(10	μg)	 Capture	mAb,	1.09	mg/mL	
4	 B_4346	(5	μg)	 Capture	mAb,	0.93	mg/mL	
5	 B_4346	(10	μg)	 Capture	mAb,	0.93	mg/mL	
	
Figure	3.3.1.1	SDS-PAGE	analysis	of	rabbit	monoclonal	anti-TAP	IgG	antibodies	(lots	
B_4168	and	B_4346).	The	heavy	chain	domain	was	observed	at	~50kDa	and	the	light	
chain	domain	at	~25kDa	for	both	lots	of	antibody.	The	heavy	and	light	chains	were	
both	 consistent	 with	 the	 expected	 molecular	 weights	 of	 an	 IgG	 antibody.	 Two	
different	concentrations	(5	and	10	μg)	were	run	to	ensure	protein	band	visibility.	As	
expected,	slightly	larger	bands	were	observed	for	the	10	μg	samples,	nonetheless,	5	
μg	 was	 sufficient	 for	 characterisation.	 Both	 lots	 of	 antibody	 were	 comparable.	
Additional	contaminating	bands	were	observed	around	the	light	chain	for	lot	B_4168	
(strongest	 in	 Lane	 2).	 It	 was	 possible	 that	 these	 bands	 were	 due	 to	 minor	
contaminants	from	the	supernatant	or	insufficient	denaturation	of	the	antibody.	This	
was	 feasible	 as	 the	 bands	 were	 clearer	 at	 the	 higher	 concentration	 of	 10	 μg.	
Nonetheless,	 lot	B_4168	was	selected	 for	 the	ELISA	prototype	development	as	 this	
had	the	largest	stock	availability.	
			1											2											3											4												5 kDa 
98 
62 
49 
38 
28 
14 
6 
3 
		 54	
	
	
Lane:	 Sample	ID	 Sample	Type	
1	 MARKER	 MARKER	
2	 B_37042	(5	μg)	 0.52	mg/mL.	EKF	5X	Reducing	Buffer	
3	 B_37042	(8.3	μg)	 0.52	mg/mL.	EKF	5X	Reducing	Buffer	
4	 B_37042	(5	μg)	 0.52	mg/mL.	5X	Non-Reducing	Buffer	with	fresh	2-mercaptoethanol	
5	 B_37042	(8.3	μg)	 0.52	mg/mL.	5X	Non-Reducing	Buffer	with	fresh	2-mercaptoethanol	
	
Figure	 3.3.1.2	 SDS-PAGE	 analysis	 of	 rabbit	 monoclonal	 anti-TAP	 IgG	 antibody	 (lot	
B_37042).	 Heavy	 and	 light	 chain	 domains	 were	 observed	 at	 ~50	 and	 ~25kDa,	
respectively.	This	was	consistent	with	previous	antibody	lots	(Figure	3.3.1.1).	The	8.3	
μg	 sample	 was	 run	 in	 place	 of	 a	 10	 μg	 sample	 due	 to	 the	 low	 antibody	 stock	
concentration	(0.52	mg/mL).	Concentration	by	ultracentifugation	was	not	attempted	
at	this	time	to	limit	use	of	antibody	stock	for	future	use,	if	required.	Reducing	buffer	
referred	to	a	formulation	that	included	2-mercaptoethanol	and	non-reducing	buffer	
contained	 no	 2-mercaptoethanol	 until	 addition	 immediately	 before	 use.	 No	
difference	 was	 observed	 for	 protein	 bands	 resulting	 from	 these	 buffers,	 and	 only	
very	minor	 contaminating	 bands	 were	 observed	 when	 compared	 with	 lot	 B_4168	
(Figure	 3.3.1.1).	 The	 non-reducing	 buffer	 formulation	 appeared	 to	 improve	 the	
appearance	 of	 these	 additional	 bands,	 suggesting	 that	 the	 contaminating	 bands	
were	due	to	insufficient	denaturation	of	the	antibodies.	Extended	boiling	of	samples	
may	have	improved	this	further.	
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No	 characterisation	 of	 the	 TAP	 antigen	 by,	 for	 example,	 Western	 blot,	 was	
undertaken	 due	 to	 the	 small	 size	 of	 the	 peptide	 (~770	 Da)	 and	 the	 limited	 stock	
availability	 for	 this	 project.	 In	 addition,	 the	 exact	 structure	 of	 the	 synthesized	
peptide	was	known	and	controlled	by	instructions	delivered	to	Bachem®.		
	
	
3.3.2	 Saturation	testing	for	monoclonal	14-8	anti-TAP	antibody	coated	by	passive	
adsorption	to	the	microtitre	assay	plate	and	titration	of	TAP-HRP	conjugate	
	
The	 initial	 competitive	 ELISA	 prototype	 was	 prepared	 by	 coating	 the	 monoclonal	
anti-TAP	antibody	onto	 the	microtitre	plate	 surface	via	passive	adsorption.	Passive	
adsorption	 involves	the	 immobilisation	of	the	capture	antibody	onto	the	microtitre	
plate	 through	 van	 der	 Waals	 forces	 developed	 during	 incubation	 over	 time	
(Deshpande,	1996).	The	TAP	antigen	was	conjugated	to	HRP	using	a	commercial	kit	
from	Innova	Biosciences	(section	2.2.3)	for	use	in	colourimetric	signal	development	
in	the	presence	of	TMB	susbstrate.	This	kit	binds	primary	amine	and	lysine	groups	on	
the	peptide	and	HRP	molecules.	The	TAP-HRP	conjugate	competes	for	binding	to	the	
immobilised	 antibody	 with	 TAP	 antigen	 calibrator	 standards	 prepared	 at	
predetermined	 concentrations	 or,	 “free”	 TAP	 antigen	 present	 in	 urine	 samples.	
Various	concentrations	(2,	4,	6	and	8	μg/mL)	of	anti-TAP	antibody	were	coated	onto	
microtitre	plates	(section	2.2.2)	and	their	saturation	points	compared	i.e.	where	an	
increase	 in	 immobilised	 antibody	 concentration	 does	 not	 lead	 to	 enhanced	 signal	
development.		
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Figure	 3.3.2.1	 Saturation	 testing	 of	 monoclonal	 anti-TAP	 antibody.	 No	 notable	
difference	 was	 observed	 between	 coating	 concentrations,	 and	 thus,	 the	 2	 μg/mL	
concentration	 was	 selected	 for	 further	 use	 to	 minimise	 antibody	 use	 and	 reduce	
costs	for	future	manufacture.	
	
	
	
Figure	 3.3.2.2	 TAP-HRP	 conjugate	 titration	 using	 microtitre	 plates	 coated	 with	 2	
μg/mL	 anti-TAP	mAb.	 Increasing	 conjugate	 dilution	 resulted	 in	 a	 reduction	 of	 the	
assay	 signal,	 with	 dilutions	 of	 1/25,000	 up	 to	 1/1,600,000	 tested.	Microtitre	 plate	
wells	coated	with	buffer	only	(0	μg/mL)	were	used	as	a	control	to	demonstrate	that	
there	was	no	non-specific	binding	of	the	TAP-HRP	conjugate	to	the	plastic	microtitre	
wells	 in	 the	 absence	 of	 immobilised	 anti-TAP	 antibody,	 a	 highly	 important	
characteristic	of	any	robust	ELISA.	
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3.3.3	 Standard	 curve	 generation	 for	 monoclonal	 anti-TAP	 ELISA	 prototype	
(coated	by	passive	adsorption)		
	
To	assess	the	performance	of	this	ELISA	prototype,	a	standard	calibration	curve	was	
prepared	using	the	TAP	antigen	diluted	into	sample	diluent	(proprietary)	as	follows:	
	
Calibrator	
(nmol/L)	
Calibrator	
Volume	(μL)	
Diluent	
Volume	(μL)	
200	(A)	 20	(i)*	 980	
100	(B)	 200	(A)	 200	
50	(C)	 200	(B)	 200	
25	(D)	 200	(C)	 200	
12.5	(E)	 200	(D)	 200	
6.3	(F)	 200	(E)	 200	
3.1	(G)	 200	(F)	 200	
0	(H)	 0	 200	
	
*(i)	Intermediate	dilution	of	TAP	antigen:	1/100	=	1	μL	(TAP	antigen)	+	99	μL	(diluent).	
(A)	–	 (H)	 refers	 to	calibrator	names	and	are	used	to	 track	dilution	preparation.	For	
example,	 calibrator	 (B)	 was	 prepared	 at	 a	 concentration	 of	 100	 nmol/L	 by	 the	
addition	of	200	μL	of	calibrator	(A)	to	200	μL	of	sample	diluent.	
	
The	 assay	 was	 performed	 as	 described	 in	 section	 2.2.4	 using	 conjugate	 dilutions	
ranging	from	1/10,000	to	1/50,000.		
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Figure	 3.3.3.1	 Standard	 calibration	 curve	 test	 using	 various	 TAP-HRP	 conjugate	
dilutions	 and	 2	 μg/mL	 anti-TAP	 antibody-coated	 microtitre	 plates.	 The	 calibrator	
standard	 range	was	0	 -	 200	nmol/L.	 This	prototype	appeared	 to	 lack	 the	ability	 to	
distinguish	between	TAP	standards	while	also	limiting	the	amount	of	conjugate	used,	
i.e.	maintaining	a	higher	dilution	and	thus	reducing	the	stock	material	requirements.	
Additionally,	producing	an	acceptable	signal	that	could	withstand	a	certain	drop-off	
over	 a	 period	 of	 time,	 ensuring	 reproducibility	 of	 the	 standard	 curve	 was	 of	 high	
importance.	This	allowance	 lengthens	the	shelf	 life	of	any	product,	as	a	drop-off	 in	
activity	for	biological	material	 is	 inevitable.	Internal	observations	at	EKF	Diagnostics	
have	pointed	to	an	OD	of	approximately	2.5	as	a	satisfactory	target	for	the	highest	
level	 (top	 standard)	of	a	 calibration	curve.	This	 is	 reversed	 for	a	 competitive	ELISA	
where	 the	blank	or	 zero	 standard	 should	provide	 the	highest	 signal	 response.	 The	
zero	 standard	 OD	 absorbance	 varied	 from	 3.1	 to	 1.0	 for	 conjugate	 dilutions	 of	
1/10,000	to	1/50,000,	respectively.	
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3.3.4	 Saturation	testing	for	biotinylated	monoclonal	14-8	anti-TAP	antibody	when	
used	with	a	streptavidin-coated	microtitre	assay	plate	
	
Due	to	the	perceived	lack	of	sensitivity	for	the	monoclonal	anti-TAP	antibody	and	the	
limited	 time	 available	 to	 generate	 an	 alternative	 antibody,	 it	 was	 decided	 that	
biotinylation	 of	 the	 current	 anti-TAP	 antibody	 using	 a	 commercial	 kit	 from	 Innova	
Biosciences,	was	the	best	option	(section	2.2.5).	The	biotin-streptavidin	system	is	a	
highly	 specific,	non-covalent	 interaction	 that	has	been	employed	 in	applications	of	
biotechnology,	 including	 immunoassays.	 As	 a	 small	 molecule,	 biotin	 (vitamin	 H)	
usually	does	not	alter	the	biological	properties	of	macromolecule	complexes	upon	its	
introduction.	 Biotinylation	 of	 antibodies	 generally	 involves	 the	 irreversible	 labeling	
of	 primary	 amine	 groups,	 such	 as	 lysine,	 using	 an	 N-hydroxysuccinimide	 ester	
attached	to	a	biotin	molecule	by	a	long	chain	which	ensures	that	the	biotin	is	more	
exposed	 for	 binding	 to	 the	 streptavidin	 protein.	 Streptavidin	 is	 a	 protein	 isolated	
from	 the	 bacterium	 Streptomyces	 avidinii	 that	 is	 used	 in	 place	 of	 the	 traditional	
avidin	 (from	egg-white)	due	 to	 its	 lower	non-specific	binding	capacity.	 Streptavidin	
contains	 four	 biotin-binding	 sites	 per	 molecule,	 adding	 to	 the	 highly	 specific	
interaction	 that	 is	 103-106	 times	 greater	 than	 the	 interaction	 of	 ligands	with	 their	
specific	 antibodies.	 Through	 this	 increased	 specificity,	 coating	 of	 the	 anti-TAP	
antibody	onto	the	microtitre	plate	and	assay	sensitivity	are	improved	(Diamandis	&	
Christopoulos,	 1991;	 Ylikotila	et	 al.,	 2009).	 The	biotinylated	 anti-TAP	 antibody	was	
incubated	with	a	streptavidin-coated	microtitre	plate	(Fisher	Scientific)	and	the	assay	
performed	as	described	by	section	2.2.6.	
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Figure	3.3.4.1	Checkerboard	 testing	 for	 biotinylated	monoclonal	 anti-TAP	 antibody	
incubated	 with	 streptavidin-coated	 microtitre	 assay	 plate.	 Conjugate	 dilutions	 of	
1/25,000	 to	 1/800,000	 were	 tested	 with	 biotinylated	 anti-TAP	 antibody	
concentrations	 ranging	 from	0	–	10.0	μg/mL.	The	0.3125	μg/mL	concentration	was	
selected	for	use	in	this	prototype	due	to	similar	performance	when	compared	to	the	
higher	concentrations	of	0.625	–	10.0	μg/mL.	The	zero	μg/mL	microtitre	plate	wells	
demonstrated	 that	 there	was	no	non-specific	binding	of	 the	TAP-HRP	conjugate	 to	
the	 streptavidin-coated	 microtitre	 wells	 in	 the	 absence	 of	 biotinylated	 anti-TAP	
antibody.	 Increasing	 conjugate	 dilution	 resulted	 in	 a	 reduction	 of	 the	 assay	 signal	
towards	zero	in	all	other	conditions	tested,	as	expected.		
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3.3.5	 Comparison	 of	 streptavidin	 /	 biotinylated	 anti-TAP	 ELISA	 and	 passive	
adsorption	anti-TAP	ELISA	
	
To	compare	the	different	ELISA	formats;	standard	calibration	curves	were	prepared	
for	both	assays	with	prepared	calibrators	of	0,	3.1,	6.3,	12.5,	25,	50,	100,	200,	500	
and	 1000	 nmol/L.	 Assays	 were	 performed	 as	 per	 sections	 3.3.3	 and	 3.3.4,	
respectively.	The	calibration	curves	were	prepared	as	follows:	
	
Calibrator	
(nmol/L)		
Calibrator	
Volume	(μL)	
Diluent	
Volume	(μL)	
1000	(A)	 50	(i)*	 450	
500	(B)	 300	(A)	 300	
200	(C)	 160	(B)	 240	
100	(D)	 300	(C)	 300	
50	(E)	 300	(D)	 300	
25	(F)	 300	(E)	 300	
12.5	(G)	 300	(F)	 300	
6.3	(H)	 300	(G)	 300	
3.1	(I)	 300	(H)	 300	
0	(J)	 0	 300	
	
*(i)	Intermediate	dilution	of	TAP	antigen:	1/100	=	1	μL	(TAP	antigen)	+	99	μL	(diluent).	
(A)	 –	 (J)	 refers	 to	 calibrator	names	and	are	used	 to	 track	dilution	preparation.	 For	
example,	 calibrator	 (B)	 was	 prepared	 at	 a	 concentration	 of	 500	 nmol/L	 by	 the	
addition	of	300	μL	of	calibrator	(A)	to	300	μL	of	sample	diluent.	
	
	
		 62	
	
	
Figure	 3.3.5.1	 Comparison	 of	 calibration	 curves	 for	 streptavidin/biotinylated	 anti-
TAP	 ELISA	 and	 passive	 adsorption	 anti-TAP	 ELISA	 formats.	 The	 A/A0	 values	 were	
calculated	 as	 calibrator	 mean	 OD	 response	 divided	 by	 zero	 calibrator	 mean	 OD	
response	 times	 100	 to	 express	 as	 a	 percentage.	 This	 calculation	 normalised	 the	
absorbance	 or	 OD	 response	 for	 each	 calibrator	 (A-I)	 against	 the	 maximum	 OD	
response	for	the	zero	calibrator	(J).	B_4168	refers	to	the	lot	number	of	the	anti-TAP	
antibody	 used.	 TAP-HRP	 conjugate	 was	 utilised	 at	 a	 1/50,000	 dilution.	 The	 half	
maximal	 inhibitory	 concentrations	 (IC50)	 were	 23.3	 nmol/L	 (dashed	 blue	 line)	 and	
44.7	nmol/L	(dashed	purple	line)	for	the	streptavidin/biotinylated	anti-TAP	ELISA	and	
the	passive	adsorption	anti-TAP	ELISA	curves,	respectively	(Findlay	&	Dillard,	2007).	
The	streptavidin/biotinylated	anti-TAP	ELISA	demonstrated	an	ability	to	offer	greater	
discrimination	between	calibrator	responses	with	a	more	even	distribution	between	
calibrator	responses	overall	and	importantly,	at	the	lower	end	of	the	curve	between	
calibrators	6.3,	12.5	and	25	nmol/L.	 The	passive	adsorption	anti-TAP	ELISA	offered	
greater	discrimination	at	the	upper	end	of	the	curve,	but	this	was	of	less	value	based	
on	TAP	concentrations	described	 in	 the	 literature	 for	patients	of	acute	pancreatitis	
(Neoptolemos	et	al.,	2001).	These	results	also	 indicated	that	the	upper	 limit	of	 the	
measuring	 range	was	 close	 to	 1000	nmol/L.	 Further	 optimisation	 could	 potentially	
improve	the	sensitivity	of	the	streptavidin/biotinylated	anti-TAP	ELISA	at	this	 lower	
limit	of	the	measuring	range.		
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3.3.6	 Comparison	 of	 three	 monoclonal	 anti-TAP	 IgG	 antibody	 lots	 in	 the	
streptavidin	/	biotinylated	anti-TAP	ELISA	
	
Three	individual	lots	of	anti-TAP	antibody	were	received	for	this	project	from	AbCam	
International.	 Each	 lot	 of	 antibody	 was	 concentrated	 to	 ~1	mg/mL	 as	 per	 section	
2.2.7.1,	with	concentrations	confirmed	by	use	of	the	Nanodrop	spectrophotometer	
(A280nm).	 The	 ranges	 of	 the	 calibration	 curves	were	 extended	 (0	 –	 1600	 nmol/L)	 in	
order	to	determine	the	entire	measurement	capacity	for	the	prototype.	Calibration	
curves	were	prepared	for	testing	with	each	lot	as	follows:	
	
Calibrator	
(nmol/L)		
Calibrator	
Volume	(μL)	
Diluent	
Volume	(μL)	
1600	(A)	 128	(i)*	 672	
800	(B)	 300	(A)	 300	
400	(C)	 300	(B)	 300	
200	(D)	 300	(C)	 300	
100	(E)	 300	(D)	 300	
50	(F)	 300	(E)	 300	
25	(G)	 300	(F)	 300	
12.5	(H)	 300	(G)	 300	
6.3	(I)	 300	(H)	 300	
3.1	(J)	
1.56	(K)		
0.78	(L)	
0.39	(M)	
300	(I)	
300	(J)	
300	(K)	
300	(L)	
300	
300	
300	
300	
0	(N)	 0	 300	
	
*(i)	 Intermediate	 dilution	 of	 TAP	 antigen:	 1/100	 =	 2	 μL	 (TAP	 antigen)	 +	 198	 μL	
(diluent).	 (A)	 –	 (M)	 refers	 to	 calibrator	 names	 and	 are	 used	 to	 track	 dilution	
preparation.	 For	 example,	 calibrator	 (B)	 was	 prepared	 at	 a	 concentration	 of	 800	
nmol/L	by	the	addition	of	300	μL	of	calibrator	(A)	to	300	μL	of	sample	diluent.	
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Figure	3.3.6.1	Comparison	of	three	separate	 lots	of	biotinylated	anti-TAP	antibody.	
Performance	 of	 all	 three	 biotinylated	 anti-TAP	 antibodies	 was	 comparable,	
demonstrating	reproducibility	of	the	method	and	ensuring	that	individual	batches	of	
prototype	 could	 be	 produced	with	 uniform	performance	 across	 all	 batches	 should	
any	 potential	 commercial	 use	 arise.	 Extension	 of	 the	 calibrator	 curve	 at	 both	 the	
lower	 and	 upper	 ends	 allowed	 for	 a	 clearer	 definition	 of	 the	 lower	 and	 upper	
limitations	 to	 the	measuring	 range.	 The	 calibrator	 dilutions	 of	 0.39,	 0.78	 and	 1.56	
nmol/L	demonstrated	that	the	curve	did	not	plateau	at	the	3.1	nmol/L	calibrator	as	
the	 streptavidin/biotinylated	 anti-TAP	 ELISA	 curve	 for	 lot	 B_4168	 appeared	 to	
indicate	 in	 Figure	 3.3.5.1.	 Also,	 the	 OD	 absorbance	 (<0.01)	 for	 the	 1600	 nmol/L	
calibrator	sample	was	comparable	across	all	curves	and	thus,	the	upper	limit	of	the	
calibration	 curve	was	 also	determined.	With	 the	extended	measuring	 range	of	 the	
calibration	curve	defined,	optimisation	could	be	pursued.	
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3.3.7	 Freeze-thaw	stability	study	of	TAP	antigen	in	various	matrices	
	
A	stability	study	was	designed	to	determine	any	effects	on	the	peptide	antigen	when	
stored	at	-20°C	and	thawed	at	room	temperature	for	use.	This	study	investigated	the	
effect	 of	 the	 freeze-thaw	 action	 on	 peptide	 concentration	when	 spiked	 into	 three	
different	 matrices	 –	 dH20,	 urine	 and	 stabilised	 urine.	 Stabilised	 urine	 had	 7.5mM	
EDTA	 buffer	 at	 a	 1/5	 dilution	 (1	 part	 buffer	 to	 4	 parts	 of	 urine)	 added.	 EDTA	 is	 a	
known	 chelating	 agent	 used	 to	 bind	 metal	 ions	 required	 for	 catalytic	 activity	 of	
metallopeptidases,	which	could	potentially	degrade	the	TAP	antigen.		
	
	
	
Analyte	 recovery	 for	 initial	 freeze-thaw	 cycle	 in	 each	 matrix	 was	 calculated	 as	
follows:	
	
Recovery	(%)	=	Freeze-Thaw	Cycle	1	Concentration	x	100	
				 			 	 														Freeze-Thaw	Cycle	1	Concentration	
	
	
	
Analyte	 recovery	 in	 each	 matrix	 following	 initial	 freeze-thaw	 cycle	 (FTx1)	 was	
calculated	using	the	following	formula:	
	
Recovery	(%)	=	Observed	Analyte	Concentration				x	100	
				 			 	 												Freeze-Thaw	Cycle	1	Concentration	
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Table	3.3.7.1	Effect	of	freeze-thawing	on	peptide	concentration	in	various	matrices:	
	
Matrix	 Sample	 FT	Cycle	 Conc.	(nmol/L)	 %Rec	vs	FTx1	
dH2O	
1	
1	 289.4	 100	
2	 294.6	 102	
3	 315.4	 109	
2	
1	 161.9	 100	
2	 150.5	 93	
3	 178.7	 110	
3	
1	 86.4	 100	
2	 82.2	 95	
3	 95.6	 111	
4	
1	 23.1	 100	
2	 23.8	 103	
3	 25.3	 110	
Urine	
1	
1	 249.1	 100	
2	 227.5	 91	
3	 240.9	 97	
2	
1	 145.4	 100	
2	 138.8	 95	
3	 143.1	 98	
3	
1	 74.3	 100	
2	 75.1	 101	
3	 71.8	 97	
4	
1	 19.6	 100	
2	 18.0	 92	
3	 20.2	 103	
Urine	Stabilised	
1	
1	 236.4	 100	
2	 257.5	 109	
3	 252.3	 107	
2	
1	 150.7	 100	
2	 138.4	 92	
3	 123.4	 82	
3	
1	 66.5	 100	
2	 72.8	 109	
3	 68.7	 103	
4	
1	 21.1	 100	
2	 21.4	 101	
3	 22.2	 105	
	
Samples	1	–	4	were	prepared	by	spiking	TAP	antigen	into	each	matrix	at	approximate	
concentrations	 of	 200,	 100,	 50	 and	 25	 nmol/L.	 Recovery	 of	 initial	 peptide	
concentration	 was	 acceptable	 (100	 ±	 10%)	 across	 all	 matrices	 tested,	 with	 the	
exception	of	FTx3	for	sample	2	in	stabilised	urine.	The	higher	recovery	at	FTx3	for	the	
samples	stored	in	dH20	was	probably	due	to	assay	variation.	This	demonstrated	that	
storage	 of	 the	 peptide	 in	 dH20	 was	 suitable	 for	 reconstitution	 of	 stocks.	 Peptide	
concentration	in	urine	was	not	affected	following	up	to	3	freeze-thaw	cycles	and	no	
difference	in	peptide	recovery	was	observed	upon	addition	of	stabilisation	buffer	to	
urine.	This	indicates	that	urine	samples	can	be	collected	and	stored	at	-20°C	without	
the	need	for	an	additional	stabilising	step.	
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3.3.8	 Optimisation	 of	 standard	 calibration	 curve	 for	 streptavidin	 /	 biotinylated	
anti-TAP	ELISA	
	
To	 finalise	 the	 calibration	 curve	 for	 use	 in	 performance	 testing	 of	 the	 ELISA	
prototype,	an	extended	curve	(0,	0.8,	1.6,	3.1,	6.3,	12.5,	25,	50,	100,	200,	400,	800,	
1600	nmol/L)	was	tested	before	selection	of	the	optimal	standards	to	be	included	in	
the	calibration	curve.	Each	standard	was	 tested	 in	 triplicate	 (n=3)	and	additionally,	
Quality	 Control	 (QC)	 urine	 samples	 were	 tested	 in	 quadruplicate	 (n=4).	 The	 QC	
samples	were	prepared	by	spiking	TAP	antigen	into	pooled	bulk	urine	sourced	from	
an	 apparently	 healthy	 donor	 (no	 known	 clinical	 illness)	 group	 at	 theoretical	
concentrations	 of	 200,	 110,	 50	 and	 20	 nmol/L	 for	 QC	 samples	 1-4,	 respectively.	
Further	 discussion	 of	 this	 sample	 panel	 is	 described	 in	 section	 3.3.9	 below.	 The	
variation	between	replicates	or	the	repeatability	to	produce	an	OD	response	close	to	
the	average	of	all	replicates	of	a	standard/sample	was	calculated	to	demonstrate	the	
robustness	 of	 the	 calibration	 curve	 and	 evaluate	 operator	 error.	 To	 define	 the	
precision	between	replicates,	the	coefficient	of	variation	(CV)	was	determined	using	
the	following	formula:	
	
	
Precision	=	CV	(%)	=	Standard	Deviation	x	100	
																									Mean	
	
	
	
Analyte	 recovery	 for	 calibration	 curve	 and	 QC	 sample	 panel	 was	 calculated	 as	
follows:	
	
Recovery	(%)	=	Observed	Concentration	x	100	
				 			 	 																						Theoretical	Concentration	
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Two	separate	software	programmes	were	used	to	plot	the	standard	calibration	curve	
of	the	streptavidin/biotinylated	anti-TAP	ELISA.	GEN5	MicroPlate	Reader	software	is	
validated	 software	 (US	 FDA’s	 21	 CFR	 Part	 11	 and	 ISO	 9001/ISO	 13485	 software	
requirements)	 provided	 by	 Biotek	 Instruments,	 Inc.	 and	 is	 used	 in-house	 at	 EKF	
Diagnostics	 for	ELISA	development.	This	 software	has	 security	controls	 that	ensure	
the	 integrity	 of	 all	 data.	MyCurveFit	 is	 a	 free	 online	 curve-fitting	 tool	 provided	 by	
MyAssays	Limited	that	was	employed	for	an	independent	comparison	with	the	GEN5	
software.	A	four-parameter	logistic	(4-PL)	curve	with	non-linear	regression,	originally	
described	by	Healy	(1972),	was	employed	by	both	software	programmes	due	to	 its	
ability	to	fit	the	extremes	of	a	calibration	curve	better	and	produce	results	that	are	
less	 susceptible	 to	 variation	 compared	 to	 alternative	methods	 (Deshpande,	 1996).	
The	 curve	 equation	 utilises	 four	 independent	 parameters	 which	 models	 signal	
response	using	the	following	function:	
	
y	=	d	+	(a	–	d)	/	1	+	(X/c)b	
	
	
The	 parameters	 a	 and	 d	 refer	 to	 responses	 at	 zero	 and	 infinite	 calibrator	
concentration.	 The	 parameter	 c	 refers	 to	 the	 concentration	 of	 the	 calibrator,	
resulting	 in	 a	 decrease	 of	 A/A0	to	 a	 value	 at	 the	midpoint	 between	 a	 and	 d,	 also	
called	 IC50	 value,	 i.e.	 where	 the	 concentration	 of	 an	 inhibitor	 (in	 this	 case,	 TAP	
antigen)	 causes	 the	 OD	 response	 to	 be	 halved.	 The	 parameter	 b	 determines	 the	
steepness	of	the	curve	at	its	centre	or	any	other	point.	From	this,	the	concentration	
of	any	calibrator	 /	 sample	can	be	determined	using	 the	OD	response	“X”	 from	the	
curve	equation	(Findlay	&	Dillard,	2007).	
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Figure	3.3.8.1	GEN5	MicroPlate	Reader	 software	generated	standard	calibration	curve	 for	
streptavidin/biotinylated	anti-TAP	ELISA.	The	4-PL	curve	selected	to	plot	the	data	returned	
an	R2	value	=	0.999,	showing	that	the	standards	fitted	closely	to	the	curve	regression	line.	
Recovery	of	TAP	concentration	for	all	standards	was	within	100	±	20%.	Precision	testing	of	
the	 calibration	 curve	 over	 several	 days	would	 determine	 the	 true	 variability.	 Recovery	 of	
TAP	 concentration	 for	 all	QC	 samples	was	within	 100	 ±	 10%,	with	 the	 exception	 of	 QC4.	
Over-recovery	of	this	sample	was	irrelevant	at	this	time	due	to	the	calculation	being	based	
on	a	theoretical	concentration.	Actual	quantified	concentration	for	each	QC	sample	would	
need	to	be	established	over	several	days	of	testing.	
T P	(nmol/L)	
M
ea
n	
Ab
so
rb
an
ce
	(4
50
nm
)	
	
Calibrator 
(nmol/L) Mean OD CV (%) 
TAP 
(nmol/L) %Recovery 
400 0.137 5 >420.0 #VALUE! 
200 0.256 4 210.6 105 
100 0.47 2 90.5 91 
50 0.737 4 47.3 95 
25 1.115 5 23.9 96 
12.5 1.428 2 14.5 116 
6.3 1.93 1 6.3 101 
3.1 2.336 3 2.6 83 
0 2.752 3 <0.2 #VALUE! 	
Sample	 Mean	OD	 %CV	 TAP	(nmol/L)	 %Recovery		
QC1	 0.254	 4	 213.3	 107	
QC2	 0.421	 2	 105.6	 96	
QC3	 0.723	 2	 48.6	 97	
QC4	 1.102	 3	 24.4	 122		
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Figure	 3.3.8.2	 MyCurveFit	 software	 generated	 standard	 calibration	 curve	 for	
streptavidin/biotinylated	anti-TAP	ELISA.	Mean	values	from	GEN5	data	were	entered	
into	 MyCurveFit.com	 online	 account.	 Recovery	 of	 TAP	 concentration	 for	 all	
calibrators	and	samples	was	100	±	10%.	Slight	differences	 in	predicted	values	were	
observed	compared	to	GEN5	data,	however,	 these	were	negligible.	The	MyCurveFit	
software,	 therefore,	 represented	 a	 functional	 and	 easy	 to	 use	 tool	 for	 plotting	
calibration	 curve	 data	 in	 the	 absence	 of	GEN5	MicroPlate	 Reader	 software.	 As	 per	
GEN5,	a	4-PL	curve	fit	was	selected	to	plot	the	data	and	returned	an	R2	value	=	0.999.	
This	 is	 reflected	 in	 the	 agreement	 between	 the	 expected	 and	 predicted	
concentrations	for	the	calibrators	and	samples	tested.	
TAP	Calibrator	
(nmol/L)	 Mean	OD	
Predicted	TAP	
(nmol/L)	 %Recovery	
3.1	 2.336	 3.2	 101	
6.3	 1.930	 6.0	 97	
12.5	 1.428	 13.5	 108	
25	 1.115	 23.3	 93	
50	 0.737	 50.3	 101	
100	 0.470	 100.8	 101	
200	 0.256	 213.2	 107	
400	 0.137	 376.7	 94		
Sample	 Expected	TAP	(nmol/L)	
Predicted	TAP	
(nmol/L)	 %Recovery	
QC1	 200	 215.0	 107	
QC2	 110	 117.2	 107	
QC3	 50	 52.0	 104	
QC4	 20	 23.9	 119		
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3.3.9	 Establishment	 of	 urinary	 TAP	 quality	 control	 sample	 panel	 and	 intra	 and	
inter-assay	precision	for	streptavidin	/	biotinylated	anti-TAP	ELISA	
	
To	 establish	 a	 set	 concentration	 range	 for	 each	 of	 the	 QC	 panel	 samples	 and	
determine	 the	 intra	 and	 inter-assay	 precision	 of	 the	 ELISA	 prototype,	 five	 assays	
were	 run	on	 five	 separate	 days	with	 the	 calibrator	 curve	 tested	 in	 duplicate	 (n=2)	
and	the	QC	samples	tested	in	triplicate	(n=3)	on	each	day.	The	results	were	tabulated	
and	 analysed	 using	 the	 Analyse-it	 statistical	 software.	 Analyse-it	 is	 quality	 control	
and	method	validation	tool	developed	to	implement	experimental	design	in	line	with	
the	Clinical	Laboratory	Standards	Institute	(CLSI)	guidelines.	The	CLSI	has	developed	
clinical	 laboratory	 testing	 standards	 based	 on	 a	 consensus	 among	 industry,	
government	and	healthcare	professionals	that	are	routinely	implemented	in	FDA	and	
ISO	 accredited	 laboratories	 around	 the	 world	 as	 part	 of	 their	 individual	 quality	
systems,	whether	 it	 is	 sample	 testing	 or	 diagnostic	 test	 development	 laboratories.	
The	 CLSI	 guideline	 document	 used	 for	 this	 experiment	 was	 EP5A2:	 Evaluation	 of	
precision	performance	of	quantitative	measurement	methods;	approved	guideline.	
	
A	Grubb’s	 (1950)	 test	was	performed	for	each	QC	sample	set	 to	detect	any	outlier	
data	that	deviated	from	the	mean	sample	value.	To	do	this,	the	Z	value,	which	is	the	
largest	deviation	from	the	sample	mean,	was	calculated	as	follows:	
	
Z	=	Mean	of	dataset	–	Individual	Measurement	
Standard	Deviation	of	dataset	
	
The	expected	Z	value	range	is	defined	based	on	the	number	of	tests	performed.	For	
5	tests,	the	range	is	±	1.71.	
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	 	 	 	 	 	 	QC2	
	
	
	 	 	 	 	 	 	QC3	
	
	
	 	 	 	 	 	 	QC4	
	
Figure	3.3.9.2	 Inter-assay	 precision	 for	 QC	 samples	 1-4.	 QC1	 =	 4.8%,	 QC2	 =	 8.9%,	
QC3	 =	 10.4%	 and	 QC4	 =	 7.0%.	 All	 samples	 were	 evenly	 distributed	 and	 were	
comfortably	 within	 an	 allowable	 imprecision	 of	 %CV	 =	 <20%.	 The	 blue	 line	
represents	the	mean	value	of	each	QC	sample	as	displayed	in	Table	3.3.9.1.	
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3.3.10	 Establishment	of	TAP	positive	control	sample	
	
A	 Positive	 Control	 (PC)	 sample	 was	 prepared	 by	 spiking	 TAP	 antigen	 into	 a	
proprietary	diluent	 formulation	 from	EKF	Diagnostics	 to	maximise	antigen	stability.	
This	 bulk	 sample	 was	 tested	 in	 a	 single	 assay	 (n=22)	 and	 quantified	 from	 the	
standard	calibration	curve	(0	–	400	nm/L).	Establishment	of	a	positive	control	sample	
allows	for	an	additional	control	that	may	be	run	in	place	of	QC	samples	but	also	for	
potential	 future	 use	 in	 a	 commercial	 anti-TAP	 ELISA.	 Such	 a	 sample	 can	 provide	 a	
reference	 check	 for	 information	 on	 intra-	 and	 inter-assay	 precision	 and	 long-term	
performance	of	an	assay,	such	as	inter-batch	variation	(Deshpande,	1996).	
	
	
	
	
Figure	 3.3.10.1	 Measuring	 interval	 for	 Positive	 Control	 sample	 with	 individual	
concentration	distribution.	A	quality	control	range	of	the	mean	value	(62.5	nmol/L)	±	
20%	was	calculated	with	the	minimum	and	maximum	values	for	this	range	being	50	
and	75	nmol/L,	respectively.	This	range	can	be	used	for	future	assays	run	with	this	PC	
sample	to	demonstrate	whether	quantified	results	are	valid.	The	variation	between	
replicates	was	%CV	=	5%.	
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3.3.11	 Establishment	of	limit	of	quantification	for	streptavidin	/	biotinylated	anti-
TAP	ELISA	
	
To	 fully	 define	 the	 measuring	 range	 of	 any	 assay,	 the	 limitations	 of	 the	 assay	 to	
accurately	measure	 low	 concentrations	 of	 analyte	must	 be	 established.	 There	 are	
several	 parameters	 that	 have	 been	 defined	 and	 used	 to	 describe	 the	 smallest	
concentration	 of	 an	 analtye	 that	 can	 be	 reliably	 quantified	 by	 a	 measuring	
procedure.	 	 The	 CLSI	 defines	 three	 individual	 parameters	 in	 relation	 to	 assay	
sensitivity.	These	are	the	Limit	of	Blank	(LoB),	Limit	of	Detection	(LoD)	and	Limit	of	
Quantification	 (LoQ).	 The	 LoB	 is	 the	 highest	 apparent	 analyte	 concentration	
expected	when	 replicates	of	 a	 blank	 sample	 containing	no	 analyte	 are	 tested.	 The	
LoD	 is	 the	 lowest	analyte	concentration	 likely	 to	be	 reliably	distinguished	 from	the	
LoB	 and	 at	 which	 detection	 is	 feasible.	 To	 investigate	 the	 differences	 in	 results	
obtained	from	using	the	CLSI	guideline	formula	and	more	traditional	methods	often	
employed	in	laboratories,	the	LoD	was	calculated	from	the	same	data,	as	described	
in	Table	3.3.11.1	below.	The	 LoQ	 is	 the	 lowest	 concentration	at	which	 the	analyte	
can	not	only	be	reliably	detected,	but	at	which	some	predefined	goals	for	bias	and	
imprecision	 are	 met.	 The	 LoQ	 can	 be	 equivalent	 to	 the	 LoD	 or	 at	 a	 much	 higher	
concentration	and	 is	 therefore	 the	most	 important	parameter	 to	define	 for	clinical	
utility	of	 an	assay	 (Armbruster	&	Pry,	2008).	 The	predefined	allowable	 imprecision	
for	the	LoQ	of	this	prototype	was	a	%CV	=	≤10%.	While	the	number	of	replicates	for	
establishing	each	of	the	parameters	was	less	than	the	figure	indicated	(60	replicates)	
in	 the	 CLSI	 document	 EP17-A2:	 Evaluation	 of	 detection	 capability	 for	 clinical	
laboratory	 measurement	 procedures;	 approved	 guideline,	 these	 experiments	 were	
sufficient	to	demonstrate	the	performance	of	the	ELISA	prototype.	
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The	LoB	and	LoD	were	calculated	using	the	following	formulae:	
	
Limit	of	Blank	(LoB)	=	Mean	Blank	OD	-	1.645(SD	Blank	OD) 
	
	
Limit	of	Detection	(LoD)	=	Mean	Blank	OD	-	2(SD	Blank)	
	
or	
	
Limit	of	Detection	(LoD)	=	Mean	Blank	OD	-	3(SD	Blank)	
	
or	
	
Limit	of	Detection	(LoD)	=	LoB	-	1.645(SD	low	sample	concentration)	
	
	
	
	
	
	
Figure	3.3.11.1	Determination	of	LoB	for	the	streptavidin/biotinylated	anti-TAP	ELISA	
using	44	 replicates	of	 the	 zero	 (blank)	 standard.	 The	variability	between	 replicates	
was	 %CV	 =	 4%,	 with	 a	 mean	 absorbance	 (OD450nm)	 value	 of	 2.765	 (indicated	 by	
dashed	line).	The	OD450nm	values	were	inputted	into	the	GEN5	PlateReader	software	
to	 back-calculate	 the	 TAP	 concentrations	 for	 each	 individual	 replicate	 from	 the	
standard	calibration	curve	used	for	assay	testing.	Using	the	formula	above,	the	LoB	
was	calculated	to	be	1.2	nmol/L.	
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Figure	 3.3.11.2	 Determination	 of	 LoD	 for	 the	 streptavidin/biotinylated	 anti-TAP	
ELISA	 using	 16	 replicates	 of	 the	 3.1	 nmol/L	 TAP	 standard.	 The	 variability	 between	
replicates	was	%CV	=	4%,	with	a	mean	LoD	absorbance	(OD450nm)	value	of	1.910.	The	
LoD	OD450nm	values	were	inputted	into	the	GEN5	PlateReader	software	as	per	figure	
3.3.11.1.	These	concentrations	were	then	utilised	 in	the	formulae	 in	table	3.3.11.1.	
Note,	the	“+”	was	replaced	by	a	“-“	in	these	formulae	due	to	the	competitive	assay	
format.	 A	 “+”	would	 cause	 the	 concentrations	 to	 be	 unquantifiable	 as	 they	would	
have	an	OD450nm	value	greater	than	the	zero	standard.	
	
	
Table	3.3.11.1	Calculation	of	limit	of	detection	using	various	parameters:	
	
LoD	Parameter	 LoD	(OD)	 LoD	(nmol/L)	
Mean	Blank	OD	-	2*SD		 		 		 2.523	 1.6	
Mean	Blank	OD	-	3*SD		 		 		 2.401	 2.6	
Mean	Blank	OD	-	1.645*SD	Blank	-	1.645*SD	Std	3.13	 2.429	 2.3	
	
With	a	predefined	imprecision	requirement	of	%CV	=	≤10%	successfully	met,	the	LoQ	
was	equivalent	to	the	LoD	and	was	therefore	2.3	nmol/L.	
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3.3.12	 Establishment	of	linear	measuring	range	for	streptavidin	/	biotinylated	anti-
TAP	ELISA	
	
The	relationship	between	analyte	concentration	or	response,	when	measured	by	an	
analytical	method,	and	a	pathophysiological	disease	process	is	generally	non-linear.	
However,	 the	 measuring	 procedure	 must	 be	 able	 to	 report	 results	 with	 a	 linear	
relationship	between	the	response	and	the	recorded	analyte	concentration.	So,	 for	
the	 dilution	 of	 a	 sample	 of	 known	 concentration	 (quantified	 from	 the	 calibration	
curve),	 the	 measured	 or	 expected	 sample	 concentration	 must	 be	 directly	
proportional	to	the	dilution	level.	It	is	not	possible	to	interpolate	for	response	values	
that	fall	between	calibrator	standards	without	a	defined	linear	measuring	range.	The	
CLSI	 document:	 EP6-A:	 Evaluation	 of	 the	 linearity	 of	 quantitative	 measurement	
procedures:	A	 statistical	approach;	approved	guideline,	defines	 the	 ideal	matrix	 for	
linearity	assessment	as	a	patient	 specimen	with	an	analyte	concentration	near	 the	
expected	upper	reportable	limit	that	is	diluted	with	another	patient’s	sample	having	
an	analyte	concentration	at	 the	expected	or	 tested	 lower	 limit	of	 the	assay.	 It	also	
states	that	to	establish	linear	ranges,	a	laboratory	should	use	7	to	11	concentration	
levels	 across	 the	 measuring	 range,	 with	 2	 to	 4	 replicates	 per	 level.	 	 As	 a	 trusted	
control,	the	QC1	urine	sample	was	used	for	the	highest	concentration	(100%)	of	the	
linear	measuring	range	to	be	assessed.	This	sample	was	diluted	to	 levels	of	90,	80,	
70,	 50,	 40,	 30,	 20,	 10,	 5	 and	 2.5%	 using	 donor	 urine	 from	 an	 apparently	 normal	
individual.	 This	 donor	 urine	 represented	 the	 0%	 level	 and	 was	 quantified	 by	 the	
ELISA	 prototype	 to	 confirm	 as	 “analyte-free”	 urine.	 Each	 of	 the	 sample	 levels	was	
tested	in	triplicate.		
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Figure	3.3.12.1	Linearity	of	streptavidin/biotinylated	anti-TAP	ELISA.	A	strong	linear	
fit	 (R2	 =	 0.9916)	 between	 the	 expected	 and	 observed	 TAP	 concentrations	 was	
achieved	 across	 the	 measuring	 range.	 The	 linear	 measuring	 range	 extended	 from	
10.2	–	175.5	nmol/L	from	the	samples	tested	and	the	variability	between	replicates	
of	each	sample	level	was	%CV	=	≤10%.		
	
	
3.3.13	 Streptavidin-coated	microtitre	plate	stability	study	
	
To	 investigate	 whether	 the	 streptavidin-coated	 microtitre	 plates	 purchased	 from	
Thermo	Fisher	Scientific	maintained	their	performance	characteristics	under	specific	
storage	 temperature	 conditions,	 an	 accelerated	 stress	 stability	 study	 was	
undertaken.	 Accelerated	 stability	 testing	 allows	 for	 a	 shorter	 study	 time	 where	
stressed	and	unstressed	product	can	be	compared,	thereby	reducing	the	possibility	
of	 instability	 in	 the	 measurement.	 Data	 taken	 from	 storage	 of	 a	 product	 at	 a	
temperature	 that	 is	 higher	 than	 the	 desired	 storage	 temperature	 can	 be	 used	 to	
predict	the	degradation	rate	of	the	product	signal	using	the	Arrhenius	equation.	This	
equation	states	that	the	relationship	between	time	and	stability	of	a	product	stored	
under	constant	conditions	is	dependent	on	the	order	of	reaction	and	a	rate	constant	
that	determines	the	speed	of	the	reaction:	
	
	
y	=	0.9719x	+	9.6522	
R²	=	0.9916	
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k	=	Ae-Ea/(RT)	
	
or	
	
Ln(k2/k1)	=	-Ea/2.303R*(1/T2-1/T1)		
	
The	 parameters	 k1	 and	 k2	 are	 the	 rate	 constants	 at	 temperatures	 T1	 (4°C)	 and	 T2	
(37°C),	A	is	the	Arrhenius	factor,	Ea	is	the	activation	energy	of	the	reaction	and	R	is	
the	gas	constant.	The	diagnostic	industry	simplifies	the	Arrhenius	equation	using	the	
“Q	Rule”	to	estimate	product	shelf-life	using	certain	assumptions.	The	Q	Rule	states	
that	 product	 degradation	 decreases	 by	 a	 constant	 factor	 (Q10)	 when	 the	 storage	
temperature	 is	 lowered	 by	 10°C.	 The	 Q10	 value	 can	 be	 2,	 3	 or	 4,	 ranging	 from	
probable	 to	 possible	 results,	 respectively	 (Anderson	 &	 Scott,	 1991).	 Using	 this	
information,	 the	accelerated	aging	time	(AAT)	 required	 for	predicting	the	real	 time	
stability	(RT)	was	calculated	using	the	following	formula:	
	
AAT	=	Desired	Real	Time	Stability	(RT)	
Q10[(TAA-TRT)/10]	
	
where	TAA	refers	to	the	accelerated	aging	temperature	(°C)	and	TRT	refers	to	the	
ambient	temperature	(°C)	(Schueneman	&	Campos,	2014).	
	
For	this	study,	the	microtitre	plates	were	placed	in	a	37°C	incubator	for	a	period	of	
time	as	 indicated	 in	table	3.3.13.1,	and	then	removed	and	placed	at	4°C	storage.	A	
microtitre	 plate	 was	 maintained	 at	 4°C	 throughout	 as	 an	 unstressed	 control	 and	
tested	alongside	the	stressed	components.	Calibrators,	PC	and	QC	samples	were	run	
with	each	of	the	microtitre	plates.	
	
Table	3.3.13.1	Accelerated	stress	stability	study	time-points	
Incubation at 37°C (Days) 1 3 9 18 37 
Equivalent to storage at 
4°C (Months) 0.25 1 3 6 12 
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Figure	 3.3.13.1	The	A/A0	signal	 response	 for	TAP	calibration	standards	3.1	and	400	
nmol/L	during	predicted	real	time	stability	period	of	12	months.	Month	“0”	refers	to	
control	microtitre	plate.	Response	remained	constant	for	both	calibrators	(CAL1	and	
CAL8),	 demonstrating	 good	 stability	 at	 both	 low	 and	 high	 TAP	 concentrations.	
Response	values	were	taken	from	Table	3.3.13.2.	
	
	
	
Figure	3.3.13.2	Trending	quantification	of	PC	and	QC	samples	data	during	predicted	
real	time	stability	period	of	12	months.	
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Figure	3.3.13.3	Overlay	of	TAP	calibration	curves	during	predicted	real	time	stability	
period	 of	 12	months.	 As	 shown	 for	 the	 raw	 data	 in	 the	 overview	 table	 of	 Figure	
3.3.13.1,	 no	major	 ‘drop-off’	 in	 assay	 response	 signal	was	 observed	 and	 thus,	 the	
calibration	curves	for	each	of	the	stressed	time-points	were	equivalent	to	the	control	
in	the	quantification	of	the	TAP	standards.	
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3.3.14	 Establishment	 of	 a	 reference	 range	 for	 urinary	 TAP	using	 “normal”	 donor	
group	
	
In	order	to	truly	understand	a	measured	analyte	test	result	from	a	patient	sample,	it	
is	essential	to	have	a	reference	range	that	defines	the	expected	values	in	a	“normal”	
patient	sample,	i.e.	a	person	who	does	not	have	a	medical	diagnosis	for	the	disease	
in	 question.	 The	 most	 accurate	 way	 to	 achieve	 this	 is	 to	 collect	 samples	 from	
patients	 with	 no	 clinical	 symptoms	 relating	 to	 the	 disease.	 All	 test	 results	 can	
subsequently	be	compared	to	this	range	and	contribute	to	therapeutic	management	
decisions	 in	 the	 clinical	 setting.	 The	CLSI	 document	C28-A3c:	Defining,	 establishing	
and	 verifying	 reference	 intervals	 in	 the	 clinical	 laboratory;	 approved	 guideline,	
recommends	 that	 all	 laboratories	 should	 verify	 the	 reference	 range	 supplied	 with	
any	commercial	product	or	establish	their	own	in	cases	where	none	is	supplied.	The	
reference	group	for	the	anti-TAP	ELISA	consisted	of	15	anonymous	donor	urines	that	
were	collected	at	DCU	following	research	ethics	committee	approval	of	the	protocol.	
Due	to	the	time	constraints,	this	donor	group	was	the	closest	substitute	to	a	group	
with	no	known	clinical	complications	relating	to	acute	pancreatitis.	All	donor	urines	
were	tested	in	duplicate	and	quantified	using	the	TAP	standard	calibration	curve.		
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		 Frequency	Distribution	 		 		 		 		 		
	 	 	 	 	 	 	 	
	 	
Class		 Frequency	
Relative	
frequency	 Density	
Cumulative	
frequency	
Cumulative	relative	
frequency	
	 	
≥0	to	<2	 8	 0.533	 0.2667	 8	 0.533	
	 	
≥2	to	<4	 4	 0.267	 0.1333	 12	 0.800	
	 	
≥4	to	<6	 3	 0.200	 0.1000	 15	 1.000	
	 	 	 	 	 	 	 	
	
	
	
	
	
Figure	3.3.14.1	Frequency	distribution	plots	and	data	for	the	TAP	reference	group	-	
(a)	histogram	of	frequency	distribution,	illustrating	8	donors	between	0	to	<2	nmol/L,	
4	donors	between	2	to	<4	nmol/L	and	3	donors	between	4	to	<6	nmol/L	and;	(b)	box-
plot	frequency	distribution,	illustrating	the	mean	of	the	reference	range	at	2	nmol/L.	
The	TAP	reference	range	was	established	as	0	-	5.3	nmol/L	in	this	group.	
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3.4	 DISCUSSION	AND	CONCLUSION	
	
The	development	of	an	anti-TAP	ELISA	capable	of	quantifying	the	TAP	analyte	within	a	
defined	 measuring	 range	 and	 with	 the	 pre-desired	 performance	 characteristics	 was	
described	in	this	chapter.	Three	separate	lots	of	monoclonal	anti-TAP	IgG	antibody	were	
produced	 under	 a	 license	 agreement	 with	 AbCam®	 and	 characterised	 by	 SDS-PAGE	
analysis	 to	 demonstrate	 strong	 reproducibility.	 Initial	work	 to	 establish	 a	 competitive	
anti-TAP	 ELISA	 showed	 a	 lack	 of	 discrimination	 between	 calibration	 curve	 standards	
alongside	 a	 requirement	 for	 a	 low	 conjugate	dilution	 that	would	 see	 the	use	of	 large	
stock	volumes.	Biotinylation	of	the	anti-TAP	IgG	antibody	and	its	use	with	streptavidin-
coated	microtitre	plates	demonstrated	enhanced	discrimination	between	standards	and	
subsequently,	the	optimisation	and	establishment	of	performance	characteristics	were	
outlined	 for	 this	 assay	 format.	 The	 purchase	 of	 commercially	 available	 streptavidin-
coated	microtitre	plates	was	made	in	the	interest	of	the	antibody	and	peptide	material	
limitations	 for	 this	 project.	 Further	 cost	 saving	 could	 be	 made	 in	 future	 through	
production	 of	 streptavidin-coated	 microtitre	 plates	 by	 alternative	 methods	 such	 as	
cross-linking	with	glutaraldehyde	(Välimaa	et	al.,	2003)	or	chemical	modification	such	as	
thiol	group	introduction	(Ylikotila	et	al.,	2009).	
The	 streptavidin/biotinylated	 anti-TAP	 ELISA	 standard	 calibration	 curve	 was	
cross-checked	 using	 two	 separate	 forms	 of	 curve-fitting	 software	 to	 establish	 the	
optimal	 TAP	 analyte	 measuring	 range.	 The	 stability	 of	 the	 TAP	 analyte	 was	 then	
investigated	 in	 various	 matrices	 by	 repeated	 freeze	 thawing	 from	 -20°C	 to	 room	
temperature,	an	action	that	would	be	performed	daily	in	the	use	of	any	diagnostic	test	
for	patient	sample	testing.	The	TAP	analyte	demonstrated	exceptional	stability	 in	both	
dH20	and	urine,	leaving	no	apprehension	for	the	next	step	in	prototype	assessment	with	
clinical	urine	samples.	To	further	ensure	reproducibility	of	the	assay	prototype,	several	
quality	 control	 samples	were	 prepared	with	 TAP	 analyte	 in	 urine	 (QC	 1	 -	 4)	 and	 in	 a	
specialised	buffer	 formulation	 for	 the	PC	 to	quantify	at	various	concentrations	spread	
across	 the	 assay	 measuring	 range.	 Specification	 ranges	 were	 established	 for	 each	
sample	 and	 precision	 testing	 indicated	 very	 low	 variability	 (%CV≤	 10%).	 These	
controls	were	essential	in	determining	the	prototype’s	capacity	to	be	utilised	in	clinical	
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testing	and	 its	potential	 as	 a	 commercial	 test.	 The	 stability	of	 the	 streptavidin-coated	
microtitre	 plate	 and	 the	 established	 reference	 range	 for	 the	 TAP	 analyte	 were	
additional	 experiments	 that	 clearly	 also	 highlighted	 the	 capability	 of	 this	 ELISA	
prototype	to	be	progressed	for	use	in	a	clinical	sample	evaluation	and	to	be	considered	
for	potential	commercialisation.	
The	 strong	 performance	 characteristics	 and	 robustness	 of	 the	
streptavidin/biotinylated	anti-TAP	ELISA	outlined	 in	this	chapter	demonstrate	that	this	
prototype	has	the	potential	to	be	commercialised	following	scale-up	production	studies	
that	would	also	include	additional	performance	testing	experiments	such	as	testing	for	
endogenous	interfering	substances	found	in	human	urine,	including	lipids	and	bilirubin	
(Dimeski,	2008).	Although	having	a	 longer	test	 time	duration	(3h	15mins	versus	2h	15	
mins	 total	 incubation	 time)	 compared	 to	 the	 polyclonal	 anti-TAP	 ELISA	 marketed	
previously,	this	streptavidin/biotinylated	anti-TAP	ELISA	prototype	should	provide	more	
reproducible	performance	due	to	the	use	of	the	anti-TAP	mAb.	In	addition,	the	overall	
performance	 characteristics	 compared	 favourably	 with	 the	 polyclonal	 ELISA	 and	 are	
outlined	in	Table	3.4.1	below.	In	fact,	the	ELISA	prototype	described	in	this	chapter	has	
undergone	much	more	vigorous	performance	testing	than	when	compared	to	the	data	
provided	 in	 the	 polyclonal	 ELISA	 product	 insert	 (Appendix	 8.1).	 In	 conclusion,	 the	
streptavidin/biotinylated	anti-TAP	ELISA	prototype	described	 in	 this	 chapter	 can	 serve	
as	 the	 reference	 method	 for	 quantification	 of	 TAP	 analyte	 during	 the	 next	 phase	 of	
development	 –	 a	 rapid	 lateral	 flow	 test	 strip	 device.	 The	 establishment	 of	 a	 “gold	
standard”	reference	method,	such	as	an	ELISA,	is	an	essential	step	for	the	development	
of	any	POC	device.	
Table	3.4.1	Comparison	of	performance	characteristics	for	streptavidin/biotinylated	
anti-TAP	ELISA	and	commercial	polyclonal	anti-TAP	ELISA:	
Parameter	 Streptavidin/Biotinylated	anti-TAP	ELISA	
Commercial	Polyclonal	
anti-TAP	ELISA	
Sample	dilution	 Not	required	 1/4	recommended	
Spike	recovery	(%)	 100	±	10%	 100	±	10%	
Intra-assay	precision	(%CV)	 0.8	-	13.3%	 10.0	-	16.7%	
Inter-assay	precision	(%CV)	 4.8	-	10.4%	 11.9	-	18.7%	
Measuring	range	(nmol/L)	 2.3	-	400	 0.56	-	800	
		 	 	
	
	
	
	
	
	
Chapter	4	
	
Development	of	an	Anti-TAP	
Lateral	Flow	Test	Strip	
Device	
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4.1	 INTRODUCTION	
	
The	genesis	of	the	lateral	flow	immunoassay	(LFIA)	in	the	1950s	was	the	result	of	a	
confluence	of	scientific	activity,	 including	the	latex	agglutination	test	first	described	
by	 Singer	 and	 Plotz	 in	 1956.	 In	 the	 following	 decades,	 the	 LFIA	 concept	 was	
improved,	with	 the	human	pregnancy	test	becoming	the	 first	major	success	of	 this	
assay	format	(Gubala	et	al.,	2012).	Since	then,	the	LFIA	has	been	adapted	for	large-
scale	clinical	diagnostic	use	in	many	fields	including	infectious	and	cardiac	diseases,	
cancer	and	drugs	of	abuse	 (Gubala	et	al.,	2012;	Sharma	et	al.,	2015).	The	LFIA	has	
grown	to	become	the	most	popular	commercial	point-of-care	(POC)	device	format	of	
today,	with	an	estimated	market	size	of	US$18	billion	predicted	by	2016	(Gubala	et	
al.,	 2012;	 St	 John	 &	 Price,	 2014).	 The	 prevalence	 of	 infectious	 diseases,	 an	 aging	
population	and	the	drive	for	more	home-based	and	decentralised	POC	testing,	are	all	
significant	contributors	to	this	anticipated	growth.	The	LFIA	is	particularly	well	suited	
to	this	emerging	requirement	for	decentralised	testing	due	to	numerous	factors	such	
as	 ease	 of	 use,	 small	 sample	 volume	 requirement,	 large-scale	 production	within	 a	
short	timeframe	and	the	ability	to	be	integrated	with	reader	and	central	information	
systems	(Wong,	2009).	 	
Typically,	a	LFIA	involves	the	flow	of	a	liquid	sample,	containing	the	analyte	of	
interest,	 through	a	porous	membrane	where	biological	 interactions	occur	 from	the	
binding	of	labeled	particles	or	analyte	by	immobilised	antibodies	to	produce	a	signal	
that	can	be	visualised	or	detected	optically.	This	lateral	flow	test	strip	format	would	
consist	of	a	nitrocellulose	 (NC)	membrane	that	 transports	 the	sample	 (applied	to	a	
sample	pad)	by	capillary	action,	through	a	conjugate	release	pad	and	onwards	to	an	
analyte	 detection	 zone	 before	 reaching	 an	 absorbent	 pad	 that	 terminates	 flow	
(Posthuma-Trumpie	 et	 al.,	 2009).	 The	 format	 of	 the	 lateral	 flow	 device	 for	 TAP	
antigen	(Figure	4.1.1)	was	restricted	to	a	competitive	assay	due	to	the	small	size	of	
the	peptide.	The	use	of	a	similar	format	to	the	ELISA	prototype,	described	in	chapter	
3,	 also	 allowed	 for	 a	 direct	 comparison	 in	 performance	 between	 both	 assays.	 The	
use	 of	 a	 competitive	 format	 meant	 that	 results	 would	 be	 inversely	 correlated	 to	
analyte	 concentration	 i.e.	 a	 lower	 signal	 response	 indicates	 that	 more	 analyte	 is	
present	and	the	highest	response	is	observed	for	analyte-free	sample.		
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Figure	4.1.1	Schematic	of	magnetic	LFIA	prototype	for	the	detection	of	TAP	antigen.	
The	 urine	 sample	 is	 mixed	 with	 two	 independent	 super-paramagnetic	 particle	
(SPMP)	conjugates;	TAP-SPMP	“test”	conjugate	and	polyclonal	rabbit	IgG	or	chicken	
IgY-SPMP	 “control”	 conjugate.	 Sample/conjugate	 mixture	 travels	 through	 the	
nitrocellulose	membrane	with	binding	occurring	at	 test	and	control	 lines	before	an	
absorbent	 pad	 soaks	 up	 any	 residual	 particles	 and	 ”free”	 antigen.	 The	 Test	 line	
incorporates	 streptavidin,	 biotinylated	 anti-TAP	 capture	 antibody	 which	 binds	 to	
TAP-SPMP	conjugate	and,	control	line	incorporates	goat	anti-rabbit	IgG	(Prototype	
1)	or	goat	anti-chicken	IgY	(Prototype	2)	capture	antibodies.	The	degree	of	binding	
at	the	test	and	control	regions	is	read	using	the	magnetic	immunochromatographic	
test	(MICT®)	instrument	from	MagnaBioSciences	LLC,	which	quantitatively	measures	
and	expresses	the	signal	as	a	magnetic	assay	reading	(MAR).	The	MICT®	instrument	
was	 utilised	 for	 all	 of	 the	 magnetic	 TAP	 LFIA	 prototype	 work	 described	 in	 this	
chapter.	
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All	 lateral	 flow	 test	 strip	 components	 were	 selected	 based	 on	 supplier	
recommendations	for	sample	flow	characteristics,	including	rate	of	flow	and	testing	
of	urine	samples.	The	sample	pad	for	this	assay	was	pre-treated	with	a	proprietary	
buffer	 formulated	with	high	 concentration	 salts	 to	neutralise	urine	 sample	pH	 (pH	
~6-8)	and	addition	of	surfactant	to	increase	wettability	of	the	pad.	Human	urine	can	
have	a	pH	varying	between	5	and	10	and	high	 fluctuations	can	alter	 the	specificity	
and	 sensitivity	 of	 capture	 antibodies	 by	 affecting	 changes	 in	 charge	 densities	
(Millipore,	 2008). Inclusion	 of	 a	 pre-treatment	 step	 from	 the	 outset	 assured	
suitability	 for	 future	use	with	clinical	samples,	 if	warranted.	A	glass	 fibre	conjugate	
pad	 was	 also	 included	 in	 all	 test	 strips	 for	 potential	 drying	 of	 magnetic	 particle	
conjugates	 in	 future	 iterations	 of	 the	 assay	 prototype.	 Several	 factors	were	 taken	
into	 account	 for	 the	NC	membrane.	 The	pore	 size	 in	 relation	 to	 label	 size	 and	 the	
capillary	 flow	 time	was	 considered	 vitally	 important	 for	 an	 optimal	 reaction	 time.	
Use	of	polyethylene	material	can	offer	control	over	membrane	pore	size,	improving	
material	reproducibility	and	thus,	test	result	reproducibility.	A	NC	membrane	is	also	
generally	 treated	 with	 surfactant	 to	 make	 it	 hydrophilic	 for	 test	 use	 and	 it	 is	
supported	with	a	plastic	layer	for	handling	and	cutting	purposes	(Posthuma-Trumpie	
et	al.,	2009;	Koczula	&	Gallotta,	2016).	An	absorbent	“upper	wick”	cotton	pad	with	
an	 absorption	 capacity	 greater	 than	 the	 sample	 volume	 was	 also	 essential.	 The	
dispensing	 buffer	 used	 for	 application	 of	 capture	 antibodies	 to	 the	NC	membrane	
was	PBS.		
Magnetic	particles	have	been	described	for	use	in	medical	areas	including;	as	
MRI	 contrast	 agents,	 for	 cell	 labeling	 and	 separation,	 drug	 delivery;	 and	 more	
recently	 as	 immunoassay	 labels	 in	 LFIAs.	 Superparamagnetic	 particles	 (SPMPs)	 are	
magnetic	 iron	 oxide	 or	 magnetite	 (Fe3O4)	 particles	 produced	 by	 various	 wet	
chemistry	 techniques	 where	 external	 conditions	 such	 as	 pH	 and	 temperature	 are	
carefully	 controlled.	 These	 techniques	 control	 the	 size	 and	 uniformity	 of	 the	
resulting	particles	with	nanoparticles	of	diameter	<100	nm	and	>200	nm	used	for	in	
vivo	 and	 in	 vitro	 applications,	 respectively.	 SPMPs	 used	 in	 LFIAs	 offer	 many	
advantages	 over	 the	 traditional	 and	most	widely	 used	 LFIA	 labels	 of	 colloidal	 gold	
and	 latex.	 SPMPs	 have	 low	 background	 noise	 due	 to	 biological	 materials	 lacking	
magnetism	and	are	inactive	until	required;	becoming	magnetic	only	when	placed	in	a	
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strong	magnetic	 field	 and	 subsequently	maintaining	 a	 stable	 signal.	 The	 surface	of	
SPMPs	can	also	be	extensively	modified	with	various	coating	chemistries	to	facilitate	
bio-conjugation.	The	resultant	magnetic	signal	at	a	detection	zone	can	be	measured	
quantitatively	 through	 the	 entire	 volume	 of	 the	membrane	 whereas	 conventional	
detection	methods	 with	 gold	 and	 latex	 particles	 are	 interpreted	 visually	 and	 only	
account	 for	 the	 surface	 reaction	observed	 (qualitative)	 (LaBorde	&	O’Farrell,	 2002;	
Tartaj	et	 al.,	 2003;	 Nor	 et	 al.,	 2012;).	 SPMP-labeled	 conjugates	were	 prepared	 for	
this	 assay	 using	 EDC-NHS	 coupling	 chemistry	 (section	 2.2.7)	 that	 utilised	 the	
carboxyl-functionalised	surface	of	the	SPMPs	(Figure	4.1.2)	and	the	amine	groups	of	
the	TAP	antigen	or	control	antibodies.		
	
 
 
Figure	 4.1.2	 TEM	 image	 of	 Estapor®	 SPMPs,	 taken	 from	Merck	 Millipore	 product	
information	 brochure.	 The	 SPMPs	 pictured	 are	 uniformly	 separated	 or	
“monodisperse”	and	demonstrate	no	sign	of	particle	grouping	or	aggregation.	
	
	
The	 precision	 or	 repeatability	 of	 the	 lateral	 flow	 prototype	 was	 calculated	
throughout	 the	 experimental	 work	 by	 performing	 multiple	 measurements	 (n	 =	 5)	
within	 each	 testing	 run	 on	 the	 same	 day.	 To	 define	 the	 precision	 between	 these	
replicates,	 the	 coefficient	 of	 variation	 (CV)	 was	 determined	 using	 the	 following	
formula:	
	
Precision	=	CV	(%)	=	Standard	Deviation	x	100	
																									Mean	
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Figure	 4.1.3	 MICT®	 platform	 system	 is	 an	 in	 vitro	 diagnostic	 device	 which	 can	
quantitatively	 detect	 SPMP-labelled	 analyte	 in	 numerous	 biological	 samples.	 1:	
Lateral	flow	test	strips	are	enclosed	in	disposable	test	cassettes	which	are	patented	
to	fit	in	the	MICT®	instrument.	Test	cassettes	have	barcode	information	detailing	test	
parameters	such	as	test	and	control	line	locations	and	a	standard	calibration	curve;	
2:	 The	 MICT®	 instrument,	 with	 a	 touch-screen	 interface,	 is	 used	 to	 measure	 the	
magnetic	 signal	 of	 the	 developed	 test	 device;	 3:	 Measurement	 of	 particles	 which	
accumulate	 at	 the	 test	 and	 control	 regions	 following	 biological	 binding	 requires	
excitation	 of	 the	 SPMPs	 inside	 a	 magnetic	 field.	 A	 C-shaped	 electromagnet	 is	
positioned	around	the	test	strip	and	a	voltage	applied	to	produce	a	magnetic	field.	
The	 resulting	 magnetic	 intensity	 (magnetic	 assay	 reading,	 MAR)	 is	 read	 and	
converted	 into	 analytical	 units	 of	 measurement	 using	 mathematical	 algorithms	
programmed	into	the	MICT®	software.	Figure	taken	from	magnabiosciences.com.	
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4.2	 AIMS	OF	THIS	CHAPTER	
	
The	feasibility	of	developing	a	 lateral	 flow	test	strip	prototype	for	measurement	of	
urinary	TAP	using	the	MICT®	system	will	be	investigated.	
	
The	 development	 of	 this	 test	 will	 involve	 profiling	 optimal	 concentrations	 and	
conditions	 for	 use	 of	 the	 same	 biological	 materials	 used	 in	 the	 ELISA	 prototype,	
detailed	 in	 chapter	 3.	 Conjugation	 to	 SPMPs	 and	 buffer	 formulation,	 which	 could	
potentially	 deliver	 a	 quantified	 TAP	 concentration	 within	 45	minutes,	 will	 also	 be	
described.	 This	 would	 offer	 a	 significant	 improvement	 on	 the	 ELISA	 protocol	 time	
and	contribute	to	the	 important	clinical	requirement	for	a	device	that	can	report	a	
rapid	TAP	result.	
	
4.3	 RESULTS	
	
4.3.1	 Technical	 evaluation	 of	MICT®	 instrument	 using	 a	 commercially	 available	
test	
	
Several	rapid	point-of-care	diagnostic	tests	are	currently	available	to	purchase	from	
MagnaBioSciences	 for	 detection	 of	 biomarkers	 of	 acute	myocardial	 infarction	 and	
hormones	 involved	 in	 stimulation	 and	 maturation	 of	 the	 human	 reproductive	
system.	 A	 commercial	 test	 for	 cardiac	 troponin	 I	 (cTnI)	 was	 selected	 for	 internal	
evaluation	of	the	MICT®	system,	whereby	the	manufacturer’s	performance	claims,	as	
stated	 in	 the	 product	 instructions	 for	 use	 (IFU),	would	 be	 assessed.	 In	 addition	 to	
intra	 and	 inter-assay	 precision	 testing,	 this	 evaluation	 also	 established	 a	 linear	
measuring	 range,	 sample	 recovery	 and	 stability	 (recombinant	 cTnI	 used)	 and	 a	
laboratory	 reference	 interval	 for	 testing	 of	 patient	 samples.	 Intra-	 and	 inter-assay	
precision	returned	higher	results	(%CV	=	14	and	15%,	respectively)	when	compared	
to	 the	precision	characteristics	 stated	 in	 the	product	 IFU.	However,	a	%CV	=	<20%	
was	 still	 acceptable	 for	 further	 use	 of	 this	 test	 system	 as	 a	 development	 tool.	 An	
overview	of	results	from	the	evaluation	is	displayed	below	in	Table	4.3.1.1.	
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Table	4.3.1.1	Cardiac	Troponin	I	technical	evaluation	-	overview	of	results:	
	
Parameter Result 
Intra-assay precision 
Lot #509B0015: 
CV Mean 14% (min 10%, max 19%) – 3 samples; triplicate; 5 days; 1 reader; 2 operators 
Inter-assay precision 
CV Mean 15% (min 11%, max 19%) – 3 samples; 3 replicates x 5 days 
CV Mean 15% (min 8%, max 23%) – 3 samples; 17 replicates x 1 day, 3 separate lots 
Sensitivity (Limit of 
Quantification) Mean LoQ 0.14 ng/mL - Mean Analyte Concentration (n = 20) + 2*SD  
Linearity Linear fit from 0.2 – 28 ng/mL. Mean Recovery = 121%. 
Reference Interval 0 – 0.19 ng/mL (n=21) 
Spike Recovery 
Heparin Plasma   (LOW) 
Mean Recovery 113%  
(Measured Conc. 7.9 ng/mL, Theoretical Conc. 7.0 ng/mL; n = 3) 
Heparin Plasma   (MED)   
Mean Recovery 108%  
(Measured Conc. 15.2 ng/mL, Theoretical Conc. 14.0 ng/mL; n = 3) 
Heparin Plasma  (HIGH)   
Mean Recovery 101%  
(Measured Conc. 28.3 ng/mL, Theoretical Conc. 28.0 ng/mL; n = 3) 
Sample Stability 
Freeze Thaw (LOW) Recovery 96% after 1 x FT cycle (lithium heparin plasma) 
Freeze Thaw (MED)   Recovery 82% after 1 x FT cycle (lithium heparin plasma) 
Freeze Thaw (HIGH)   Recovery 88% after 1 x FT cycle (lithium heparin plasma) 
		
4.3.2		 Optimisation	 of	 LFIA	 test	 conditions	 using	 rabbit	 IgG	 control	 line	
configuration	
	
4.3.2.1	Covalent	 coupling	 of	 polyclonal	 rabbit	 IgG	 to	 carboxylated	
superparamagnetic	particles	and	optimisation	of	conjugate	dilution	
	
Estapor®	 (Merck)	 carboxyl-modified	 superparamagnetic	 particles	 (diameter	 =	 200	
nm)	were	used	for	coupling	to	primary	amines	(-NH2)	of	the	rabbit	IgG	antibody	(see	
Figure	 4.3.2.1	 (a)).	 This	 conjugate	 would	 be	 utilised	 as	 part	 of	 the	 control	 line	 in	
Prototype	1	of	the	lateral	flow	assay.	The	particles	were	conjugated	with	310	μg	of	
IgG	 per	 3	mg	 of	 particles,	which	was	 optimised	 for	 use	 as	 per	 the	manufacturer’s	
generic	protocol,	described	in	section	2.2.8.		
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Figure	 4.3.2.1	 (a)	 Carboxyl-amine	 group	 coupling	 of	 antibodies	 or	 TAP	 antigen	 to	
SPMPs.	EDC	cross-linker	activates	carboxyl	groups	coated	on	SPMPs	 in	preparation	
for	reaction	with	primary	amine	groups	of	antibodies/target	antigen.	NHS	stabilises	
this	 reaction,	 aiding	 in	 the	 immobilisation	 of	 antibodies	 and/or	 antigen	 to	 the	
particle	 surface.	 A	 proprietary	 lyophilisation	 buffer	 (LYOPH),	 which	 is	 available	
commercially	 to	 EKF	 Diagnostics	 through	 a	 partner	 company,	 was	 used	 for	 initial	
assessment	of	the	rabbit	 IgG-SPMP	“control”	conjugate.	This	specialised	buffer	was	
developed	for	freeze-drying	of	protein	conjugates,	resulting	in	improved	stability	and	
reproducibility,	 reduced	 handling	 and	 decreased	 risk	 of	 contamination.	 It	 was	
envisaged	 that	 any	 lateral	 flow	 assay	 prototype	 would	 ultimately	 use	 this	 buffer	
should	production	scale-up	and	commercialisation	ensue.	The	conjugate	was	titrated	
based	on	previous	knowledge	of	working	dilutions	and	tested	with	goat	anti-rabbit	
(GAR)	 IgG	 capture	 antibody	 spotted	 at	 1	mg/mL	 on	 the	 nitrocellulose	membrane.	
Results	are	shown	in	Figure	4.3.2.1	(b)	below.	
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Figure	 4.3.2.1	 (b)	 Optimisation	 of	 rabbit	 IgG-SPMP	 conjugate	 dilution.	 Dilutions	
tested	 were	 based	 on	 previous	 internal	 work	 with	 similar	 conjugates	 at	 EKF	
Diagnostics.	 A	 1/16	 dilution	 provided	 a	 MAR	 response	 adequately	 within	 the	
required	response	range	of	600	-	800	MAR	and	was	selected	for	use	in	Prototype	1.	
	
4.3.2.2	Selection	of	optimal	conjugate	diluent	buffer	
	
When	 formulating	 the	 conjugate	 dilution	 buffer,	 it	 is	 essential	 to	 include	
components	that	will	maximise	uniform	distribution	of	the	magnetic	particles	in	the	
sample	 solution.	 Use	 of	 detergents	 such	 as	 Tween20	 increase	 the	 viscosity	 of	 the	
solution,	 enhancing	 the	 homogeneity	 and	maintaining	 a	medium-fast	 sample	 flow	
across	 the	 NC	 membrane.	 Inclusion	 of	 a	 blocker	 protein,	 such	 as	 BSA,	 is	 also	
recommended	to	reduce	the	possibility	of	non-specific	binding	to	the	NC	membrane.	
Multiple	 dilution	 buffers,	 including	 PBS	 (0.01M,	 pH	 7.3);	 TBS	 (0.02M,	 pH	 8.2)	
containing	 NaCl	 (0.14M)	 and	 Tween20	 (1.1%,	 w/v)	 (TBST);	 TBST	 containing	 BSA	
(0.5%,	w/v)	 (TBSTB);	 Tris	buffer	 containing	NaCl	 (0.15M)	and	Tween20	 (0.5%,	w/v)	
(TNT)	and	TNT	containing	BSA	(0.5%,	w/v)	(TNTB)	were	evaluated	for	their	effects	on	
MAR	 response	 at	 the	 control	 line	 position	when	 tested	with	 the	 rabbit	 IgG-SPMP	
“control”	 conjugate.	 The	 performance	 of	 these	 buffers	 was	 compared	 with	 the	
proprietary	buffer	(LYOPH)	described	above	in	Figure	4.3.2.1	(a).		
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Figure	 4.3.2.2.1	 Comparison	 of	 conjugate	 diluent	 buffer	 formulations	 used	 for	
preparation	 of	 rabbit	 IgG-SPMP	 “control”	 conjugate	 at	 a	 1/16	 dilution.	 The	 TNTB	
buffer	 returned	 a	 MAR	 response	 closest	 to	 that	 of	 the	 commercial	 lyophilisation	
buffer	(LYOPH)	and	thus,	was	selected	for	use	with	Prototype	1.	
	
	
	
4.3.2.3	Application	 and	 optimisation	 of	 goat	 anti-rabbit	 IgG	 capture	 antibody	 for	
use	on	a	nitrocellulose	membrane	at	the	control	line	position	
	
Goat	 anti-rabbit	 (GAR)	 IgG	 was	 spotted	 onto	 the	 NC	 membrane	 at	 a	 range	 of	
concentrations	(1.0,	0.8,	0.5,	0.2,	0.1	mg/mL)	via	a	standard	laboratory	pipette	(see	
section	 2.2.8).	 MAR	 response	 was	 shown	 to	 decrease	 as	 GAR	 concentration	 was	
reduced	and	use	of	“control”	conjugate	at	1/16	dilution	with	1	mg/mL	GAR	IgG	gave	
sufficient	signal	for	the	control	line	(approximately	600	-	800	MAR).		
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Figure	4.3.2.3.1	Titration	of	goat	anti-rabbit	IgG	capture	antibody	at	the	control	line	
position.	Antibody	was	prepared	 in	 PBS	 for	 spotting.	A	 concentration	of	 1	mg/mL,	
which	gave	the	highest	MAR	value,	was	selected	for	use	 in	Prototype	1.	The	rabbit	
IgG-SPMP	 “control”	 conjugate	 was	 utilised	 at	 a	 1/10	 dilution	 for	 this	 titration	 as	
opposed	 to	 the	 1/16	 dilution	 employed	 for	 subsequent	 testing	 events,	 including	
those	described	above	in	section	4.3.2.1.	Unfortunately,	there	was	 insufficient	GAR	
material	remaining	to	repeat	this	experiment	at	a	1/16	dilution.	
	
	
The	MICT®	system	 is	programmed	to	measure	magnetic	 signal	at	 specific	 locations	
on	the	 lateral	 flow	test	strip	which	correspond	to	the	test	and	control	regions.	The	
locations	of	 these	positions	are	communicated	to	the	reader	via	a	barcode	printed	
on	each	 test	 cassette.	 To	 investigate	 the	effect	of	 inaccurate	 spotting	on	 reported	
measurements,	 GAR	 IgG	 capture	 antibody	 was	 pipetted	 up	 to	 2	 mm	 in	 both	
directions	 from	 the	 known	 control	 line	 location	 (43.8	mm).	As	 illustrated	 in	 Figure	
4.3.2.3.2,	spotting	at	>1	mm	in	both	directions	from	the	control	line	position	resulted	
in	a	vast	drop	 in	MAR	response	reported	by	the	MICT®	 instrument.	Therefore,	 it	 is	
highly	 important	 to	ensure	 that	capture	antibody	 is	 spotted	 in	 the	precise	 location	
required.	
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Figure	4.3.2.3.2	Effect	of	capture	antibody	spot	position	on	MAR	response.	Position	1:	
2mm	above	control	line	position;	Position	2:	1mm	above	control	line	position;	Position	
3:	centre	of	control	line	position;	Position	4:	1mm	below	control	line	position;	Position	
5:	2mm	below	control	 line	position.	Spotting	of	antibody	at	the	centre	or	up	to	1mm	
above	this	position	is	required	to	ensure	maximum	signal	intensity.	
	
	
4.3.2.4	Selection	of	optimal	control	spot	drying	conditions	
	
To	ensure	 reproducibility	of	 the	 lateral	 flow	 test	 strip	prototype,	 it	 is	 important	 to	
standardise	 the	 drying	 conditions	 of	 the	 antibody	 spots.	 The	 GAR	 IgG	 capture	
antibody	 was	 spotted	 onto	 the	 NC	 membrane	 as	 described	 in	 section	 2.2.9.	 The	
wetted	 membrane	 was	 placed	 into	 foil	 pouches	 and	 incubated	 with	 desiccant	 to	
facilitate	drying	overnight	at	room	temperature	(20-25°C)	and	37°C.	A	superior	MAR	
response	was	observed	for	strips	dried	at	20-25°C.		
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Figure	 4.3.2.4.1	 Drying	 of	 control	 line	 spot	 overnight	 at	 varying	 incubation	
temperatures.	 The	 GAR	 IgG	 capture	 antibody	 produced	 a	 greater	 MAR	 response	
following	drying	at	20-25°C.	 It	 is	possible	 that	 the	higher	 temperature	of	37°C	may	
have	resulted	in	reduced	antibody	activity.	
	
4.3.2.5	Immobilisation	of	“control”	conjugate	on	a	glass	fibre	conjugate	pad	
	
To	reduce	the	number	of	handling	steps	in	the	lateral	flow	assay	protocol,	drying	of	
the	“control”	conjugate	was	attempted	by	pipetting	 the	diluted	conjugate	across	a	
clean	conjugate	pad	followed	by	drying	at	37°C	for	2	hours	prior	to	assembly	in	the	
test	strip.	On	the	first	assessment,	the	MAR	response	was	similar	between	the	“wet”	
and	 “dry”	 test	 methods	 (638.5	 vs.	 608.9	 MAR),	 indicating	 that	 a	 dried	 conjugate	
format	could	be	pursued.	However,	on	the	second	attempt	responses	of	1333.5	MAR	
and	 369.8	MAR	were	 recorded	 at	 the	 test	 and	 control	 line	 positions,	 respectively.	
There	 was	 clearly	 aggregation	 of	 SPMPs	 following	 release	 from	 the	 pad	 and,	
consequently,	 increased	 signal	 at	 the	 test	 line	 (the	 first	 position	 reached	 during	
sample	flow).	Due	to	the	dragging	and	deposition	of	the	SPMPs	at	this	location,	the	
control	 line	 signal	 was	 greatly	 reduced.	 To	 establish	 the	 feasibility	 of	 a	 working	
prototype,	 it	 was	 decided	 that	 the	 liquid	 format	 would	 be	 sufficient	 for	 current	
development	requirements.	
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Figure	4.3.2.5.1	Glass	fibre	conjugate	pad	following	loading	and	drying	of	rabbit	IgG-
SPMP	“control”	conjugate.	This	pad	was	sufficient	for	use	in	10	separate	test	strips,	
each	of	5mm	width.	
	
	
	
Figure	 4.3.2.5.2	Comparison	of	 lateral	 flow	 test	 strips	when	using	“dry”	and	“wet”	
rabbit	IgG-SPMP	“control”	conjugate	–	first	assessment.	
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4.3.3	 Optimisation	of	LFIA	test	conditions	for	the	test	line	configuration	
	
4.3.3.1	Covalent	 coupling	 of	 TAP	 antigen	 to	 carboxylated	 superparamagnetic	
particles	and	optimisation	of	conjugate	dilution	
	
Estapor	carboxyl-modified	SPMPs	were	used	 for	coupling	 to	primary	amines	 (-NH2)	
of	 the	TAP	antigen,	 as	per	 sections	2.2.7	 and	4.3.2.	 The	particles	were	 conjugated	
with	0.31,	0.47,	0.94	and	1.5	mg	of	peptide	per	3	mg	of	particles	and	the	resulting	
TAP-SPMP	 conjugates	were	 tested	 at	 various	 dilutions,	 as	 shown	 in	 Figure	 4.3.5.1.	
The	0.31	and	0.94	mg	TAP-SPMP	conjugates	returned	lower	MAR	response	for	their	
respective	1/2	and	1/3	dilutions	when	compared	to	the	other	conjugate	preparations	
and	thus,	were	deemed	inadequate	for	further	use.	The	1.5	mg	TAP-SPMP	conjugate	
maintained	 a	 response	 >900	 MAR	 up	 to	 a	 1/4	 dilution,	 demonstrating	 a	 greater	
likelihood	that	the	SPMPs	had	been	saturated	by	the	TAP	antigen.	Further	increases	
in	 dilution	 were	 required	 to	 reduce	 the	 MAR	 response	 for	 this	 conjugate	 when	
compared	to	the	other	TAP-SPMP	concentrations.	However,	the	0.47	mg	TAP-SPMP	
conjugate	was	able	to	closely	match	this	response	at	1/2	and	1/3	dilutions	and	thus	
was	selected	for	further	use	due	to	the	lower	peptide	stock	requirement.	
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Figure	 4.3.3.1.1	 Titration	 of	 TAP	 antigen	 used	 in	 SPMP	 conjugation	 protocol	 and	
optimisation	 of	 TAP-SPMP	 “test”	 conjugate	 dilution.	 An	 approximate	 response	 of	
1000	MAR	 was	 targeted	 for	 the	 test	 line.	 The	 0.47	 mg	 TAP-SPMP	 conjugate	 was	
selected	for	further	use	due	to	similar	MAR	response	seen	for	1/2	and	1/3	dilutions	
when	compared	to	use	of	1.50	mg	of	TAP.		
	
	
4.3.3.2	Titration	 of	 streptavidin	 and	 biotinylated	 anti-TAP	 capture	 antibody	 on	
nitrocellulose	membrane	at	the	test	line	position	
	
Streptavidin	protein	was	prepared	at	concentrations	of	10,	5,	2	and	1	mg/mL	in	PBS,	
containing	0.5%	(v/v)	green	dye	before	spotting	onto	NC	membrane	(section	2.2.9).	
The	 MAR	 response	 decreased	 as	 streptavidin	 concentration	 increased,	 potentially	
demonstrating	that	saturation	of	membrane	had	occurred	at	1	mg/mL.	The	variation	
in	MAR	 response	between	 replicates	may	also	have	 contributed	 to	 this	decreasing	
trend,	 e.g.	 for	 10	 mg/mL	 streptavidin,	 the	 %CV	 between	 replicates	 was	 72%.	
Nonetheless,	use	of	streptavidin	at	1	mg/mL	has	been	demonstrated	as	an	effective	
working	 concentration	 previously	 (Holstein	 et	 al.,	 2015)	 and	 would	 serve	 the	
requirements	for	development	feasibility.	
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Figure	 4.3.3.2.1	 Titration	 of	 streptavidin	 coating	 concentration	 on	 the	 NC	
membrane.	 Biotinylated	 anti-TAP	 capture	 antibody	 was	 used	 at	 1	 mg/mL.	 The	
highest	MAR	response	was	observed	for	1	mg/mL	concentration	and	was	considered	
sufficient	for	further	use	at	test	line.	
	
	
Biotinylated	 anti-TAP	 capture	 antibody	 was	 prepared	 at	 1.0,	 0.8,	 0.5,	 0.25,	 0.125,	
0.0625,	 and	 0.03125	 mg/mL	 concentrations	 in	 PBS	 prior	 to	 spotting	 onto	 the	
streptavidin-coated	NC	membrane	 (section	2.2.9).	 As	 expected,	 the	MAR	 response	
decreased	as	capture	antibody	concentration	was	reduced.	Due	to	the	high	cost	of	
producing	 the	biotinylated	material	 via	a	 commercial	 kit	 and	 the	 similar	 responses	
recorded	 for	 spotting	 concentrations	 of	 1.0	 and	 0.8	 mg/mL,	 use	 of	 the	 lower	
concentration	 of	 antibody	 was	 selected	 to	 reduce	 project	 costs.	 The	 TAP-SPMP	
“test”	conjugate	was	utilised	at	a	1/4	dilution	for	this	titration	as	opposed	to	the	1/2	
dilution	 employed	 for	 subsequent	 testing	 events.	 This	 was	 simply	 due	 to	 initial	
performance	testing	of	the	TAP-SPMP	conjugate	being	completed	before	the	larger	
scale	conjugate	titration	described	above	in	section	4.3.3.1.		
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Figure	4.3.3.2.2	(a)	Titration	of	biotinylated	anti-TAP	capture	antibody	in	conjunction	
with	1	mg/mL	streptavidin.	A	concentration	of	0.8	mg/mL	was	selected	 for	 further	
use	as	minimal	difference	in	MAR	response	was	observed	versus	1.0	mg/mL.	
	
	
	
Figure	 4.3.3.2.2	 (b)	TAP	test	 line	spot	devices	 following	 incubation	 for	45	minutes.	
Visual	 spot	 formation	 was	 strong	 following	 optimisation	 of	 streptavidin	 and	
biotinylated	anti-TAP	antibody	spot	concentrations.		
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4.3.3.3	Selection	of	optimal	test	line	spot	drying	conditions	
	
Numerous	 drying	 conditions	 were	 assessed	 for	 the	 test	 line	 spot	 in	 an	 effort	 to	
compare	both	the	incubation	conditions	used	for	the	ELISA	prototype	(section	2.2.6)	
and,	 other	 successful	 lateral	 flow	 devices	 dried	 at	 varying	 temperatures	
(Pattarawarapan	et	al.,	2007)	and	37°C	(Holstein	et	al.,	2015).	The	incubation/drying	
conditions	 investigated	 were	 as	 follows:	 Condition	 1:	 Streptavidin	 for	 2	 hours	 at	
37°C,	biotinylated	anti-TAP	antibody	overnight	at	37°C;	Condition	2:	Streptavidin	for	
2	hours	at	20-25°C,	biotinylated	anti-TAP	antibody	overnight	at	20-25°C;	Condition	3:	
Streptavidin	 and	 biotinylated	 anti-TAP	 antibody	 together	 at	 37°C	 overnight;	
Condition	 4:	 Streptavidin	 and	 biotinylated	 anti-TAP	 antibody	 together	 at	 20-25°C	
overnight;	 Condition	 5:	 Streptavidin	 overnight	 at	 37°C	 and	 biotinylated	 anti-TAP	
antibody	for	2	hours	at	37°C;	Condition	6:	Streptavidin	for	24	hours	at	20-25°C	and	
biotinylated	anti-TAP	antibody	for	24	hours	at	20-25°C	(separate	days);	Condition	7:	
Streptavidin	for	24	hours	at	37°C	and	biotinylated	anti-TAP	antibody	for	24	hours	at	
37°C	(separate	days).	
	
	
Figure	 4.3.3.3.1	 Drying	 of	 test	 line	 spot	 using	 various	 conditions.	 Condition	 4,	
whereby	the	streptavidin	and	biotinylated	anti-TAP	capture	antibody	were	incubated	
together	 overnight	 at	 room	 temperature,	 was	 selected	 for	 final	 test	 strip	
preparation.	 This	 condition	was	 also	 selected	 considering	 a	 drying	 temperature	 of	
37°C	appeared	to	reduce	signal	for	control	line	spot	result	(Figure	4.3.2.4.1).	
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4.3.4	 Complete	LFIA	device	testing	–	test	and	control	lines	(Prototype	1)	
	
4.3.4.1	Titration	of	test	and	control	line	configurations	in	combination	
	
Following	 separate	 optimisation	 of	 test	 and	 control	 line	 configurations,	 as	 per	
sections	4.3.2	and	4.3.3,	finalised	lateral	flow	test	strips	were	assembled	containing	
both	test	and	control	spotted	reagents.	A	decrease	in	the	control	line	MAR	response	
was	observed	for	these	devices	when	compared	to	testing	of	the	control	line	alone,	
as	seen	in	Figure	4.3.2.5.2,	for	example.	Alternative	dilutions	were	tested	to	increase	
MAR	response	for	the	“control”	conjugate	in	combination	with	the	“test”	conjugate	
(Figure	 4.3.4.1.1).	 However,	 it	 was	 noted	 that	 decreasing	 the	 “control”	 conjugate	
dilution	 also	 increased	 MAR	 response	 at	 the	 test	 line,	 indicating	 that	 there	 was	
possible	cross-reactivity	between	the	test	and	control	 lines.	A	reliable	 independent	
control	line	is	an	important	part	of	any	LFIA	POC	device,	particularly	when	the	device	
is	 designed	 to	 provide	 a	 diagnostic	 outcome	 whilst	 operated	 by	 untrained	
individuals.	A	specified	measuring	range	can	be	included	in	the	barcode	software	of	
the	 finalised	 test	 to	 indicate	 that	 a	 device	 has	 met	 the	 required	 response	 at	 the	
control	 line	 and	 therefore,	 the	 test	 result	 can	 be	 considered	 as	 valid.	 Hence,	 the	
control	line	ensures	that	the	test	strip	has	been	run	successfully.	Before	investigating	
the	potential	specificity	issue	further,	it	was	decided	to	continue	with	evaluation	of	
the	prototype	device	to	assess	performance	with	TAP	antigen-spiked	urine	samples.	
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Figure	 4.3.4.1.1	 Titration	 of	 rabbit	 IgG-SPMP	 “control”	 conjugate	with	 lateral	 flow	
test	 strip	 devices	 prepared	with	 test	 and	 control	 line	 configurations	 (Prototype	1).	
TAP-SPMP	“test”conjugate	 remained	at	1/2	dilution	 throughout	 testing.	All	 diluted	
conjugates	were	mixed	with	PBS	prior	to	loading	to	test	devices	(see	section	2.2.11).	
Decreasing	 “control”	 conjugate	 dilution	 increased	MAR	 response	 at	 both	 the	 test	
and	control	line	positions.	The	combination	of	“test”	and	“control”	conjugates	at	1/2	
and	1/8	dilutions,	 respectively,	was	 selected	 for	use	 in	 TAP	antigen	dose	 response	
testing	of	urine	samples.						
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Figure	 4.3.4.1.2	 Lateral	 flow	test	 strips	 (Prototype	1)	 showing	 test	and	control	 line	
spot.	 Visual	 spot	 formation	 appeared	 to	 be	 proportional	 to	 the	 intensity	 of	 MAR	
response,	particularly	at	the	control	line	position.	
	
	
4.3.4.2	Dose	response	curve	testing	using	GAR	/	rabbit	IgG-SPMP	control	 line	and	
biotinylated	anti-TAP	/	TAP-SPMP	test	line	(Prototype	1)		
	
To	determine	the	performance	of	the	lateral	flow	test	prototype,	the	urinary	TAP	QC	
panel	 established	 with	 the	 ELISA	 (section	 3.3.9)	 was	 tested	 to	 generate	 a	 dose	
response	 curve	 (QC1	=	207.4,	QC2	=	127.3,	QC3	=	62.6,	QC4	=	25.5	nmol/L,	mean	
concentrations	 as	 quantified	 by	 ELISA).	 Successful	 discrimination	 of	 varying	 TAP	
concentrations	would	 signify	 the	 feasibility	 of	 an	 operational	 prototype	 that	 could	
quantify	TAP	antigen	in	patient	samples.	Urine	samples	were	added	to	pooled	“test”	
and	“control”	conjugates	(1/2	and	1/8	dilutions,	respectively,	as	per	section	2.2.11)	
before	loading	to	the	test	devices	and	reading	with	the	MICT®	system.	
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Figure	4.3.4.2.1	Dose	response	curve	–	Test	Line.	The	variability	between	replicated	
was	%CV	=	<30%,	excluding	QC3.	A	signal	response	range	of	273.8	–	719.3	MAR	was	
demonstrated	 and	 some	 discrimination	 between	 QC	 samples	 also	 observed.	 The	
back-calculated	 concentrations	 for	 QC1	 –	 4	 were	 216.5,	 109.3,	 75.6,	 22.9	 nmol/L,	
respectively,	and	were	similar	to	the	mean	concentrations	established	by	the	ELISA	
prototype.	
	
	
Figure	4.3.4.2.2	MAR	response	at	control	 line	decreased	(from	894.2	–	480.7	MAR)	
with	 increasing	 sample	 concentration,	 exhibiting	 the	 possibility	 of	 cross-reactivity	
issues	due	to	rabbit	IgG-SPMP	control	conjugate	binding	to	test	line	capture	antibody	
and	 therefore	 reducing	 the	 conjugate	 available	 to	 bind	 and	 produce	 signal	 at	 the	
control	line	position.	Potential	for	aggregation	of	the	“test”	and	“control”	conjugates	
in	the	NC	membrane	also	existed.	However,	this	aggregation	was	not	visualised	upon	
inspection	of	the	test	strips.		
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4.3.5	 Optimisation	 of	 LFIA	 test	 conditions	 using	 chicken	 IgY	 control	 line	
configuration	
	
4.3.5.1	Covalent	 coupling	 of	 polyclonal	 chicken	 IgY	 to	 carboxylated	
superparamagnetic	 particles	 and	 optimisation	 of	 dilution	 for	 use	 in	 lateral	 flow	
assay	
	
The	 unsatisfactory	 results	 and	 potential	 cross-reactivity	 issue	 perceived	 with	
prototype	1,	lead	to	the	exploration	of	an	alternative	control	line	configuration	using	
a	combination	of	polyclonal	chicken	IgY-SPMP	conjugate	and	a	goat	anti-chicken	IgY	
capture	 antibody.	 There	 were	 several	 reasons	 for	 the	 selection	 of	 chicken	 IgY	 for	
evaluation.	 In	 traditional	 mammalian	 antibody	 generation,	 the	 animal	 must	 be	
repeatedly	 bled	 to	 obtain	 large	 quantities	 of	 a	 target	 antibody	 whereas	 chicken	
antibodies	are	transferred	from	serum	into	egg	yolk,	making	them	easier	to	obtain	in	
large	 quantities	 and	 so	 avoiding	 stress	 to	 the	 animal.	 Moreover,	 through	 the	
presence	of	an	extra	fragment	crystallisable	(Fc)	domain,	chicken	IgY	is	not	bound	by	
mammalian	antibodies	such	as	 rheumatoid	 factor	or	human	anti-mouse	antibodies	
(HAMA),	both	of	which	can	potentially	be	found	in	patient	samples	(incidence	of	<1	-	
10%)	and	can	be	a	source	of	false	positives	 in	diagnostic	tests	(Kricka,	1999;	Narat,	
2003;	Ismail,	2009).	Chicken	IgY	was	coupled	to	carboxyl-modified	SPMPs	via	primary	
amines	as	described	by	sections	4.3.2.1	(a)	and	2.2.8.	
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Figure	 4.3.5.1.1	Titration	of	chicken	 IgY	antibody	conjugated	to	SPMPs.	 	 Increasing	
the	amount	of	chicken	IgY	antibody	used	in	the	conjugation	protocol	beyond	0.31	mg	
did	not	 increase	 the	MAR	response,	 suggesting	 saturation	of	 the	particles.	Chicken	
IgY	 at	 a	 concentration	 of	 0.31mg	 was	 selected	 for	 preparation	 of	 the	 control	
conjugate	in	Prototype	2.	
	
	
	
Figure	4.3.5.1.2	Optimisation	of	chicken	IgY-SPMP	conjugate	dilution	in	TNTB	buffer.	
Due	 to	 a	 superior	 precision	 between	 replicates	 (CV	 =	 14%	 vs	 31%)	 and	 a	 MAR	
response	adequately	within	the	required	range	(600	-	800	MAR),	a	1/18	dilution	was	
selected	 ahead	 of	 a	 1/16	 dilution	 for	 use	 of	 the	 chicken	 IgY-SPMP	 conjugate	 in	
Prototype	2.	
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4.3.5.2	Titration	of	goat	anti-chicken	IgY	capture	antibody		
	
Goat	 anti-chicken	 (GAC)	 IgY	 was	 spotted	 onto	 the	 NC	 membrane	 at	 a	 range	 of	
concentrations	 (1.0,	 0.8,	 0.6,	 0.5,	 0.4,	 0.2,	 0.1	 mg/mL)	 via	 a	 standard	 laboratory	
pipette	(see	section	2.2.9)	and	tested	with	the	chicken	IgY-SPMP	“control”	conjugate	
at	a	1/18	dilution.	
	
	
	
	
Figure	4.3.5.2.1	Titration	of	GAC	IgY	capture	antibody.	Antibody	was	spotted	in	PBS.	
As	 for	 GAR	 titration	 (see	 4.3.2.3),	 concentrations	 <	 1	 mg/mL	 could	 potentially	 be	
used	 for	 test	 strip	 device.	 However,	 internal	 observations	 from	 previous	
development	work	have	shown	that	 it	 is	generally	preferable	 to	maintain	antibody	
concentration	at	1	mg/mL	for	specialised	 instruments	used	 in	production	of	 lateral	
flow	test	strips.	Consequently,	a	concentration	of	1	mg/mL	was	selected	 for	use	 in	
Prototype	2.	
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4.3.5.3	Comparison	 of	 complete	 lateral	 flow	 test	 strip	 device	 -	 Prototype	 2	 vs	
Prototype	1		
Following	 optimisation	 of	 the	 control	 line	 configuration	 for	 Prototype	 2,	 finalised	
lateral	 flow	 test	 strips	 were	 assembled	 containing	 both	 test	 and	 control	 spotted	
regions.	The	results	were	compared	with	Prototype	1.		
	
			
Figure	4.3.5.3.1	Testing	of	Prototype	2	lateral	flow	test	strip	device	compared	with	
previous	testing	for	Prototype	1	(taken	from	Figure	4.3.4.1).	The	test	and	control	line	
configurations	 of	 Prototype	 2	 appeared	 to	 operate	 independently,	 returning	MAR	
response	of	 652.1	 and	661.1,	 respectively.	 The	 control	MAR	was	 similar	 (661.1	 vs.	
735.6	MAR)	to	testing	performed	with	control	line	only	devices	(see	Figure	4.3.5.2.1).	
These	results	were	superior	to	Prototype	1	response	of	425.9	and	212.6	MAR	for	1/2	
and	1/16	dilutions	of	“test”	and	“control”	conjugates,	respectively.	These	Prototype	
1	results	were	specifically	selected	for	comparison	of	test	performance	at	the	highest	
“control”	 conjugate	 dilution.	 Higher	 dilutions	 were	 sought	 to	 limit	 the	 amount	 of	
particles	present,	and	reduce	the	opportunity	to	impede	sample	flow	across	the	test	
strip.	Further	cross-reactivity	testing	was	required	to	confirm	the	Prototype	2	result.		
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4.3.5.4	Dose	response	curve	testing	using	GAC	/	chicken	IgY-SPMP	control	line	and	
biotinylated	anti-TAP	/	TAP-SPMP	test	line	(Prototype	2)	–	initial	assessment	
	
To	determine	the	performance	of	this	lateral	flow	test	prototype,	the	urinary	TAP	QC	
panel	samples	were	added	to	pooled	“test”	and	“control”	conjugates	(1/2	and	1/18	
dilutions,	respectively,	as	per	section	2.2.12)	before	loading	to	the	test	devices	and	
reading	with	the	MICT®	system.	
	
	
	
Figure	 4.3.5.4.1	 Dose	 response	 curve	 –	 Test	 Line.	 Discrimination	 between	 QC	
samples	(MAR	range	=	258.2	–	862.7)	was	improved	when	compared	to	Prototype	1	
(MAR	range	=	273.8	–	719.3	MAR),	particularly	at	the	lower	end	of	the	concentration	
range	 (QC1,	 25.5	 nmol/L).	 The	 back-calculated	 concentrations	 for	 QC1	 –	 4	 were	
217.9,	 114.5,	 67.4,	 25.1	 nmol/L,	 respectively	 and	 were	 very	 similar	 to	 the	 mean	
concentrations	established	by	the	ELISA	prototype	(QC1	=	207.4,	QC2	=	127.3,	QC3	=	
62.6,	QC4	=	25.5	nmol/L).	The	improved	sensitivity	demonstrated	would	allow	users	
to	distinguish	between	“normal”	patients	and	those	with	acute	pancreatitis.	
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Figure	 4.3.5.4.2	 Control	 line	 MAR	 response	 remained	 relatively	 constant	 (565.9	
mean	 MAR),	 with	 the	 exception	 of	 response	 for	 QC3	 (447.2	 MAR).	 The	 variation	
between	replicates	for	each	QC	sample	tested	was	%CV	=	<20%,	demonstrating	good	
precision.	
	
	
	
	
Figure	4.3.5.4.3	Overlay	of	control	line	response	for	lateral	flow	prototypes	1	and	2.	
The	 use	 of	 chicken	 IgY-SPMP/GAC	 capture	 antibody	 control	 line	 configuration	 for	
Prototype	 2	 resulted	 in	 a	more	 constant	 control	 line	 response	when	 compared	 to	
prototype	 1.	 The	 control	 line	 for	 prototype	 2	 therefore	 appeared	 to	 operate	
independently	of	the	test	line.	
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4.3.6	 Cross-reactivity	 testing	 of	 biotinylated	 anti-TAP,	 goat	 anti-rabbit	 IgG	 and	
goat	 anti-chicken	 IgY	 capture	 antibodies	 for	 non-specific	 binding	 to	 “test”	 and	
“control”	conjugates	
	
To	 ensure	 that	 signal	 increase	 at	 the	 test	 and	 control	 lines	was	 specific,	 “control”	
conjugate	was	incubated	independently	with	spotted	anti-TAP	capture	antibody	test	
strips	and,	“test”	conjugate	was	incubated	independently	with	spotted	GAR	IgG	and	
GAC	 IgY	antibody	test	strips.	This	process	was	also	repeated	for	test	strips	sprayed	
using	the	Linomat	5.	MAR	response	was	subsequently	recorded	and	compared.	For	
both	 Prototype	 1	 and	 2,	 the	 MAR	 response	 for	 binding	 of	 test	 line	 to	 “control”	
conjugates	 was	 low	 (<20	 MAR),	 demonstrating	 no	 non-specific	 binding.	 GAR	 IgG	
control	 line	 binding	 to	 ‘test”	 conjugate	 was	 comparable	 (~20	 MAR),	 with	 higher	
response	 recorded	 for	GAC	 IgY	binding	of	“test”	conjugate	 (~43	MAR).	Subsequent	
comparison	of	spot	and	stripe	test	devices	with	an	 increased	dilution	of	TAP-SPMP	
“test”	 conjugate	 indicated	 that	 the	 response	 at	 GAC	 IgY	 control	 line	 could	 be	
decreased	 further	 (see	 Figure	 4.3.6.3).	 It	 is	 anticipated	 that	 the	 MAR	 response	
observed	 in	 these	 experiments	would	 be	 lowered	 further	 through	 optimisation	 of	
the	 test	 and	 control	 line	 spraying	 method	 using	 specialised	 instrumentation	 for	
lateral	flow	test	strip	preparation.		
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Figure	 4.3.6.1	 Specificity	 testing	 of	 biotinylated	 anti-TAP	 capture	 antibody	 with	
rabbit	IgG	and	chicken	IgY-SPMP	“control”	conjugates.	Minimal	cross-reactivity	(MAR	
=	 <20)	 was	 recorded	 for	 the	 anti-TAP	 capture	 antibody	 binding	 to	 both	 “control“	
conjugates.	The	MAR	response	was	even	lower	for	binding	of	chicken	IgY-SPMP	(<10	
MAR)	and	was	considered	negligible	as	it	was	close	to	background	noise	within	this	
lateral	 flow	 immunoassay.	 Rabbit	 IgG	 and	 chicken	 IgY	 “control”	 conjugates	 were	
utilised	at	1/16	and	1/18	dilutions,	respectively.	
	
	
Figure	 4.3.6.2	 Specificity	 testing	 of	 GAR	 IgG	 and	 GAC	 IgY	 capture	 antibodies	 with	
TAP-SPMP	 “test”	 conjugate.	 Response	 for	GAC	 IgY	 control	 line	was	 double	 that	 of	
GAR	 IgG	 control	 line.	 Increasing	 dilution	 of	 TAP-SPMP	 “test”	 conjugate	 to	 a	 1/3	
dilution	marginally	lowered	MAR	response	for	both	prototypes.	Further	optimisation	
was	investigated	as	shown	in	Figure	4.3.6.3.	
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Figure	 4.3.6.3	 Specificity	 testing	 –	 spot	 versus	 stripe.	 GAC	 IgY	 capture	 antibody-
spotted	 and	 striped	devices	were	 tested	with	 TAP-SPMP	 “test”	 conjugate	 at	 a	 1/4	
dilution	 as	 a	 continuation	 of	 testing	 from	 Figure	 4.3.6.2.	 The	 response	 for	 each	
device	format	was:	Spot	device	=	26.6	MAR,	stripe	device	=	20.1	MAR.	Increasing	the	
conjugate	dilution	from	the	1/2	and	1/3	dilutions,	shown	in	Figure	4.3.6.2,	reduced	
the	 number	 of	 particles	 present	 in	 the	 test	 strip,	 and	 using	 the	 Linomat5	 for	
automated	striping	of	the	capture	antibody	improved	the	non-specific	signal	further.	
Further	 improvement	 could	 reasonably	 be	 expected	 following	 preparation	 of	 test	
strips	with	more	 specialised	 instrumentation	 specific	 to	 lateral	 flow	 requirements,	
such	as	the	IsoflowTM	reagent	dispenser	system.	
	
4.3.7	 Comparison	of	test	and	control	line	performance	-	spot	vs	stripe 
	
In	an	effort	to	automate	the	preparation	of	the	lateral	flow	test	device,	the	CAMAG	
Linomat	5	dispenser	was	utilised	for	antibody	application	to	the	NC	membrane.	Test	
line	and	control	 lines	were	striped	at	54	and	44mm	from	the	base	card	end	of	 the	
absorbent	upper	wick	pad	as	 this	was	 closest	 the	 Linomat	5	 could	 conform	 to	 the	
required	 locations	 of	 54.2	 and	 43.8	 mm,	 respectively.	 Striped	 devices	 exhibited	
analogous	 variation	 to	 the	 spot	 devices	 at	 the	 control	 line	 position	 and	 improved	
precision	 at	 the	 test	 line	 position.	 The	 MAR	 response	 was	 increased	 at	 both	
positions,	offering	the	opportunity	to	increase	conjugate	dilutions	and	thus	decrease	
the	amount	of	particles	present	 in	the	test	system,	which	 in	turn	would	facilitate	a	
cleaner	signal.		
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Figure	4.3.7.1	(a)	Control	line	response	following	spotting	and	striping	of	the	GAC	IgY	
capture	antibody	on	the	NC	membrane.	The	variation	between	replicates	for	striped	
devices	was	consistent	with	spot	devices	(%CV	=	18	vs.	17%)	and	an	increased	mean	
MAR	 response	 was	 observed	 (934.7	 vs.	 776.3	 MAR).	 The	 control	 conjugate	 was	
utilised	at	a	1/18	dilution.	
	
	
	
Figure	 4.3.7.1	 (b)	 Lateral	 flow	 test	 devices	 with	 GAC	 IgY	 control	 line	 striped	 by	
Linomat.	
0	
200	
400	
600	
800	
1000	
Spot	 Stripe	
M
AR
	
Control		
		 123	
	
	
Figure	 4.3.7.2	 (a)	Test	 line	 response	 following	 spotting	and	striping	of	 streptavidin	
and	 biotinylated	 anti-TAP	 capture	 antibody	 on	 a	 NC	 membrane.	 The	 variation	
between	replicates	for	the	striped	devices	was	superior	to	spot	devices	(%CV	=	13	vs.	
21%)	and	increased	mean	MAR	response	was	observed	(1588.9	vs.	904.6	MAR).	Test	
conjugate	was	utilised	at	a	1/4	dilution.	
	
	
	
Figure	4.3.7.2	(b)	Lateral	flow	test	devices	with	anti-TAP	test	line	striped	by	Linomat.	
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4.3.8	 Dose	response	curve	testing	for	Prototype	2	–	final	assessment	
	 	
4.3.8.1	Dose	response	curve	testing	using	 lateral	 flow	devices	with	GAC	/	chicken	
IgY-SPMP	control	line	and	streptavidin	/	biotinylated	anti-TAP	/	TAP-SPMP	test	line	
(Separate	devices	–	antibody	spot)	
	
Lateral	flow	test	strips	were	prepared	with	a	GAC	IgY	control	line	only	and	test	line	
only	 for	assessment	with	 the	urinary	TAP	QC	panel	and	comparison	with	complete	
devices	containing	both	the	test	and	control	lines.	The	QC	panel	samples	were	added	
to	the	“control”	conjugate	only	at	a	1/18	dilution	(as	per	section	2.2.12)	and	“test”	
conjugate	 only	 at	 a	 1/4	 dilution	 (as	 per	 section	 2.2.12)	 before	 loading	 to	 the	 test	
devices	 and	 reading	 with	 the	 MICT®	 system.	 TAP-SPMP	 conjugate	 (1.5	 mg)	 was	
utilised	for	this	test	event.	
	
	
Figure	 4.3.8.1.1	 Control	 line	 response	 for	 spotted	 device	 with	 control	 line	
configuration	 only.	 The	 response	 was	 lower	 for	 QC2	 and	 QC3	 samples	 when	
compared	 to	 QC1,	 QC4	 and	 negative	 sample	 (NEG).	 Despite	 this,	 imprecision	 and	
MAR	responses	for	all	QC	samples	were	within	a	satisfactory	specification	with	%CV	
=	 <20%	 and	 mean	 control	 response	 of	 ±20%.	 Although	 responses	 bordered	 the	
desired	specification	range	(600	–	800	MAR),	the	signal	remained	relatively	constant	
across	 all	 samples	 tested	 and	 was	 once	 again	 not	 affected	 by	 increasing	 TAP	
concentration.	
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Figure	 4.3.8.1.2	 Test	 line	 MAR	 response	 for	 spotted	 device	 with	 test	 line	
configuration	only.	Recorded	measuring	range	was	75.2	–	766.0	MAR	for	QC1	-	4	and	
negative	 (NEG)	 samples,	 with	 greater	 distinction	 between	 sample	 concentrations	
compared	to	previous	test	formats	(see	Figures	4.3.5.4.1	and	4.3.4.2.1).	Imprecision	
(%CV)	 between	 replicates	was	 <20%	 for	 the	QC3,	 QC4	 and	 negative	 samples	 and,	
22%	 and	 46%	 for	 QC2	 and	 QC1,	 respectively.	 Higher	 variation	 observed	 for	 QC1	
sample	was	due	to	variability	of	MAR	signal	at	the	lower	end	of	the	measuring	range	
–	a	common	occurrence	with	most	immunoassays	where	the	%CV	is	higher	as	values	
approach	 zero.	 Back-calculated	 QC	 sample	 concentrations	 were	 uniform	 with	 the	
concentrations	established	using	the	ELISA	prototype.	
	
4.3.8.2	Dose	response	curve	testing	using	GAC	/	chicken	IgY-SPMP	control	line	and	
streptavidin	 /	 biotinylated	 anti-TAP	 /	 TAP-SPMP	 test	 line	 (Complete	 device	 –	
antibody	spot)	
	
Following	 improved	test	 line	performance	using	1.5	mg	TAP-SPMP	“test”	conjugate	
and	acceptable	precision	results	for	GAC	IgY	control	line	on	separate	devices	(section	
4.3.8.1),	 finalised	LFIA	devices	with	both	 test	and	control	 lines	were	assembled	 for	
evaluation.	 In	 addition,	 a	 comparison	 of	 spotted	 versus	 striped	 devices	 was	
performed.	 The	 “test”	 and	 “control”	 conjugates	 were	 diluted	 1/4	 and	 1/18,	
respectively,	prior	to	addition	of	the	urinary	TAP	QC	panel	samples,	loading	onto	test	
devices	and,	reading	with	the	MICT®	system.	
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Figure	 4.3.8.2.1	 Prototype	 2:	 Test	 line	 response	 for	 spotted	 devices.	 (a)	 Test	 line	
response	 for	 each	 QC	 sample	 was	 normalised	 against	 the	 “negative”	 urine	 sample	
response	(%MAR/MAR0).	Measuring	range	was	found	to	be	19.0	–	713.5	MAR,	with	a	
decreased	 MAR	 response	 observed	 for	 QC1	 (207.4	 nmol/L)	 and	 QC3	 (62.6	 nmol/L)	
compared	to	those	devices	run	with	the	test	line	only	(Figure	4.3.8.1.2).	For	QC1,	this	
was	 largely	 due	 to	 the	 high	 variation	 between	 replicates	 (%CV	 =	 145%)	 with	 some	
devices	 returning	 “0	MAR”	values.	 The	 increased	 “test”	 conjugate	dilution	may	have	
contributed	to	the	high	variation.	Precision	(%CV)	across	the	other	samples	tested	was	
more	satisfactory	–	QC2	=	25%,	QC3	=	19%,	QC4	=	9%,	Negative	=	13%.	Repeat	testing	
of	QC3	may	potentially	show	an	improvement	in	overall	performance	if	MAR	response	
were	to	 increase.	(b)	Overlay	of	 test	 line	dose	response	curves	showing	devices	with	
test	line	only	(black	line	curve,	see	also	Figure	4.3.8.1.2)	and	devices	with	both	test	and	
control	lines	(complete	device:	red	line)	are	also	displayed.	Curves	were	similar	for	the	
complete	device,	with	the	exception	of	the	QC3	response.	A	drop	from	369.2	to	172.2	
MAR,	despite	acceptable	variability	(%CV	=	19%),	when	compared	to	devices	run	with	
test	 line	 configuration	 only,	 would	 not	 have	 been	 foreseen.	 This	 may	 be	 another	
example	of	the	existing	variability	in	the	spotting	method.		
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Figure	 4.3.8.2.2	Prototype	2:	Control	 line	response	 for	spotted	devices.	 (a)	Control	
line	response	was	 lower	than	previous	testing	 (see	Figures	4.3.8.1.1	and	4.3.5.4.2).	
The	 reason	 for	 this	 was	 unknown.	 However,	 with	 the	 exception	 of	 QC4	 (25.5	
nmol/L),	 control	 response	 was	 within	 ±20%	 of	 mean	 control	 response	 across	 all	
samples	tested.	Response	also	remained	constant	across	QC1	-	3	and	negative	urine	
sample,	with	 variation	 between	 replicates	 (%CV)	 being	 <30%	–	QC1	 =	 29%,	QC2	 =	
16%,	 QC3	 =	 11%,	 QC4	 =	 28%,	 Negative	 =	 22%.	 (b)	 Overlays	 of	 control	 line	 dose	
response	 testing	 using	 devices	with	 control	 line	 only	 (blue	 line)	 and,	 devices	with	
both	test	and	control	lines	(complete	device:	red	line))	are	also	shown.	
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4.3.8.3	Dose	response	curve	testing	using	GAC	/	chicken	IgY-SPMP	control	line	and	
streptavidin	 /	 biotinylated	 anti-TAP	 /	 TAP-SPMP	 test	 line	 (Complete	 device	 –	
antibody	stripe)	
	
	
Figure	 4.3.8.3.1	 Prototype	 2:	 Striped	 devices	 -	 Test	 line	MAR	 response	 for	 striped	
lateral	flow	test	devices.	The	“test”	and	“control”	conjugates	were	used	at	the	same	
dilution	 as	 the	 spot	 devices	 (1/4	 and	 1/18	 respectively).	 The	 results	 for	 all	 QC	
samples	 were	 normalised	 against	 the	 “negative”	 urine	 sample	 response	
(%MAR/MAR0).	Recorded	measuring	range	was	232.3	–	712.2	MAR,	showing	12-fold	
higher	response	for	QC1	(232.2	vs.	19.0	MAR).	This	demonstrated	the	potential	 for	
the	 striped	device	 to	extend	 the	TAP	 concentration	measuring	 range	beyond	~200	
nmol/L,	if	required.	MAR	response	was	comparable	to	spot	device	for	negative	urine	
sample	 (712.2	 vs.	 713.5	 MAR),	 indicating	 the	 maximum	 signal	 response	 of	 the	
current	 prototype.	 There	 was	 less	 distinction	 between	 negative,	 QC4	 and	 QC3	
samples	 in	 comparison	 to	 the	 spot	device	prototype	 (%MAR/MAR0	of	 spot	device:	
Negative	=	100%;	QC4	=	64%;	QC3	=	24%;	QC2	=	15%;	QC1	=	3%),	(%MAR/MAR0	of	
stripe	device:	Negative	 =	 100%;	QC4	=	 96%;	QC3	=	 75%;	QC2	=	 58%;	QC1	=	 33%),	
indicating	that	the	stripe	device	may	have	a	reduced	sensitivity.	This	was	not	ideal	as	
the	 reliability	 to	distinguish	between	 response	values	 is	paramount	 to	a	prototype	
that	must	be	capable	of	segregating	patient	prognosis	based	on	differences	 in	TAP	
levels.	Imprecision	(%CV)	for	all	samples	tested	was	<20%,	with	the	exception	of	QC2	
(32%).	Overlay	of	test	line	dose	response	curves	showing	devices	with	test	line	only	
and	 devices	 with	 both	 test	 and	 control	 lines	 (complete	 device,	 spot)	 are	 also	
displayed.	
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Figure	 4.3.8.3.2	 Prototype	2:	 Striped	devices	 -	Control	 line	 response	was	generally	
higher	 compared	 to	 spot	 device	 testing.	Mean	 response	 of	 all	 samples	was	 413.0	
MAR	 for	 striped	 devices	 and	 330.4	 MAR	 for	 spot	 devices.	 QC1	 -	 3	 control	 line	
responses	were	within	±20%	of	the	mean	control	response.	QC4	(25.5	nmol/L)	and	
negative	urine	 (0	nmol/L)	produced	a	higher	and	 lower	 response	 (523.2	and	276.8	
MAR,	respectively)	than	the	413.0	±	20%	MAR	range,	and	were	therefore	outside	of	
this	mean	control	range.	This	was	due	to	the	variability	observed	between	replicates,	
with	 precision	 results	 across	 the	 devices	 being	 predominantly	 inadequate	 (%CV	 =	
>20%)	–	QC1	=	41%,	QC2	=	32%,	QC3	=	15%,	QC4	=	17%,	Negative	=	39%.	Although	
these	 results	 demonstrated	 an	 increased	overall	MAR	 response	 at	 the	 control	 line	
position	 and	 hence;	 indicated	 the	 feasibility	 of	 a	 striped	 lateral	 flow	 device	
prototype,	 variability	 arising	 from	 the	 application	 method	 still	 existed.	 Overlay	 of	
control	line	dose	response	testing	is	also	shown	comparing	devices	with	control	line	
only	and,	devices	with	both	test	and	control	lines	(complete	device,	spot).	
	
	
	
QC1			QC2	QC3	
	QC4	
NEG	
QC1	
QC2	
QC3	QC4	
NEG	
QC1	QC2	
QC3	
QC4	
NEG	
0	
200	
400	
600	
800	
1000	
0	 50	 100	 150	 200	 250	
M
AR
	
TAP	ConcentraQon	(nmol/L)	
Control	Line	(Complete	Device,	Spot)	
Control	Line	(Complete	Device,	Stripe)	
Control	Line	Only	(from	ﬁgure	4.3.8.1.1)	
		 130	
	
	
Figure	4.3.8.3.3	Prototype	2	devices	with	test	and	control	lines	striped	by	Linomat.	
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4.4	 DISCUSSION	AND	CONCLUSION	
	
The	 feasibility	 of	 developing	 a	 lateral	 flow	 test	 strip	device	 capable	of	 distinguishing	
between	varying	concentrations	of	urinary	TAP	was	described	in	this	chapter.	Initially,	
a	lateral	flow	device	(Prototype	1)	utilising	a	rabbit	IgG-SPMP	conjugate	and	goat	anti-
rabbit	IgG	capture	antibody	for	the	control	line	was	constructed	and	evaluated.	Issues	
were	observed	for	this	prototype	when	both	the	test	and	control	lines	were	combined.	
However,	 specificity	 testing	 demonstrated	 that	 there	 was	 negligible	 cross-reactivity	
between	 the	 capture	 reagents	 and	 the	 opposing	 test	 or	 control	 SPMP	 conjugates.	
Therefore,	 stability	 of	 the	 rabbit	 IgG-SPMP	 conjugate	 may	 have	 contributed	 to	 the	
difficulties	 encountered	 for	 this	 prototype.	 An	 alternative	 independent	 control	 line	
configuration	 was	 investigated	 using	 a	 chicken	 IgY-SPMP	 conjugate	 and	 goat	 anti-
chicken	IgY	capture	antibody	(Prototype	2).	This	control	line	configuration	was	shown	
to	 be	 reproducible	 and	 functioned	 independently	 of	 fluctuating	 TAP	 antigen	
concentrations.	 While	 variation	 between	 replicates	 was	 higher	 than	 desirable	 for	
certain	 samples	 tested,	 this	 did	 not	 reduce	 the	 ability	 of	 Prototype	 2	 to	 distinguish	
between	TAP	antigen	concentrations	when	spiked	into	urine.	Repeat	testing	with	the	
urinary	TAP	QC	panel	samples	and	Prototype	2	could	not	be	performed	due	to	funding	
availability	 at	 this	 time.	 However,	 future	 work	 would	 investigate	 the	 points	 raised	
surrounding	improvement	of	the	dose	response	curve	shape.	
Once	feasibility	of	a	functional	test	strip	that	met	the	predefined	requirements	
was	demonstrated,	 initial	 assessment	of	 alternative	buffer	 formulations	 for	antibody	
spotting	 was	 undertaken.	 This	 work	 included	 addition	 of	 surfactants,	 such	 as	
Synperonic	 F108	 and	 Triton	 X-100,	 at	 very	 low	 concentrations	 (0.006%,	w/v)	 in	 PBS	
(Mujawar,	 2001).	 Unfortunately,	 high	 variation	 was	 observed	 between	 replicates	 as	
well	as	the	migration	of	antibody	spot	location	across	the	NC	membrane	on	inclusion	
of	Synperonic	F108.	MAR	responses	for	antibody	spots	using	Triton	X-100	were	shown	
to	be	lower	than	use	of	PBS	alone.	Use	of	carbonate	buffer	(100	mM,	pH	9.6)	was	also	
assessed	due	to	its	potential	to	aid	in	the	formation	of	a	more	uniform	spot	(Mujawar,	
2001).	The	MAR	response	using	the	carbonate	buffer	was	slightly	lower	than	with	use	
of	PBS	and	no	improvement	to	spot	formation	was	observed.	Thus,	the	use	of	PBS	for	
antibody	spotting	was	deemed	suitable	for	prototype	development.	
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Blocking	of	the	NC	membrane	with	proteins	such	as	BSA	to	reduce	non-specific	binding	
and	 background	 noise	 in	 the	 assay	 is	 sometimes	 applied	 in	 lateral	 flow	 test	 strip	
preparation	(Mansfield,	2014).	The	MICT®	system	used	for	this	project	had	the	ability	
to	 monitor	 background	 signal	 throughout	 all	 testing	 events	 and	 consequently,	
indirectly	 aided	 test	 strip	 preparation	 by	 eliminating	 the	 need	 for	 an	 additional	
blocking	 step	 prior	 to	 use.	 The	 barcode	 supplied	with	 the	 test	 cassette	 contains	 an	
algorithm	to	instruct	the	MICT®	system	to	read	three	individual	positions	across	all	test	
strips	which	correspond	to	two	test	regions	(54.2	mm	and	49mm	from	upper	wick	end	
of	the	base	card,	respectively)	and	a	control	(43.8	mm)	region.	The	raw	data	from	this	
project	continuously	and	conclusively	demonstrated	that	it	was	unnecessary	to	include	
a	nitrocellulose-blocking	step	during	test	strip	preparation.	 In	addition	to	providing	a	
simple	method	 to	monitor	 non-specific	 binding	 or	 deposition	 of	 particles	 in	 the	 NC	
membrane,	this	barcode	also	allows	for	the	inclusion	of	another	test	line.	This	feature	
would	 facilitate	 the	development	of	 a	multiplex	 test	 strip	 capable	of	measuring	 two	
individual	markers	with	an	independent	control	line,	should	such	a	need	arise.	
The	CAMAG	Linomat	5	dispenser	instrument	was	utilised	for	capture	antibody	
striping	 on	 the	 NC	membrane	 to	 reduce	 the	 hands-on	 requirement	 of	 the	 spotting	
method	 and	 thus	 potentially	 improve	 variability	 observed.	 The	 striping	method	was	
not	applied	in	the	first	instance	due	to	the	concern	that	the	limited	materials	available	
would	 be	 exhausted	 before	 prototype	 feasibility	 was	 established.	 Ultimately,	 the	
striping	 method	 was	 refined	 to	 ensure	 that	 the	 same	 volume	 of	 capture	 antibody	
solution	was	used	for	application	to	the	NC	membrane	(0.1	μL	per	5	mm,	totaling	0.5	
μL	 per	 test	 strip).	 Of	 course,	 an	 additional	 volume	 was	 still	 required	 to	 prime	 the	
dispenser.	As	discussed	by	Wong	et	al.	(2009)	and	the	Millipore	Corporation	(2008),	it	
is	 imperative	 to	optimise	 the	 final	width	of	 the	dried	 capture	 line	 as	 signal	 intensity	
increases	 with	 decreasing	 capture	 line	 width.	 This	 is	 due	 to	 the	 same	 amount	 of	
particles	being	bound	and	concentrated	in	small	area	within	the	required	line	location	
versus	a	larger	area. When	the	antibody	solution	was	striped	onto	the	NC	membrane	
for	Prototype	2,	the	width	of	the	dried	capture	line	was	narrower	than	the	striped	line	
width	 following	 initial	 application	 on	 the	 NC	 membrane. However,	 during	 testing,	
some	binding	was	observed	at	the	horizon	beyond	the	actual	reading	location	for	the	
test	line.	Numerous	factors	can	affect	the	width	of	the	dried	capture	line,	including	the	
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thickness	of	the	NC	membrane,	the	distance	of	the	striping	head	from	the	membrane	
and	 the	 rate	 of	 striping	 (Millipore,	 2008).	 It	was	 believed	 that	 the	 force	 of	 spraying	
antibody	 solution	 onto	 the	 NC	 membrane	 caused	 the	 capture	 antibody	 to	 travel	
outside	the	required	line	location.	Attempts	to	reduce	the	rate	of	application	did	not	
curtail	 the	 extent	 to	 which	 the	 solution	 travelled	 across	 the	 NC	 membrane. The	
capillary	flow	rate	of	the	membrane	can	also	cause	the	capture	 line	width	to	spread. 
Still,	this	issue	was	only	observed	with	the	test	line	and	may	therefore	simply	require	
optimisation	of	test	line	reagents	rather	than	the	excessive	and	laborious	assessment	
of	NC	materials. The	final	recorded	result	was	not	affected	but	demonstrated	that	the	
Linomat	5	instrument	was	truly	inadequate	for	the	specialised	preparation	of	LFIA	test	
strips.		
While	the	Prototype	2	lateral	flow	test	device	will	require	further	optimisation	
to	 improve	 variability	 observed	 during	 this	 work,	 testing	 of	 urinary	 QC	 samples	
indicated	 that	 discrimination	 between	 varying	 TAP	 concentrations	 was	 possible.	
Therefore,	 evaluation	 with	 TAP	 positive	 and	 negative	 clinical	 urine	 samples	 from	
patients	with	confirmed	cases	of	acute	pancreatitis	should	be	undertaken	as	the	next	
step	 to	 confirm	 that	 the	 prototype	 is	 capable	 of	 distinguishing	 between	 highly	
contrasted	concentrations	of	native	TAP	in	the	urine	matrix.	
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5.1	 INTRODUCTION	
	
Clinical	 evaluation	 is	 an	 essential	 step	 in	 fully	 defining	 the	 performance	 of	 any	
medical	device.	This	assessment	provides	both	feedback	on	product	performance	in	
the	 field	 and	 relevant	 clinical	 data	 for	 the	 biomarker	 of	 interest.	 It	 also	 verifies	
clinical	 safety,	 thus	 identifying	 potential	 risks.	 Consequently,	 it	 is	 best	 practice	 to	
begin	a	clinical	evaluation	of	any	test	device	prototype	at	the	earliest	convenience,	
once	 technical	 performance	and	 reproducibility	have	been	established.	 This	 allows	
the	manufacturer	to	stagger	the	development	process,	gaining	sufficient	information	
prior	 to	 marketing	 or	 submitting	 a	 device	 for	 conformity	 assessment	 by	 the	
regulatory	 authorities.	 Moreover,	 the	 clinical	 evaluation	 process	 is	 ongoing	
throughout	the	 life-cycle	of	any	test	device	and,	 therefore,	 it	 is	highly	beneficial	 to	
begin	this	process	as	soon	as	possible	(European	Commission,	2009).	
The	 EU	 has	 sought	 to	 provide	 guidelines	 on	 clinical	 evaluation	 through	
continued	consultation	with	relevant	parties	in	the	medical	device	industry,	including	
National	Competency	Authorities	and	Notified	Bodies.	These	guidelines	seek	to	work	
towards	 a	 uniform	 application	 in	 member	 states	 and	 are	 summarised	 in	 the	
document	 “Clinical	 Evaluation:	 A	 Guide	 for	 Manufacturers	 and	 Notified	 Bodies	
(MEDDEV	2.7.1	Rev.3)“.	They	are	not	legally	binding	but,	are	relevant	to	the	Medical	
Devices	Directive	(Directive	2007/47/EC)	and	the	international	standards	ISO	14155-
1:	 2011,	 and	 14971:	 2007	 relating	 to	 clinical	 investigations	 and	 medical	 device	
application.	 The	 scope	 of	 the	 clinical	 study	must	 include	 a	 defined	 patient	 cohort	
that	the	device	is	intended	to	analyse	and	the	identification	of	the	current	treatment	
standards	 in	 this	 area,	 including	 any	 harmonised	 guidelines	 or	 scoring	 systems,	
diagnostic	 biomarkers	 or	 imaging	 detection	 methods	 and	 treatment	 or	 surgical	
interventions	employed	by	the	clinician.	These	considerations	must	be	described	in	
complete	detail	in	a	clinical	sample	collection	protocol	and	submitted	to	the	hospital	
ethics	board	 for	approval.	Additionally,	 a	patient	 consent	 form	must	be	drafted	 to	
supply	potential	study	participants	with	sufficient	information	that	is	clear	and	easily	
understood	by	a	non-scientific	audience.	Sample	collection	can	only	commence	once	
ethical	 approval	 is	 granted	 (Friedman	et	al.,	 2010).	As	mentioned	before,	 previous	
clinical	 studies	 have	 been	 undertaken	 with	 a	 polyclonal	 anti-TAP	 ELISA	 that	
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performed	 well	 in	 the	 prediction	 of	 patients	 with	 AP	 who	 would	 subsequently	
develop	 severe	 disease.	 A	 literature	 search	 was	 completed	 to	 assess	 the	 sample	
collection	 protocols	 of	 these	 various	 studies	 and	 guide	 the	 drafting	 of	 the	 clinical	
protocol	 for	 the	 study	 discussed	 herein.	 This	 study	 would	 seek	 to	 establish	 an	
exploratory	phase	assessment	of	device	capability	to	measure	TAP	antigen	in	10	-	50	
clinical	urine	samples,	with	blinded	interpretation	of	data	required	to	avoid	bias	and	
uphold	diagnostic	accuracy	(Weinstein	et	al.,	2005).		
There	are	several	approaches	for	measuring	the	diagnostic	performance	of	a	
test	to	detect	a	patient	with	disease	versus	a	patient	without	disease.	These	include	
negative	predictive	value	 (NPV),	positive	predictive	value	 (PPV)	and,	sensitivity	and	
specificity	 analyses.	 The	 NPV	 and	 PPV	 refer	 to	 the	 probability	 that	 a	 test	
measurement	 will	 lead	 to	 the	 correct	 diagnosis	 of	 a	 patient.	 The	 NPV	 is	 the	
proportion	of	patients	who	are	not	likely	to	have	disease	given	a	negative	result	and	
the	PPV	is	the	proportion	of	patients	who	are	likely	to	have	disease	given	a	positive	
result.	 The	 PPV	 and	 NPV	 are	 particularly	 pertinent	 to	 patient	management	 in	 the	
clinical	setting,	providing	likelihood	of	whether	a	patient	does	or	does	not	have	the	
disease	 based	 on	 the	 test	 result	 (Akobeng,	 2007).	 Thus,	 a	 patient	with	 a	 negative	
result	can	require	only	minor	observation	or	be	discharged	from	hospital,	 reducing	
the	 demand	 placed	 on	 resources.	 This	 would	 be	 of	 particular	 relevance	 to	 the	
treatment	 of	 AP,	 where	 segregation	 of	 patients	 into	 mild,	 moderate	 and	 severe	
categories	 is	 paramount	 to	 patient	 management	 and	 outcome.	 Sensitivity	 and	
specificity	are	properties	of	the	diagnostic	test,	indicating	accuracy	of	performance.	
Altman	and	Bland	(1994)	defined	sensitivity	as	“the	proportion	of	true	positives	that	
are	 correctly	 identified	 by	 the	 test”	 and	 specificity	 as	 “the	 proportion	 of	 true	
negatives	 that	 are	 correctly	 identified	by	 the	 test”.	 In	 this	way,	 the	 sensitivity	 and	
specificity	 are	 post-treatment	 parameters	 that	 are	 defined	 from	 known	 patient	
outcomes	 and	 cannot	 be	 used	 to	 define	 the	 probability	 that	 a	 test	 result	 is	 an	
indicator	of	disease	or	no	disease.	A	 test	with	high	 sensitivity	will	detect	a	greater	
amount	of	patients	with	the	disease	such	that,	a	negative	result	would	indicate	that	
a	patient	is	highly	unlikely	to	have	the	disease.	However,	this	is	also	reliant	on	a	high	
specificity,	where	a	negative	result	 is	truly	negative	and	therefore,	a	patient	with	a	
positive	 result	 is	 likely	 to	have	 the	disease	 (Akobeng,	2007).	Consequently,	neither	
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parameter	should	be	reported	without	the	other	(Weinstein	et	al.,	2005).	As	PPV	and	
NPV	 are	 parameters	 that	 can	 be	 defined	 post-test,	 their	 value	 is	 greater	 in	 the	
clinical	setting	where	patient	management	is	the	highest	priority	(Akobeng,	2007).	
	
The	validity	of	diagnostic	performance	is	calculated	using	sensitivity,	specificity	and	
PPV	and	NPV	as	follows	(Indrayan	&	Sarmukaddam,	2001):	
	
					 	 	Sensitivity	=																	True	Positive	(n)																						x	100	
																	 	 True	Positive	(n)	+	False	Negative	(n)	
	
						 								 		Specificity	=															True	Negative	(n)																							x	100	
																 	 True	Negative	(n)	+	False	Positive	(n)	
	
			Positive	Predicitve	Value	(PPV)	=																True	Positive	(n)																								x	100	
														 	 True	Positive	(n)	+	False	Positive	(n)	
	
	Negative	Predicitve	Value	(PPV)	=																True	Negative	(n)																							x	100	
														 	 True	Negative	(n)	+	False	Negative	(n)	
	
	
5.2	 AIMS	OF	THIS	CHAPTER	
	
The	analysis	and	evaluation	of	a	patient	group	with	confirmed	clinical	cases	of	acute	
pancreatitis	 using	 the	 competitive	 anti-TAP	 ELISA	 prototype,	 developed	 as	 per	
chapter	3,	will	be	described.	
	
The	clinical	utility	of	the	TAP	biomarker	to	segregate	patients	based	on	potential	to	
develop	mild,	moderate	and	severe	conditions	of	acute	pancreatitis	will	be	explored.	
The	analysis	of	the	clinical	urine	samples	will	also	include	dipstick	urinalysis	testing	to	
assess	the	urine	matrix	collected	from	each	of	the	study	participants.	
	
In	addition,	the	 lateral	 flow	test	strip	device	prototype,	described	 in	chapter	4,	will	
be	evaluated	for	its	ability	to	distinguish	between	TAP	positive	and	negative	clinical	
urines.	This	will	further	serve	the	feasibility	investigation	of	an	anti-TAP	lateral	flow	
test	strip.	
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5.3	 RESULTS	
	
5.3.1	 Stratification	of	patient	cohort	according	to	clinical	criteria	of	the	AMNCH,	
Tallaght	
	
5.3.1.1	Patients	treated	as	having	mild	acute	pancreatitis	
	
A	total	of	15	patients	were	included	in	this	clinical	evaluation	of	TAP	as	a	predictive	
biomarker	for	stratification	of	mild,	moderate	and	severe	AP,	with	sample	collection	
taking	place	from	October	2015	to	April	2016.	Of	these	15	patients,	8	were	male	and	
7	 were	 female	 with	 a	 median	 age	 of	 48.5	 and	 36	 years,	 respectively	 (see	 Table	
5.3.1.1.1	 below).	 The	 Adelaide	 and	 Meath	 National	 Children’s	 Hospital	 (AMNCH),	
Tallaght	 treatment	 regime	 for	 AP	 patients	 incorporates	 three	 separate	 criteria	 to	
segregate	 patients	 into	 the	 mild,	 moderate	 and	 severe	 categories.	 These	 criteria	
include	clinical	symptom	assessment	such	as	for	peripancreatic	complications;	Imrie	
score	 allocation	 and	 C-reactive	 protein	 (CRP)	measurement	 in	 heparinised	 plasma	
across	the	first	two	days	following	presentation	to	the	emergency	department	(ED).	
A	CRP	level	rise	of	>75	mg/L	within	these	two	days	or	a	measurement	of	>150	mg/L	
on	day	two	are	considered	to	be	indicators	of	a	potential	case	of	severe	AP.	Although	
not	included	in	clinical	decision-making	at	AMNCH,	Tallaght,	amylase	measurements	
were	 also	 recorded	 from	 serum	 samples	 for	 all	 patients	 and	 are	 plotted	 in	 this	
chapter	for	information	purposes.	Amylase	is	commonly	measured	internationally	as	
part	 of	 pancreatitis	 diagnosis	 (Vissers	 et	 al.,	 1999)	 Both	 CRP	 and	 amylase	 test	
measurements	 were	 made	 at	 the	 AMNCH,	 Tallaght	 central	 laboratory	 using	 the	
Cobas®	clinical	chemistry	analyser	from	Roche/Hitachi.	
All	 sample	 time-points	 collected	 (as	 described	 by	 section	 2.2.13)	 for	 each	
patient	 admitted	 to	 the	 AMNCH,	 Tallaght	 were	 analysed	 in	 duplicate	 using	 the	
competitive	 anti-TAP	 ELISA	 prototype.	 The	 analysis	 was	 performed	 as	 per	 section	
2.2.6	with	the	TAP	standard	calibration	curve	(0	–	400	nmol/L)	and	Positive	Control	
(PC)	sample	run	in	duplicate.	Furthermore,	each	urine	time-point	was	also	analysed	
by	dipstick	urinalysis	using	Multistix	10SG	 reagent	 strip	 tests	 (Siemens).	 These	 test	
strips	are	generally	utilised	for	the	detection	of	urinary	tract	infections	(UTI)	through	
		 139	
leukocyte	and	nitrate	analysis	but	also	provide	extensive	 information	on	blood	and	
protein	 content	 as	 well	 as	 urine	 pH.	 Thus,	 a	 more	 comprehensive	 patient	 profile	
could	be	assembled	from	a	single	dipstick	test.	A	full	 list	of	the	tests	available	with	
this	strip	is	outlined	in	Table	5.3.1.1.2.	
	
Table	5.3.1.1.1	Patient	cohort	breakdown	based	on	Sex	and	Age.	IQR	=	interquartile	
range:	
	
Sex	 #	of	Patients	
Median	Age	
(IQR)	(Years)	
<30	 30	-	40		 40	-	50		 60	-	70		 70	–	80	
	#	 #	 #	 #	 	#	
Male	 8	 48.5	(23-77)	 1	 2	 2	 1	 2	
Female	 7	 36	(27-69)	 1	 3	 1	 2	 0	
	
	
Table	5.3.1.1.2	Siemens	Multistix	10SG	reagent	strip	test	colour	chart	for	
interpretation	of	dipstick	results:	
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Test	 strips	are	 immersed	 into	patient	urine	and	 then	 removed	and	compared	with	
the	 chart	 above	 for	 information	 on	 10	 different	 test	 criteria	 that	 are	 graded	
accordingly.	The	colour	development	times	for	each	test	parameter	were	taken	into	
account	prior	 to	 recording	of	 the	 final	 results.	The	presence	of	nitrites	 from	gram-
negative	bacteria	 or	 leukocyte	 esterase	 from	neutrophils	 can	 indicate	 a	UTI.	Urine	
specific	gravity	 (USG)	 is	an	 indicator	of	a	patient’s	hydration	 status,	measuring	 the	
density	 of	 the	 urine	 compared	 to	water.	USG	 can	 indicate	 patients	 that	may	have	
impaired	renal	 function.	Glucose	 is	normally	filtered	and	completely	reabsorbed	by	
the	 kidney.	 However,	 if	 this	 reabsorption	 ability	 is	 exceeded,	 glycosuria	 can	 occur	
and	 be	 indicative	 of	 diabetes	 and	 liver	 and	 pancreatic	 diseases.	 Urinalysis	 is	
recommended	 within	 two	 hours	 of	 sample	 collection	 (Simerville	 et	 al.,	 2005).	
However,	 for	 this	 study,	 analysis	was	 not	 performed	 until	 freeze	 thawing	 of	 urine	
specimens	and	thus,	results	expressed	for	each	parameter	within	this	chapter	are	for	
information	purposes	only.		
	
Table	5.3.1.1.3	Clinical	study	parameters	categorised	in	relation	to	causes	and	
treatment	of	AP	from	patient	information	supplied	by	AMNCH,	Tallaght:	
	
Parameter	 Etiology	
Treated	as	Mild	AP	 Alcohol	 Gallstones	 Idiopathic	 Other	
n	 2	 2	 2	 N/A	
Men/Women	 2	(100%)/0	 1	(50%)/1(50%)	 0/2	(100%)	 N/A	
Age	(Years)	 36	(23-48)	 71	(69-72)	 48	(30-65)	 N/A	
Admission	Delay/Symptom	Onset	(Days)	 1	(1)	 3	(2-3)	 1	(1)	 N/A	
Hospital	Stay	(Days)	 5	(5)	 8	(7-9)	 4	(1-7)	 N/A	
Treated	as	Severe	AP	
	 	 	 	n	 5	 3	 N/A	 1	
Men/Women	 4	(80%)/1	(20%)	 0/3	(100%)	 N/A	 1	(100%)/0		
Age	(Years)	 36	(32-60)	 34	(27-46)	 N/A	 77	(77)	
Admission	Delay/Symptom	Onset	(Days)	 3	(1-6)	 2	(1-7)	 N/A	 1	(1)	
Hospital	Stay	(Days)	 16	(8-19)	 10	(6-30)	 N/A	 21	(21)	
Note:	value	ranges	are	median	(interquartile	range)	
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The	“Other”	etiology	referred	to	steroid-induced	AP	and	was	most	 likely	associated	with	
the	patient’s	underlying	respiratory	disease.	Of	the	15	patients	in	total,	six	were	treated	as	
cases	of	mild	AP	and	nine	were	 treated	as	cases	of	 severe	AP	using	 the	AMNCH	clinical	
treatment	protocol.	 The	median	admission	delay	 for	patients	 treated	as	mild	was	1	day	
and	for	patients	treated	as	severe	was	2	days.	The	median	hospital	stay	was	4	and	10	days	
for	the	mild	and	severe	patient	groups,	respectively.	
	
	
	
Figure	5.3.1.1.1	Mean	TAP	concentrations	for	patients	treated	as	having	mild	AP	defined	
by	the	AMNCH,	Tallaght	clinical	criteria.	TAP	values	were	low	for	all	samples	analysed	with	
a	 maximum	 concentration	 of	 5.4	 nmol/L	 recorded	 from	 the	 zero	 hour	 time-point	 of	
Patient	C.	This	matched	closely	with	the	maximum	concentration	recorded	for	reference	
range	 testing	 (5.3	 nmol/L,	 section	 3.3.14).	 Despite	 limited	 or	 non-uniform	 time-point	
collections	 for	 some	 patients,	 TAP	 concentrations	 were	 predominantly	 lower	 than	 the	
reference	range	(0	-	5.3	nmol/L)	established	from	the	apparently	healthy	donor	group	at	
DCU	(see	section	3.3.14).	The	six	patients	of	this	treated	as	mild	AP	group	were	an	even	
split	 of	 male	 and	 female	 patients.	 The	 causes	 of	 AP	 in	 the	 three	 male	 patients	 were	
gallstones	(Patient	B)	and	alcohol	(Patients	C	and	D).	The	causes	of	AP	in	the	three	female	
patients	were	idiopathic	(Patient	A	and	F)	and	gallstones	(Patient	E).	Patient	A	was	listed	
as	 idiopathic,	however,	a	 subsequent	X-ray	computed	 tomography	 (CT)	 scan	 showed	no	
sign	 of	 pancreatitis,	 and	 Patient	 F	 had	 reported	 pancreatitis	 previously	 at	 15	 years	 and	
may	potentially	have	signaled	the	presence	of	reoccurring	or	chronic	pancreatitis.		
0	
5	
10	
15	
20	
25	
30	
0	 24	 48	 72	 96	 120	
TA
P	
(n
m
ol
/L
)	
Time	(hours)	
PaÅent	A	 PaÅent	B	 PaÅent	C	
PaÅent	D	 PaÅent	E	 PaÅent	F	
		 142	
	
	
Figure	 5.3.1.1.2	 CRP	 concentrations	 for	 mild	 AP	 patients	 as	 defined	 by	 the	 AMNCH,	
Tallaght	clinical	criteria.	The	CRP	measurements	were	taken	on	presentation	to	the	ED	and	
in	the	morning	of	Days	1	and	2	(equivalent	to	24	and	48	hours).	Although	a	large	decrease	
in	CRP	level	(126	to	0	mg/L)	was	recorded	for	Patient	B	between	admission	and	Day	1,	the	
CRP	measurement	returned	to	132	mg/L	on	Day	2.	As	the	overall	CRP	level	was	less	than	
the	specified	 level	of	<150	mg/L	on	Day	2,	 the	patient	was	 treated	as	mild	 (see	section,	
5.3.1.1).	 The	 overall	 CRP	 level	 increases	 observed	 for	 Patient	 C	 and	 E	were	 considered	
closely,	with	Patient	C	showing	a	drop	in	CRP	level	(184	to	170	mg/L)	from	Day	1	to	2	and	
thus,	being	categorised	as	improving	and	therefore	had	mild	AP.	The	rise	in	CRP	level	for	
Patient	 E	 was	 due	 to	 ascending	 cholangitis	 from	 the	 apparent	 gallstones	 and	 was	
therefore	 not	 localised	 to	 the	 pancreas.	 However,	 the	 raised	 CRP	 level	 for	 this	 patient	
meant	that	additional	clinical	acumen	was	required	to	establish	a	diagnosis	of	mild	AP.	For	
Patient	D,	the	rise	in	CRP	level	between	Day	1	and	2	was	<75	mg/L	and	thus,	was	defined	
as	mild.	All	of	these	patients	were	in	contrast	to	the	low	CRP	levels	recorded	for	Patient	A	
and	F	across	the	two	days	from	admission.	Nonetheless,	the	CRP	biomarker	specifications	
validated	at	the	AMNCH,	Tallaght	designated	the	majority	of	these	patients	as	having	mild	
AP	based	on	CRP	measurement.	The	established	reference	range	for	AMNCH,	Tallaght	was	
0	-	5	mg/L.	
0	
50	
100	
150	
200	
250	
300	
350	
400	
0	 24	 48	
CR
P	
(m
g/
L)
	
Time	(hours)	
PaÅent	A	 PaÅent	B	 PaÅent	C	
PaÅent	D	 PaÅent	E	 PaÅent	F	
		 143	
	
Figure	5.3.1.1.3	Amylase	concentrations	for	patients	treated	as	having	mild	AP	as	defined	
by	the	AMNCH,	Tallaght	clinical	criteria.	The	highest	amylase	measurement	recorded	for	
patients	treated	as	mild	was	2300	U/L	for	Patient	E.	The	established	reference	range	for	
AMNCH,	Tallaght	was	<100	U/L.	
	
The	 Glasgow	 (Imrie)	 score	 (as	 described	 in	 section	 1.3.1)	 took	 into	 account	 various	
biochemical	 risk	 factors	 including	 glucose	 and	 blood	 urea	 nitrogen	 (BUN)	 levels	 and	
ranged	from	0	–	1	for	this	patient	group,	where	a	score	of≤3	was	defined	as	mild	AP	by	
AMNCH,	 Tallaght	 guidelines	 (Steinberg	&	Tenner,	 1994).	Dipstick	 urinalysis	 showed	 that	
patient	sample	pH	ranged	from	5.0	-	7.5	with	some	samples	containing	trace	amounts	of	
protein.	Normal	urinary	pH	can	range	from	4.5	-	8.0	(Simerville	et	al.,	2005).	A	high	level	of	
protein	in	urine	is	referred	to	as	proteinuria,	however,	only	repeated	testing	can	confirm	
that	this	is	a	recurring	issue	that	may	be	caused	by	kidney	disease	due	to	diabetes	or	high	
blood	 pressure.	 Small	 levels	 of	 protein	 can	 often	 be	 detected	 in	 the	 urine	 of	 healthy	
individuals	during	stressful	periods	or	following	exercise	(Carroll	&	Temte,	2000).	Patient	C	
had	 sample	 time-points	with	 a	 small	 amount	 of	 bilirubin	 “+”	 and	 Patient	 E	 had	 sample	
time-points	with	a	trace	amount	of	non-hemolysed	blood	as	 listed	 in	the	colour	chart	 in	
Table	5.3.1.1.2.	Only	very	high	levels	of	bilirubin	are	indicative	of	liver	disease,	however,	it	
should	not	be	present	 in	 the	urine	of	a	healthy	 individual	 (Simerville	et	al.,	 2005).	Non-
hemolysed	 blood	 in	 urine	 can	 occur	 from	 kidney	 or	 UTI	 but	 can	 also	 occur	 during	 the	
female	 menstrual	 cycle	 (Kelly	 et	 al.,	 2009).	 The	 other	 test	 parameters	 for	 dipstick	
urinalysis	 generally	 returned	 negative	 or	 inconsequential	 results.	 None	 of	 these	 test	
parameters	were	at	 levels	 that	were	expected	to	cause	 interference	with	the	biomarker	
measurements.	
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5.3.1.2	Patients	treated	as	having	severe	acute	pancreatitis	
	
	
	
Figure	 5.3.1.2.1	 Mean	 TAP	 concentrations	 for	 patients	 treated	 as	 having	 severe	 AP	
defined	by	AMNCH,	Tallaght	clinical	criteria.	This	patient	group	consisted	of	5	males	and	4	
females	with	 the	prevailing	 cause	of	AP	being	 alcohol	 and	 gallstones	 for	 the	males	 and	
females,	 respectively.	 Patient	N	was	 the	 only	 female	with	 a	 cause	of	AP	 recorded	 from	
alcohol.	 Gallstones	 were	 the	 cause	 of	 AP	 in	 the	 male	 Patient	 O,	 with	 Patient	 I	 having	
underlying	 respiratory	 disease	 that	 resulted	 in	 steroid-induced	 AP.	 This	 patient	
demonstrated	 the	 second	highest	peak	 in	TAP	 concentration	at	24	hours	 (13.2	nmol/L).	
The	revised	Atlanta	classification	 indicates	that	systemic	complications	can	be	related	to	
exacerbations	of	underlying	co-morbidities	and	are	more	likely	to	occur	in	the	early	phase	
of	AP	(Banks	et	al.,	2013).	The	highest	TAP	concentration	recorded	was	26.0	nmol/L	at	48	
hours	 for	 Patient	 L,	 a	 female	 patient	 with	 gallstones.	 The	 admission	 of	 Patient	 K	 and	
Patient	 O	 at	 2	 and	 4	 days	 following	 onset	 of	 symptoms,	 respectively,	 may	 explain	 the	
higher	TAP	concentrations	recorded	(10.3	and	8.4	nmol/L)	for	these	patients	at	zero	hours	
and	the	subsequent	concentration	drop-off	recorded.	Perhaps	this	may	demonstrate	that	
TAP	antigen	release	into	urine	reaches	a	critical	mass	within	a	short	window	of	time	from	
symptom	onset	and	would	very	much	be	an	early	prognostic	marker.	Clear	profiles	of	TAP	
concentration	 increase	 to	 decrease	 were	 observed	 over	 time	 for	 several	 patients,	
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however,	Patient	G	and	Patient	J	did	not	share	this	profile.	The	TAP	levels	for	Patient	G	did	
not	 significantly	 change	 from	 the	 zero	hour	baseline	 result	 across	 all	 of	 the	 time-points	
analysed.	 It	should	also	be	noted	that	Patient	 J	was	admitted	to	the	hospital	a	reported	
nine	days	after	symptoms	and	only	supplied	 two	sample	 time-points	 for	analysis	 from	a	
total	10	day	length	of	stay.	Subsequent	analysis	of	this	patient	cohort	would	demonstrate	
that	 this	 group	 in	 fact	 contained	 both	mild	 and	moderate	 cases	 of	 AP	 when	 using	 the	
revised	Atlanta	classification,	with	Patient	G	and	Patient	J	designated	as	cases	of	mild	AP	
under	this	classification.	
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Figure	 5.3.1.2.2	CRP	concentrations	 for	patients	 treated	as	having	severe	AP	defined	by	
AMNCH,	 Tallaght	 clinical	 criteria.	 Plasma	 samples	 from	 Patients	 G,	 J,	 M,	 I	 and	 O	 were	
subject	 to	 a	 CRP	 level	 increase	 >75	 mg/L,	 generally	 by	 Day	 1,	 and	 were	 consequently	
treated	 as	 cases	 of	 severe	 AP.	 As	 the	 CRP	 level	 for	 Patient	 J	 between	 Day	 1	 and	 2	
increased	only	slightly	(96	to	121	mg/L),	an	additional	measurement	was	made	on	Day	3	
(148	mg/L)	to	confirm	that	the	CRP	level	was	not	beginning	to	decrease,	and	would	have	
potentially	 indicated	 that	 this	 patient	 should	 be	 considered	 for	 treatment	 as	mild.	 This	
patient	was	subsequently	designated	as	mild	under	the	revised	Atlanta	classification	and	
the	TAP	levels	remained	below	the	initial	baseline	measurement	(Figure	5.3.1.2.1).	In	spite	
of	 the	 decrease	 in	 CRP	 level	 on	 Day	 2	 for	 Patient	 M	 (from	 93	 to	 15	 mg/L)	 and,	 an	
indifferent	TAP	concentration	profile	(see	Figure	5.3.1.2.1),	these	results	were	not	flagged	
as	 indicators	of	 improving	condition	and	 thus,	 this	patient	was	 treated	as	having	severe	
AP.	This	decision	was	complimented	when	the	patient	was	also	designated	as	an	Atlanta	
moderate.	Patient	H	maintained	a	CRP	level	>150	mg/L	across	the	two	days	of	assessment,	
remaining	 at	 the	 higher	 end	 of	 the	 established	 CRP	 specification	 for	 AMNCH,	 Tallaght.	
Patients	 K,	 N	 and	 L	 showed	 a	 rise	 in	 CRP	 level	 to	 >150	 mg/L	 on	 Day	 2,	 therefore	
adequately	meeting	the	change	in	CRP	level	specification	requirement.	When	analysed	for	
the	TAP	biomarker,	Patient	K	showed	an	overall	“drop-off”	in	TAP	levels	from	a	high	initial	
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baseline	value	of	10.2	nmol/L	(Figure	5.3.1.2.1).	However,	this	patient	was	designated	as	
mild	under	the	revised	Atlanta	classification	and	Patient	L	(designated	as	moderate	under	
Atlanta)	 did	 demonstrate	 the	 largest	 increase	 in	 TAP	 levels	 observed	 for	 this	 study.	
Unfortunately,	 only	 a	 baseline	 TAP	measurement	was	 recorded	 for	 Patient	 N	 despite	 a	
hospital	 stay	 lasting	 17	 days	 and	 thus,	 a	more	 accurate	 TAP	 profile	 of	 the	 only	 female	
patient	 with	 alcohol-induced	 AP	 and	 moderate	 classification	 under	 Atlanta,	 was	 not	
afforded.	While	there	was	clearly	some	time-varied	sample	collections,	albeit	more	a	lack	
of	sample	time-point	availability	for	TAP	measurement	when	compared	to	CRP	levels,	the	
opportunity	to	explore	the	distribution	of	the	biomarkers	values	at	important	time-points	
still	existed	and	is	discussed	at	a	later	stage	in	this	chapter.		
	
	
	
	
Figure	5.3.1.2.3	Amylase	concentrations	for	patients	treated	as	having	severe	AP	defined	
by	 AMNCH,	 Tallaght	 clinical	 criteria.	 The	 highest	 amylase	 measurement	 recorded	 for	
patients	 treated	as	 severe	was	6276	U/L	 for	Patient	 I.	 The	closest	amylase	value	 to	 this	
was	3295	U/L	for	Patient	L.	Interestingly,	both	of	these	patients	also	demonstrated	large	
increases	in	CRP	and	TAP	levels,	with	Patient	O	also	showing	a	significant	increase	in	CRP	
level	by	Day	1	(Figures	5.3.1.2.1	and	5.3.1.2.2).	However,	as	can	be	seen	from	this	data,	no	
overall	 pattern	 could	 be	 established	 which	 could	 significantly	 contribute	 to	 clinical	
decision	 making	 for	 segregation	 of	 patients	 into	 cases	 of	 severe	 AP.	 Amylase	 values	
fluctuated	from	as	low	as	46	to	6276	U/L	and	thus,	were	of	no	beneficial	significance.	
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The	Glasgow	(Imrie)	score	for	this	patient	group	ranged	from	0	–	2,	where	a	score	of≥3	
was	defined	as	severe	AP	by	AMNCH,	Tallaght	guidelines.	These	results	exhibited	the	fact	
that	 Imrie	 score	 did	 not	 particularly	 contribute	 to	 the	 clinical	 decisions	 taken	 for	 this	
study.	 Dipstick	 urinalysis	 showed	 that	 patient	 sample	 pH	 ranged	 from	 5.0	 –	 8.5.	 Upon	
comparision	 to	 the	 colour	 chart	 in	 Table	 5.3.1.1.2,	 ketone	 levels	 (15	 –	 80	mg/dL)	were	
raised	(ketonuria)	in	several	sample	time-points	for	Patients	G,	J,	H,	I	and	L.	Ketonuria	can	
result	 from	 uncontrolled	 diabetes,	 however,	 it	 can	 also	 occur	 during	 fasting	 periods	
(Simerville	et	al.,	2005).	Patient	nutrition	would	have	been	closely	controlled	within	 this	
group.	 Also	 from	 this	 analysis,	 sample	 time-points	 from	 Patient	 I	 displayed	 large	
hemolysed	blood	content	(hematuria)	and	a	moderate	level	of	bilirubin;	traces	of	protein	
and	large	bilirubin	content	for	Patient	L	and,	high	hemolysed	blood	content	for	Patient	O.	
The	 high	 blood	 content	 may	 have	 been	 indicative	 of	 potential	 kidney	 or	 UTI	 issues	 in	
addition	to	the	AP	diagnosis	(Kelly	et	al.,	2009).	A	raised	bilirubin	level	may	have	pointed	
to	biliary	obstruction,	which	was	likely	as	several	patients	were	reported	to	have	evolving	
(Patient	 O)	 or	 definitive	 (Patient	 L)	 peripancreatic	 collections,	 i.e.	 bile	 blockages	 from	
issues	such	as	gallstones	(Simerville	et	al.,	2005).	These	patients	were	also	designated	as	
moderate	under	the	revised	Atlanta	classification.	Once	again,	the	dipstick	testing	served	
only	to	offer	additional	screening	information	of	these	patients.	
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5.3.2	 Stratification	of	patient	cohort	according	to	clinical	criteria	of	the	revised	Atlanta	
classification	
	
5.3.2.1	Atlanta	mild	
	
As	previously	 discussed	 in	 section	1.3.2,	 the	 revised	Atlanta	 classification	 is	 designed	 to	
provide	a	standardised	and	consistent	 international	criterion	to	aid	 in	the	assessment	of	
clinical	 severity	 and	evaluation	of	potential	 treatments	of	AP.	 It	 is	not	 intended	 to	be	a	
management	guideline	and	recognizes	that	the	severity	of	AP	is	an	evolving	condition	that	
has	the	propensity	to	change	over	the	course	of	the	disease.	In	the	early	phase	of	AP,	the	
illicit	host	response	to	pancreatic	injury	gives	rise	to	an	initial	systemic	inflammatory	wave	
that	 lasts	 for	 approximately	 one	week.	 If	 this	 cascade	 continues,	 the	 risk	 of	 developing	
organ	(local	and	multiple)	failure	is	 increased.	Local	complications	such	as	peripancreatic	
collections	present	during	the	early	phase	of	AP	are	not	sufficiently	reliable	to	define	the	
severity	of	AP	alone.	However,	the	presence	and	duration	of	organ	failure	can	distinguish	
between	moderate	and	in	particular,	severe	AP.	The	absence	of	organ	failure	and	local	or	
systemic	complications	is	associated	with	mild	AP	whereas	both	moderate	and	severe	AP	
are	attributed	to	organ	failure	and	local	or	systemic	complications.	The	duration	of	organ	
failure	 distinguishes	 between	 moderate	 AP	 (transient,	 resolving	 within	 48	 hours)	 and	
severe	AP	(persistent,	non-resolving).	The	evaluation	of	persistent	systemic	inflammation	
and	 local	 complications	 during	 the	 late	 phase	 of	 AP	 can	 further	 distinguish	 between	
moderate	and	severe	AP,	aiding	 in	 surgical	 intervention	or	 specialist	 care.	However,	 the	
identification	 of	 patients	 as	 potentially	 severe	 is	 essentially	 based	 on	 the	 early	 phase	
characteristics	 of	 AP.	 Due	 to	 the	 evolving	 nature	 of	 AP,	 the	 aggressive	 treatment	 of	
patients	as	potentially	severe	using	the	AMNCH,	Tallaght	clinical	criteria	may	have	limited	
the	presence	of	 local	 complications	and	persistent	organ	 failure	 in	 this	 study	and,	 could	
therefore	be	the	reason	why	there	was	no	cases	of	severe	AP	observed	under	the	revised	
Atlanta	classification.	Consequently,	 the	difference	between	the	TAP	and	CRP	biomarker	
levels	for	the	patients	classified	as	mild	and	moderate	are	discussed	herein.	
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Table	5.3.2.1.1	Clinical	study	parameters	categorised	in	relation	to	the	revised	Atlanta	
classification	of	acute	pancreatitis:	
	
Parameter	 Etiology	
Mild	AP	 Alcohol	 Gallstones	 Idiopathic	 Other	
n	 4	 3	 2	 N/A	
Men/Women	 4	(100%)/0	 1	(33%)/2(67%)	 0/2	(100%)	 N/A	
Age	(Years)	 40	(23-49)	 69	(34-72)	 48	(30-65)	 N/A	
Admission	Delay/Symptom	Onset	(Days)	 2	(0.5-3)	 3	(2-7)	 1	(1)	 N/A	
Hospital	Stay	(Days)	 7	(5-10)	 9	(7-10)	 4	(1-7)	 N/A	
Moderate	AP	 	 	 	n	 2	 3	 N/A	 1	
Men/Women	 1	(50%)/1	(50%)	 1	(33%)/2	(67%)	 N/A	 1	(100%)/0		
Age	(Years)	 48	(36-60)	 32	(27-46)	 N/A	 77	(77)	
Admission	Delay/Symptom	Onset	(Days)	 4	(1-6)	 2	(1-4)	 N/A	 1	(1)	
Hospital	Stay	(Days)	 18	(17-19)	 16	(6-30)	 N/A	 21	(21)	
		Note:	value	ranges	are	median	(interquartile	range)	
	
	
The	“Other”	etiology	referred	to	steroid-induced	AP	and	was	most	 likely	associated	with	
the	patient’s	underlying	respiratory	disease.	Of	the	15	patients	in	total,	nine	patients	were	
classified	as	having	mild	AP	and	six	as	moderate	AP.	No	patients	were	classified	as	having	
severe	AP	for	this	study.	The	median	admission	delay	for	both	mild	and	moderate	patients	
was	2	days	and	 the	median	hospital	 stay	was	7	and	18	days	 for	 the	mild	and	moderate	
patients,	respectively.	
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Figure	5.3.2.1.1	Mean	TAP	concentrations	for	patients	classified	as	having	mild	AP	using	
the	revised	Atlanta	classification.	 In	comparison	to	the	6	patients	treated	as	mild	by	the	
AMNCH,	 Tallaght	 criteria	 (Figure	 5.3.1.1.1),	 nine	 patients	 (five	male,	 four	 female)	 were	
considered	 as	 having	 mild	 AP	 using	 this	 classification.	 The	 three	 additional	 patients	
included	were	Patients	G,	 J	 and	K.	 TAP	 levels	 remained	 the	 same	between	both	 figures	
with	 the	exception	of	Patient	K	who	showed	a	high	 initial	baseline	value	of	10.2	nmol/L	
before	a	rapid	drop-off	to	levels	similar	to	other	mild	patients.	Therefore,	the	TAP	values	
of	 these	mild	patients	were	again	 largely	within	the	established	reference	range	(0	 -	5.3	
nmol/L).	Alcohol	was	the	predominant	cause	of	mild	AP	with	all	4	cases	of	alcohol-related	
AP	associated	with	male	patients	(Patients	C,	D,	G,	K).	The	causes	of	AP	in	the	four	female	
patients	were	an	even	split	between	idiopathic	(Patients	A	and	F)	and	gallstones	(Patients	
E	 and	 J).	 Patient	 A	 was	 listed	 as	 idiopathic	 however;	 subsequent	 X-ray	 computed	
tomography	(CT)	scan	showed	no	sign	of	pancreatitis.	A	single	male	patient	was	diagnosed	
with	gallstone-related	AP	(Patient	B).		
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Figure	 5.3.2.1.2	 CRP	 concentrations	 for	 patients	 classified	 as	 having	 mild	 AP	 using	 the	
revised	Atlanta	classification.	The	three	additional	patients	included	(Patients	G,	J	and	K)	in	
comparison	 to	 the	 patients	 treated	 as	 mild	 by	 the	 AMNCH,	 Tallaght	 criteria	 (Figure	
5.3.1.1.2)	 were	 treated	 as	 severe	 according	 to	 the	 clinical	 criteria	 employed	 by	 the	
AMNCH,	 Tallaght.	 Under	 this	 treatment	 guideline,	 both	 Patient	 G	 and	 Patient	 J	
demonstrated	an	increase	in	CRP	level	>75	mg/L	within	Day	1	(24	hours)	and	Patient	K	had	
a	CRP	>150	mg/L	by	Day	2	(48	hours).	
	
Figure	5.3.2.1.3	Amylase	concentrations	for	patients	classified	as	having	mild	AP	using	the	
revised	Atlanta	classification.	The	highest	amylase	level	recorded	for	this	group	was	2283	
U/L	for	Patient	E.	Patients	B,	C,	F	and	J	also	recorded	raised	amylase	levels	of	1165	-	1926	
U/L.	The	established	reference	range	for	AMNCH,	Tallaght	was	<100	U/L.	
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5.3.2.2	Atlanta	moderate	
	
	
	
Figure	 5.3.2.2.1	Mean	TAP	concentrations	 for	patients	 classified	as	having	moderate	AP	
using	 the	 revised	Atlanta	classification.	The	 removal	of	data	 for	Patients	G,	 J	and	K	who	
were	 treated	 as	 severe	 under	 the	 AMNCH,	 Tallaght	 clinical	 criteria	 (Figure	 5.3.1.2.1),	
refined	the	results	to	exclude	those	patients	with	a	TAP	level	<5.3	nmol/L	for	the	first	48	
hours	 following	 admission,	 with	 the	 exception	 of	 Patient	 M	 who’s	 TAP	 level	 never	
increased	outside	of	the	established	reference	range	(0	–	5.3	nmol/L).	In	addition,	the	CRP	
level	 for	 this	 patient	 demonstrated	 a	 spiked	 trend	 whereby	 an	 increase	 of	 ~60	 mg/L	
occurred	by	Day	1	but	quickly	fell	to	15	mg/L	by	Day	2	(Figure	5.3.2.2.2).	This	patient	was	
subsequently	 diagnosed	 with	 a	 pancreatic	 pseudocyst,	 i.e.	 a	 fluid-filled	 lesion	 of	 the	
pancreas	that	can	develop	following	AP,	chronic	pancreatitis	or	pancreatic	trauma	(Rabie	
et	 al.,	 2014).	 This	 cystic	 body	 carried	 no	 malignant	 potential	 (Sahani	 et	 al.,	 2012).		
Therefore,	this	was	a	local	complication,	occurring	in	the	peripancreatic	region	and	could	
have	 been	 diagnosed	 in	 the	 later	 phase	 of	 the	 AP	 episode.	 The	 use	 of	multiple	 clinical	
criteria,	combining	biomarker	scores	and	clinical	acumen	of	symptoms	and	complications	
at	AMNCH,	Tallaght	ensured	that	this	patient	received	early	aggressive	treatment	to	avoid	
any	potential	 severity.	 This	 illustrates	 that	neither	biomarker	 (CRP/TAP)	 appeared	 to	be	
capable	of	detecting	AP	in	this	patient	and	was	conducive	to	the	fact	that	there	is	rarely	a	
single	answer	for	prognosis	of	this	complicated	disease.		
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Figure	 5.3.2.2.2	 CRP	 concentrations	 for	 patients	 classified	 as	 having	moderate	AP	 using	
the	 revised	Atlanta	 classification.	As	 discussed	 in	 Figure	 5.3.2.2.1	 above,	 the	 alternative	
trend	of	CRP	level	for	Patient	M	can	be	seen	in	comparison	to	the	other	patients	included	
in	the	moderate	AP	group.	The	CRP	biomarker,	 like	TAP,	did	not	demonstrate	an	overall	
increasing	trend	for	this	patient	that	would	have	corresponded	with	the	increasing	marker	
responses	observed	 for	patients	such	as	Patient	 I	and	Patient	L.	The	CRP	results	 for	 this	
patient	demonstrate	that	the	various	clinical	criteria	employed	at	the	AMNCH,	Tallaght	are	
paramount	to	confirm	the	condition	of	a	patient	and	that	the	use	of	a	single	biomarker	for	
stratification	of	AP	patients	is	not	currently	possible.	
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Figure	 5.3.2.2.3	 Amylase	 concentrations	 for	 patients	 classified	 as	 having	 moderate	 AP	
using	the	revised	Atlanta	classification.	The	highest	amylase	level	recorded	for	the	Atlanta	
moderate	 patient	 group	was	 6276	U/L	 for	 Patient	 I.	 High	 levels	were	 also	 observed	 for	
Patient	 L	 (3295	 U/L)	 and	 Patient	 O	 (2664	 U/L).	 Both	 Patient	 I	 and	 Patient	 L	 also	
demonstrated	 large	 increases	 in	 CRP	 and,	 in	 particular,	 TAP	 levels	 (Figure	 5.3.2.2.1).	
Patient	O	also	showed	a	significant	 increase	 in	CRP	level	by	Day	1	(Figure	5.3.2.2.2).	The	
other	patients	(Patients	H,	M	and	N)	had	serum	amylase	levels	of	293,	291	and	172	U/L,	
respectively.	The	removal	of	data	for	Patients	G,	J	and	K	who	were	treated	as	severe	under	
the	AMNCH,	Tallaght	clinical	criteria	(Figure	5.3.1.2.3),	refined	the	results	to	include	only	
those	 patients	 who	 presented	 with	 an	 amylase	 level	 greater	 than	 the	 established	
reference	range	of	0	-	100	U/L.		
	
	
	
	
	
	
0	
1000	
2000	
3000	
4000	
5000	
6000	
7000	
PaÅent	H	 PaÅent	I	 PaÅent	L	 PaÅent	M	 PaÅent	N	 PaÅent	O	
Am
yl
as
e	
(U
/L
)	
		 157	
	
48h	(b)	
		
24
h	
(a
)	
	
	TAP	(nmol/L),	CRP	(mg/L)		TAP	(nmol/L),	CRP	(mg/L)	
Fi
gu
re
	5
.3
.2
.2
.4
	D
ist
rib
ut
io
n	
of
	T
AP
	a
nd
	C
RP
	le
ve
ls	
at
	2
4	
(a
)	a
nd
	4
8	
(b
)	
ho
ur
s	
fo
r	
pa
tie
nt
s	
cl
as
sif
ie
d	
as
	m
ild
	a
nd
	m
od
er
at
e	
us
in
g	
th
e	
re
vi
se
d	
At
la
nt
a	
cl
as
si
fic
at
io
n.
	B
ox
es
	=
	2
5t
h 	
an
d	
75
th
	p
er
ce
nt
ile
s;
	li
ne
	in
	b
ox
	=
	
m
ed
ia
n;
	o
ut
er
	b
ar
s	
=	
95
th
	p
er
ce
nt
ile
s.
	G
re
at
er
	d
isc
rim
in
at
io
n	
w
as
	
ob
se
rv
ed
	b
et
w
ee
n	
th
e	
m
ild
	a
nd
	m
od
er
at
e	
pa
tie
nt
	g
ro
up
s	
us
in
g	
th
e	
TA
P	
bi
om
ar
ke
r	
at
	4
8	
ho
ur
s	
w
he
n	
co
m
pa
re
d	
to
	t
he
	t
im
e-
po
in
t	
at
	2
4	
ho
ur
s.
	T
he
	a
re
a	
un
de
r	t
he
	re
ce
iv
er
	o
pe
ra
to
r	c
ha
ra
ct
er
ist
ic
	(R
O
C)
	c
ur
ve
	
w
as
	0
.8
1,
	0
.9
4	
an
d	
0.
80
	a
t	0
h,
	2
4h
	a
nd
	4
8h
,	r
es
pe
ct
iv
el
y	
(W
ei
ns
te
in
	e
t	
al
.,	
20
05
).	
N
o	
di
sc
rim
in
at
io
n	
co
ul
d	
be
	m
ad
e	
be
tw
ee
n	
th
e	
m
ild
	a
nd
	
m
od
er
at
e	
pa
tie
nt
	
gr
ou
ps
	
us
in
g	
CR
P	
le
ve
l	
at
	
24
	
ho
ur
s.
	
M
in
or
	
di
sc
rim
in
at
io
n	
w
as
	o
bs
er
ve
d	
at
	4
8	
ho
ur
s	
us
in
g	
CR
P	
le
ve
l	a
nd
	m
ay
	h
av
e	
in
di
ca
te
d	
an
	im
pr
ov
in
g	
tr
en
d	
in
	th
e	
fo
llo
w
in
g	
ho
ur
s.
	A
s	
al
so
	in
di
ca
te
d	
in
	F
ig
ur
e	
5.
3.
1.
2.
4,
	th
es
e	
re
su
lts
	s
ug
ge
st
	th
e	
le
ss
	s
pe
ci
fic
	n
at
ur
e	
of
	th
e	
CR
P	
bi
om
ar
ke
r,	
w
hi
ch
	is
	a
	g
en
er
al
ise
d	
in
fla
m
m
at
or
y	
m
ar
ke
r.	
Th
is	
id
ea
	
w
as
	f
ur
th
er
	c
om
po
un
de
d	
by
	t
he
	r
ep
or
tin
g	
of
	o
ne
	o
f	
th
e	
hi
gh
es
t	
CR
P	
le
ve
ls	
ob
se
rv
ed
	f
or
	t
hi
s	
st
ud
y	
fo
r	
pr
es
en
ce
	o
f	
th
e	
in
fla
m
m
at
or
y	
co
nd
iti
on
	o
f	
ch
ol
an
gi
tis
	in
	P
at
ie
nt
	E
.	
Th
e	
ar
ea
	u
nd
er
	t
he
	R
O
C	
cu
rv
e	
w
as
	0
.5
2,
	0
.5
2	
an
d	
0.
79
	a
t	0
h,
	2
4h
	a
nd
	4
8h
,	r
es
pe
ct
iv
el
y.
	
	
48
h	
(b
)	
		 158	
															
																							 	
																													
					
	
Ti
m
e	
(h
ou
rs
)	
TAP	(nmol/L)	
(b
) 
TAP	(nmol/L)	
Fi
gu
re
	5
.3
.2
.2
.4
	(
a)
	O
ve
rv
ie
w
	o
f	
TA
P	
co
nc
en
tr
at
io
ns
	f
or
	p
at
ie
nt
s	
se
gr
eg
at
ed
	a
s	m
ild
	(g
re
en
)	o
r	m
od
er
at
e	
(r
ed
)	u
sin
g	
th
e	
re
vi
se
d	
At
la
nt
a	
cl
as
sif
ic
at
io
n.
	A
	c
ut
-o
ff	
va
lu
e	
of
	5
.3
	n
m
ol
/L
	(d
as
he
d	
lin
e)
	b
as
ed
	o
n	
th
e	
es
ta
bl
ish
ed
	r
ef
er
en
ce
	r
an
ge
	w
as
	u
se
d	
to
	d
ist
in
gu
ish
	b
et
w
ee
n	
th
es
e	
gr
ou
ps
.	F
ro
m
	a
	to
ta
l	o
f	1
5	
pa
tie
nt
s,
	si
x	
pa
tie
nt
s	w
er
e	
de
te
rm
in
ed
	to
	b
e	
tr
ue
	p
os
iti
ve
s	
(m
od
er
at
e	
AP
)	a
nd
	n
in
e	
pa
tie
nt
s	
w
er
e	
de
te
rm
in
ed
	to
	b
e	
tr
ue
	n
eg
at
iv
es
	(
m
ild
	A
P)
.	
O
ne
	p
at
ie
nt
	w
as
	d
et
er
m
in
ed
	t
o	
be
	a
	f
al
se
	
ne
ga
tiv
e	
(P
at
ie
nt
	M
)	f
or
	T
AP
	a
nd
	n
o	
pa
tie
nt
s	
w
er
e	
de
te
rm
in
ed
	t
o	
be
	
fa
lse
ly
	p
os
iti
ve
	a
s	
th
e	
TA
P	
le
ve
l	f
or
	m
ild
	A
P	
Pa
tie
nt
	K
	ra
pi
dl
y	
de
cr
ea
se
d	
in
to
	t
he
	r
ef
er
en
ce
	r
an
ge
	w
ith
in
	2
4	
ho
ur
s.
	C
on
se
qu
en
tly
,	
us
in
g	
th
e	
At
la
nt
a	
cl
as
sif
ic
at
io
n	
of
	se
ve
rit
y	
fo
r	t
hi
s	e
xp
lo
ra
to
ry
	c
lin
ic
al
	c
oh
or
t,	
th
e	
se
ns
iti
vi
ty
	a
nd
	s
pe
ci
fic
ity
	o
f	T
AP
	w
er
e	
85
.7
%
	a
nd
	1
00
.0
%
,	r
es
pe
ct
iv
el
y.
	
Th
e	
ne
ga
tiv
e	
pr
ed
ic
tiv
e	
va
lu
e	
(N
PV
)	a
nd
	p
os
iti
ve
	p
re
di
ct
iv
e	
va
lu
e	
(P
PV
)	
w
er
e	
90
.0
%
	a
nd
	1
00
%
,	
re
sp
ec
tiv
el
y.
	T
he
	a
re
as
	u
nd
er
	t
he
	r
ec
ei
ve
r	
op
er
at
or
	c
ha
ra
ct
er
ist
ic
	(
RO
C)
	c
ur
ve
	w
er
e	
0.
81
,	
0.
94
	a
nd
	0
.8
0	
at
	0
h,
	
24
h	
an
d	
48
h,
	re
sp
ec
tiv
el
y	
(A
pp
en
di
x	
8.
2)
.	
	 Fi
gu
re
	5
.3
.2
.2
.4
	(
b)
	M
ea
n	
TA
P	
co
nc
en
tr
at
io
ns
	i
n	
pa
tie
nt
s	
w
ith
	m
ild
	
an
d	
m
od
er
at
e	
AP
	d
ur
in
g	
th
e	
fir
st
	4
8h
	in
	h
os
pi
ta
l.	
A	
cl
ea
r	
se
pa
ra
tio
n	
w
as
	o
bs
er
ve
d	
be
tw
ee
n	
th
es
e	
gr
ou
ps
	f
ro
m
	t
he
	o
ut
se
t	
of
	s
am
pl
e	
co
lle
ct
io
n.
	M
ea
n	
TA
P	
va
lu
es
	fo
r	m
ild
	A
P	
w
er
e	
0h
	=
	2
.7
;	2
4h
	=
	1
.5
;		
48
h	
=	
1.
2	
nm
ol
/L
	a
nd
,	f
or
	m
od
er
at
e	
AP
	w
er
e	
0h
	=
	5
.5
;	2
4h
	=
	1
0.
5;
		
48
h	
=	
12
.5
	n
m
ol
/L
.	
		 159	
													
	
																
Fi
gu
re
	5
.3
.2
.2
.5
	(a
)	O
ve
rv
ie
w
	o
f	C
RP
	c
on
ce
nt
ra
tio
ns
	fo
r	
pa
tie
nt
s	
se
gr
eg
at
ed
	a
s	
m
ild
	(
gr
ee
n)
	o
r	
m
od
er
at
e	
(r
ed
)	
us
in
g	
th
e	
re
vi
se
d	
At
la
nt
a	
cl
as
sif
ic
at
io
n.
	A
	c
ut
-o
ff	
va
lu
e	
of
	1
50
	m
g/
L	
(d
as
he
d	
lin
e)
	
ba
se
d	
on
	t
he
	A
M
N
CH
	C
RP
	s
pe
ci
fic
at
io
n	
at
	4
8h
	w
as
	u
se
d	
to
	
di
st
in
gu
ish
	b
et
w
ee
n	
th
es
e	
gr
ou
ps
.	F
ro
m
	a
	to
ta
l	o
f	1
5	
pa
tie
nt
s,
	si
x	
pa
tie
nt
s	
w
er
e	
de
te
rm
in
ed
	t
o	
be
	t
ru
e	
po
sit
iv
es
	(
m
od
er
at
e	
AP
)	
an
d	
ni
ne
	p
at
ie
nt
s	
w
er
e	
de
te
rm
in
ed
	t
o	
be
	t
ru
e	
ne
ga
tiv
es
	(
m
ild
	
AP
).	
O
ne
	p
at
ie
nt
	w
as
	d
et
er
m
in
ed
	t
o	
be
	a
	fa
lse
	n
eg
at
iv
e	
(P
at
ie
nt
	
M
)	
an
d	
fo
ur
	p
at
ie
nt
s	
w
er
e	
de
te
rm
in
ed
	t
o	
be
	f
al
se
	p
os
iti
ve
s	
(P
at
ie
nt
s	
E,
	G
,	
J,	
an
d	
K	
in
di
ca
te
d	
by
	d
ar
k	
gr
ee
n)
.	
Fo
r	
th
is
	
ex
pl
or
at
or
y	
cl
in
ic
al
	c
oh
or
t,	
th
e	
se
ns
iti
vi
ty
	a
nd
	s
pe
ci
fic
ity
	o
f	
CR
P	
w
er
e	
85
.7
%
	a
nd
	6
9.
2%
,	
re
sp
ec
tiv
el
y.
	T
he
	n
eg
at
iv
e	
pr
ed
ic
tiv
e	
va
lu
e	
(N
PV
)	a
nd
	p
os
iti
ve
	p
re
di
ct
iv
e	
va
lu
e	
(P
PV
)	w
er
e	
90
.0
%
	a
nd
	
60
.0
%
,	r
es
pe
ct
iv
el
y.
	T
he
	a
re
as
	u
nd
er
	t
he
	R
O
C	
cu
rv
e	
w
er
e	
0.
52
,	
0.
52
	a
nd
	0
.7
9	
at
	0
h,
	2
4h
	a
nd
	4
8h
,	r
es
pe
ct
iv
el
y	
(A
pp
en
di
x	
8.
2)
.	
	 Fi
gu
re
	5
.3
.2
.2
.5
	(
b)
	M
ea
n	
CR
P	
co
nc
en
tr
at
io
ns
	i
n	
pa
tie
nt
s	
w
ith
	
m
ild
	a
nd
	m
od
er
at
e	
AP
	d
ur
in
g	
th
e	
fir
st
	4
8h
	fo
llo
w
in
g	
ad
m
iss
io
n	
to
	
th
e	
ED
.	T
he
	s
ep
ar
at
io
n	
w
as
	le
ss
	c
le
ar
	w
ith
	a
n	
in
cr
ea
sin
g	
tr
en
d	
ob
se
rv
ed
	fo
r	b
ot
h	
gr
ou
ps
.	M
ea
n	
CR
P	
va
lu
es
	fo
r	m
ild
	A
P	
w
er
e	
0h
	
=	
23
.1
;	2
4h
	=
	7
9.
3;
	4
8h
	=
	1
47
.2
	m
g/
L	
an
d,
	fo
r	m
od
er
at
e	
AP
	w
er
e	
0h
	=
	4
5.
9;
	2
4h
	=
	1
01
.1
;	4
8h
	=
	2
61
.2
	m
g/
L.
	
	
Ti
m
e	
(h
ou
rs
)	
CRP	(mg/L)	
CRP	(mg/L)	
(b
) 
(a
) 
		 160	
	
Table	5.3.2.2.1	Overview	of	performance	to	predict	moderate	acute	pancreatitis	at	48	hours	
after	hospital	admission,	as	defined	by	the	revised	Atlanta	classification:	
	
48h	after	admission	 Sensitivity	(%)	 Specificity	(%)	 NPV	(%)	 PPV	(%)	
TAP	 85.7	 100.0	 90.0	 100.0	
CRP	 85.7	 69.2	 90.0	 60.0	
AMNCH,	Tallaght	Classification	 100.0	 75.0	 100.0	 66.7	
												
	
						 	
	
Figure	5.3.2.2.6	Overview	of	amylase	concentrations	for	patients	segregated	as	mild	(green)	or	
moderate	(red)	using	the	revised	Atlanta	classification.	A	large	proportion	of	the	mild	patients	
demonstrated	 serum	 amylase	 levels	 that	 were	 significantly	 raised,	 with	 both	 Patient	 C	 and	
Patient	E	having	results	that	were	not	completely	distant	from	that	of	Patient	O,	a	confirmed	
case	 of	moderate	 AP.	 In	 addition,	 the	 lowest	 amylase	 levels	 recorded	 for	 the	moderate	 AP	
patients	were	comparable	to	some	of	the	mild	AP	patients.	This	once	again	highlights	that	no	
overall	 pattern	 could	 be	 established	which	 could	 significantly	 contribute	 to	 clinical	 decision-	
making	for	segregation	of	patients.	
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5.3.3	 Lateral	flow	prototype	–	clinical	feasibility	assessment	
	
In	order	to	determine	the	feasibility	of	the	anti-TAP	LFIA	prototype	to	distinguish	between	TAP	
positive	and	negative	clinical	samples,	urine	from	Patient	L	(TAP	=	26.0	nmol/L,	48	hours)	and	
from	 Patient	 D	 (TAP	 =	 0.4	 nmol/L,	 24	 hours)	 was	 selected	 for	 the	 positive	 and	 negative	
samples,	 respectively.	 The	 selection	 of	 this	 negative	 sample	 was	 due	 to	 this	 time-point	
returning	the	lowest	possible	concentration	of	TAP	that	was	recorded	from	the	clinical	analysis	
as	distinguishable	from	a	zero	concentration.	These	samples	were	tested	using	both	antibody	
spot	and	stripe	LFIA	prototypes,	with	test	conjugate	only	(Figure	5.3.3.1)	and	test	and	control	
conjugates	concurrently	to	represent	a	complete	device	(Figure	5.3.3.2).	All	devices	used	the	
Prototype	 2	 control	 line	 configuration	 of	 a	 goat	 anti-chicken	 (GAC)	 IgY	 capture	 antibody	
immobilised	 onto	 the	 nitrocellulose	 (NC)	 membrane	 and	 a	 chicken	 IgY	 antibody	 conjugate	
chemically	 linked	to	superparamagnetic	particles	 (SPMPs).	This	 testing	was	performed	as	per	
sections	2.2.12	and	4.3.8.	
	
	
	
Figure	5.3.3.1	TAP	positive	and	negative	clinical	urine	samples	analysed	using	the	anti-TAP	LFIA	
prototype	 (test	 and	 control	 lines,	 complete	device)	 and	 TAP-SPMP	 “test”	 conjugate	only.	 As	
demonstrated	by	dose	response	curve	testing	in	section	4.3.8,	the	negative	sample	returned	a	
high	MAR	 response	 (Spot	 device	 =	 655.4;	 Stripe	 device	 =	 782.1	MAR)	 in	 comparison	 to	 the	
positive	sample	(Spot	device	=	11.2;	Stripe	device	=	20.6	MAR).	The	MAR	response	was	slightly	
raised	 for	 the	 striped	 device	 in	 comparison	 to	 the	 spot	 device	 and	 was	 in	 agreement	 with	
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previous	 results	 as	 shown	 in	 Figure	 4.3.8.3.1.	 The	 contrasting	 MAR	 response	 between	 the	
positive	 and	 negative	 samples	 indicated	 the	 capability	 of	 the	 LFIA	 prototype	 to	 distinguish	
between	varying	TAP	concentrations	in	clinical	urines	and	was	complimentary	to	the	previous	
dose	response	curve	analysis.	The	optimisation	of	a	finalised	LFIA	prototype	that	could	quantify	
urinary	TAP	within	a	defined	measuring	range	was	therefore	possible.	
	
	
	
Figure	5.3.3.2	TAP	negative	clinical	urine	samples	analysed	using	the	anti-TAP	LFIA	prototype	
(complete	device)	and	both	TAP-SPMP	“test”	and	chicken	IgY-SPMP	“control”	conjugates.	The	
negative	 sample	 returned	 a	 lower	 test	 line	 response	when	 compared	 to	 Figure	 5.3.3.1.	 The	
reported	values	 for	 the	spot	device	were	570.0	and	320.7	MAR	at	 the	test	and	control	 lines,	
respectively.	 This	 control	 line	 response	 was	 similar	 to	 previous	 spot	 device	 testing	 for	
Prototype	2	(Mean	=	330	MAR,	Figure	4.3.8.3.2).	The	control	line	response	for	the	stripe	device	
(373.0	 MAR)	 was	 also	 not	 very	 dissimilar	 to	 this	 previous	 testing	 (Mean	 =	 413.0	 MAR).	
However,	 the	 test	 line	 for	both	the	spot	and	stripe	devices	had	previously	 returned	a	higher	
response	for	negative	sample	testing	(Spot	=	713.5	MAR;	Stripe	=	712.2	MAR).	This	difference	
in	 signal	 response	 may	 have	 arisen	 from	 analysis	 of	 alternative	 urine	 matrices	 (apparently	
healthy	donor	versus	clinical,	diseased).	However,	the	test	 line	response	(320.7	MAR)	for	the	
striped	 device	 was	 clearly	 reduced	 and	 raised	 the	 question	 of	 variability	 in	 the	 antibody	
application	method.	 A	 sample	 flow	 issue	was	 observed	 for	 testing	 of	 the	 TAP	positive	 urine	
sample	and	resulted	in	response	values	<60	MAR.	A	lack	of	visual	development	at	the	test	and	
control	lines	further	supported	that	the	sample/conjugate	mixture	had	not	migrated	across	the	
entire	device.	Unfortunately,	 there	were	 insufficient	project	materials	to	repeat	this	analysis.
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5.4	 DISCUSSION	AND	CONCLUSION	
	
The	analysis	of	an	exploratory	cohort	of	patients	with	acute	pancreatitis	 (AP)	using	 the	anti-
TAP	ELISA	prototype	(chapter	3)	and	the	feasibility	of	the	anti-TAP	LFIA	prototype	(chapter	4)	
to	discriminate	between	TAP	positive	and	negative	clinical	urine	samples	was	described	in	this	
chapter.	The	revised	Atlanta	classification	is	the	only	clinically	based	system	for	the	description	
and	management	of	AP	that	is	widely	accepted	by	clinicians	and	radiologists	alike	(Banks	et	al.,	
2013).	This	classification	system	was	used	to	compare	the	performance	of	the	clinical	criteria	
utilised	 at	 the	 Adelaide	 and	Meath	National	 Children’s	 Hospital	 (AMNCH),	 Tallaght,	 and	 the	
TAP	and	CRP	biomarkers	in	their	ability	to	stratify	the	severity	of	AP	into	mild,	moderate	and	
severe	 categories.	 This	 exploratory	 study	 confirmed	 that	 the	 AMNCH,	 Tallaght	 clinical	
assessment	methodologies	were	excellent	at	ensuring	that	no	potentially	severe	patients	were	
excluded	from	a	treatment	regime	designed	to	reduce	the	likelihood	of	developing	symptoms	
of	 severe	 AP.	 In	 this	 15	 patient	 cohort,	 6	 patients	 were	 treated	 as	 having	 mild	 AP	 and	 9	
patients	were	treated	as	potentially	severe	AP.	The	revised	Atlanta	classification	subsequently	
determined	 that	 there	 were	 9	 patients	 with	mild	 AP	 and	 6	 patients	 with	moderate	 AP.	 No	
Atlanta	 severe	 cases	and	no	deaths	were	observed	 in	 this	 study.	 Therefore,	 3	patients	were	
treated	as	potentially	severe	prior	to	their	establishment	as	actual	cases	of	mild	AP	but	most	
importantly,	all	Atlanta	moderates	were	treated	as	severe	by	AMNCH,	Tallaght.	Consequently,	
the	 sensitivity,	 specificity,	 NPV	 and	 PPV	 of	 the	 AMNCH,	 Tallaght	 classification	 method	 to	
predict	 moderate	 AP	 at	 48h	 after	 admission	 was	 100.0%,	 75.0%,	 100.0%	 and	 66.7%,	
respectively.	 Certain	 patients	 had	 extended	 hospital	 stay	 periods	 lasting	 for	 as	 long	 as	 one	
month	 and	 there	 was	 every	 possibility	 that treating	 patients	 as	 severe	 from	 the	 beginning	
could	 prevent	 complications	 which	 would	 score	 them	 as	 severe	 using	 the	 revised	 Atlanta	
classification.	The	 length	of	hospital	stay	very	clearly	rose	for	the	moderate	AP	category	(see	
Table	 5.3.2.1.1)	 and	 demonstrated	 the	 additional	 burden	 on	 hospital	 resources	 that	 arises	
from	 this	 group.	 These	 figures	 offer	 a	 projection	 of	 the	 burden	 that	 would	 be	 faced	 for	
treatment	 of	 patients	 with	 severe	 AP.	 The	 excellent	 NPV	 (100%)	 of	 the	 AMNCH,	 Tallaght	
classification	was	a	particularly	valuable	outcome	of	this	analysis	as	NPV	decreases	the	demand	
placed	 on	 hospital	 resources,	 allowing	 greater	 focus	 to	 be	 applied	 to	more	 severe	 patients	
requiring	intensive	management	(Neoptolemos	et	al.,	2001).	
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Measurement	of	plasma	CRP	levels	following	patient	admission	to	the	Emergency	Department	
(ED)	 and	 up	 to	 48	 hours	 is	 performed	 as	 part	 of	 the	 AMNCH,	 Tallaght	 clinical	 stratification	
criteria.	CRP	has	been	shown	to	correlate	well	with	severity	of	AP	(Wilson	et	al.,	1989)	but	this	
inflammatory	marker	often	does	not	reach	a	peak	until	48	-	72	hours	(Meher	et	al.,	2015)	and	
is	part	of	the	wave	of	acute-phase	proteins	produced	by	the	body	in	response	to	inflammation	
or	 infection	 (Jain	et	al.,	2011).	CRP	 therefore	 lacks	specificity	 for	AP	but	 is	a	good	diagnostic	
tool	 for	 measuring	 the	 level	 of	 inflammation,	 which	 could	 potentially	 correlate	 to	 disease	
severity.	This	lack	of	specificity	was	highlighted	with	Patient	E	returning	one	of	the	highest	CRP	
levels	 in	 this	 study	while	suffering	 from	cholangitis.	For	 this	 study,	 the	sensitivity,	 specificity,	
NPV	and	PPV	of	CRP	to	predict	moderate	AP	at	48h,	relative	to	clinical	assessment	by	revised	
Atlanta;	was	85.7%,	69.2%,	90.0%	and	60.0%,	respectively.	In	comparison,	the	analysis	of	urine	
samples	collected	from	patients	at	set	time-points	following	hospital	admission	using	the	anti-
TAP	 ELISA	 prototype	 demonstrated	 a	 strong	 capacity	 for	 the	 TAP	 biomarker	 to	 predict	 the	
severity	of	AP	in	the	early	phase	of	the	disease.	The	sensitivity,	specificity,	NPV	and	PPV	of	TAP	
to	predict	moderate	AP	at	48h,	 relative	 to	clinical	assessment	by	 revised	Atlanta;	was	85.7%	
and	100.0%,	90.0%	and	100%	respectively.	From	these	results,	TAP	was	clearly	highly	specific	
to	 AP	 with	 a	 considerable	 NPV	 and	 PPV.	 The	 activation	 of	 trypsinogen	 to	 trypsin	 and	 the	
ensuing	release	of	TAP	into	urine	is	a	recognised	mechanism	that	precedes	all	clinical	events	in	
AP	(Gorelick,	2003).	The	proportional	proliferation	of	TAP	to trypsinogen	activation	makes	this	
peptide	a	biomarker	candidate	for	use	in	the	early	predication	of	AP	severity. As	the	first	study	
of	TAP	under	the	revised	Atlanta	classification,	it	was	demonstrated	that	TAP	could	potentially	
provide	 additional	 support	 in	 clinical	 decision	making	 for	 stratification	 of	 AP	 patients	 at	 the	
early	stages	of	disease	and	appeared	to	be	superior	 in	 this	 role	when	compared	to	CRP.	The	
increase	 in	TAP	 levels	at	an	early	 stage	of	disease	 is	also	an	 important	characteristic	 for	any	
useful	POC	biomarker.	While	a	further	and	larger	cohort	analysis	is	required	to	support	these	
results,	TAP	would	compliment	the	assessment	of	AP	patients	by	CRP,	 if	not	further	 improve	
this	 process.	 Unfortunately,	 there	 was	 insufficient	 data	 available	 from	 this	 study	 to	 truly	
determine	the	prognostic	performance	of	TAP	at	the	24h	time-point.	The	TAP	levels	observed	
for	 this	 study	 were	 complimentary	 of	 an	 original	 clinical	 study	 performed	 with	 a	
radioimmunoassay	 format	 by	 Gudgeon	 et	 al.,	 (1990).	 In	 fact,	 if	 the	 TAP	 cut-off	 value	 of	 ≥2	
nmol/L	proposed	by	this	group	for	the	prediction	of	severe	AP	upon	admission	were	applied	to	
the	data	 from	 this	 study,	TAP	would	have	a	100%	 record	 for	 sensitivity,	 specificity,	NPV	and	
PPV.	The	TAP	 levels	 for	 this	 study	were	below	 those	of	 several	other	 clinical	 studies	of	note	
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(Neoptolemos	et	al.,	2001;	Khan	et	al.,	2002;	Liu	et	al.,	2002;	Johnson	et	al.,	2004)	where	a	TAP	
cut-off	value	of	35	nmol/L	was	described	for	the	prediction	of	severe	AP.	It	is	important	to	note	
that	 these	 studies	 largely	 defined	 severity	 of	 AP	 based	 on	 the	 initial	 Atlanta	 classification,	
which	 did	 not	 include	 a	 moderately	 severe	 AP	 category	 (Bradley,	 1993).	 In	 addition,	 the	
majority	of	these	studies	enrolled	patients	who	were	admitted	within	<48h	after	the	onset	of	
symptoms	of	AP.	Unfortunately,	the	same	could	not	be	said	for	this	study	(see	Table	5.3.2.1.1).	
Consequently,	 there	was	 potential	 for	 lower	 TAP	 levels	 to	 feature	more	 prominently	 in	 the	
data.	 Still,	 it	 was	 decided	 to	 include	 all	 of	 these	 patients	 to	 capture	 a	 broader	 analysis	 and	
reflect	 the	 exploratory	 nature	 of	 this	 clinical	 study.	 The	 higher	 TAP	 levels	 recorded	 for	 the	
previous	studies	may	potentially	be	explained	by	the	use	of	a	polyclonal	ELISA	format	for	the	
analysis.	 The	 potential	 for	 binding	multiple	 target	 antigen	 epitopes	when	 using	 a	 polyclonal	
assay	could	significantly	contribute	to	the	raised	TAP	levels	observed.	Perhaps	the	binding	of	a	
single	epitope	or	isoform	of	the	TAP	biomarker	by	the	monoclonal	antibody	used	for	the	ELISA	
prototype	described	 in	 this	work	 could	be	 the	 reason	 for	 the	 lower	 TAP	 levels	 observed.	As	
analysis	of	both	these	assay	formats	could	not	be	performed	in	parallel,	and	no	gold	standard	
measurement	 of	 TAP	 currently	 exists,	 a	 direct	 comparison	 of	 the	 TAP	 levels	 could	 not	 be	
obtained	from	this	patient	cohort.	This	does	not	take	away	from	the	functionality	of	this	assay,	
or	 indeed	 the	 performance	 as	 seen	 in	 this	 study,	 but	 simply	 should	 be	 noted	 as	 a	 topic	 of	
further	 investigation.	 Nonetheless,	 this	 assay	 format	 was	 entirely	 capable	 of	 stratifying	 the	
patients	 with	 mild	 and	 moderate	 AP	 based	 on	 TAP	 levels,	 under	 the	 revised	 Atlanta	
classification.	 In	addition,	 the	concurrent	 rapid	 increase	and	decrease	observed	 in	TAP	 levels	
for	mild	and	moderate	patients	by	24h	after	admission,	respectively	(Figure	5.3.2.2.4	(b)),	again	
suggests	another	advantage	of	TAP	as	a	potential	biomarker	for	early	prediction	of	severity	and	
therefore,	early	treatment	intervention.	
The	capability	of	the	anti-TAP	LFIA	prototype	to	distinguish	between	TAP	positive	and	
negative	clinical	urines	was	investigated	to	determine	the	feasibility	of	an	anti-TAP	POC	device.	
The	use	of	 the	TAP-SPMP	 test	 conjugate	alone	 in	 this	 system	clearly	demonstrated	 that	 this	
discrimination	was	possible.	Unfortunately,	the	addition	of	the	control	conjugate	resulted	in	a	
reduced	signal	response	at	both	the	test	and	control	lines	and	this	result	could	not	be	reviewed	
further	due	to	the	costing	and	financial	constraints	of	this	project.	Future	work	with	the	LFIA	
prototype	would	demand	the	purchase	of	materials	 to	repeat	positive	clinical	sample	testing	
and	the	optimisation	of	conjugate	dilutions	used	in	complete	device	testing	to	prove	that	test	
and	control	line	responses	could	operate	within	specific	and	reproducible	ranges.	
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6.1	OVERALL	CONCLUSIONS	
	
The	aim	of	the	work	presented	 in	this	thesis	was	to	develop	assays	for	the	detection	and	
quantification	of	urinary	trypsinogen	activation	peptide	(TAP).	 It	 is	now	accepted	that	the	
inappropriate	 intracellular	 activation	 of	 the	 “zymogen”	 trypsinogen	 to	 form	 trypsin	 in	
acinar	cells	 is	a	major	event	 in	 the	pathogenesis	of	acute	pancreatitis	 (AP).	The	 improper	
activation	and	proliferation	of	zymogens	causes	auto-digestion	of	the	pancreatic	tissue	and	
can	 potentially	 trigger	 necrosis	 and	 the	 effluence	 of	 these	 activated	 enzymes	 into	 the	
bloodstream,	provoking	the	release	of	 inflammatory	cytokines	and	a	subsequent	systemic	
inflammatory	 response.	 Continued	 organ	 failure	 and	 septic	 infection	 can	 result,	 causing	
increased	incidence	of	mortality.	TAP	is	a	small,	fragmented	peptide	that	is	proportionally	
produced	 as	 a	 by-product	 to	 any	 trypsinogen	 activation	 before	 its	 expeditious	 excretion	
into	the	urine.	As	this	mechanism	occurs	at	the	earliest	phases	of	AP	and	the	structure	of	
TAP	 is	 highly	 conserved	 due	 to	 its	 small	 size,	 TAP	 is	 a	 potential	 biomarker	 for	 the	 early	
detection	of	AP	and	would	be	most	proficient	in	a	point-of-care	(POC)	test	device	capable	
of	rapid	reporting	of	results.		
The	early	detection	of	AP	is	not	sufficient	alone	in	the	management	of	this	evolving	
disease	 and	 thus,	 a	 biomarker	 of	 AP	must	 also	 exhibit	 the	 capability	 of	 predicting	 those	
patients	 who	 will	 develop	 severe	 AP.	 Previously,	 several	 multicenter	 clinical	 studies	
exploring	 the	 viability	 of	 the	 TAP	 biomarker	 as	 a	 predictor	 of	 AP	 severity	 have	 been	
completed	 using	 a	 polyclonal	 anti-TAP	 capture	 antibody	 in	 a	 competitive	 ELISA	 format.	
However,	 continued	 generation	 of	 the	 polyclonal	 antibody	 proved	 difficult	 and	 poor	
reproducibility	 of	 the	 test	 method	 followed.	 The	 strategy	 employed	 for	 this	 project	
involved	 the	 production	 of	 a	 monoclonal	 anti-TAP	 capture	 antibody	 under	 a	 contract	
agreement	with	an	industrial	partner.	This	novel	antibody	was	characterised	by	SDS-PAGE	
analysis	 to	 confirm	purity	prior	 to	 its	 application	 in	 an	 ELISA	prototype	 for	 the	detection	
and	quantification	of	the	TAP	biomarker	in	the	urine	matrix.	The	demonstration	of	an	ELISA	
prototype	capable	of	serving	as	a	“gold	standard”	reference	method	was	paramount	to	the	
subsequent	 development	 of	 a	 lateral	 flow	 test	 strip	 device.	 Finally,	 a	 small-scale	 clinical	
study	was	undertaken	using	 the	ELISA	prototype	 to	analyse	 the	 clinical	 utility	of	 the	TAP	
biomarker.	 The	 feasibility	 of	 the	 LFIA	 prototype	 to	 distinguish	 between	 TAP	positive	 and	
TAP	negative	urine	samples	from	patients	with	confirmed	AP	was	also	demonstrated	with	a	
reduced	test	duration.	The	various	segments	of	this	work	are	categorised	below.	
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Chapter	3.	Development	of	a	monoclonal	anti-TAP	ELISA		
	
• Three	individual	lots	of	14-8	monoclonal	anti-TAP	IgG	capture	antibody,	provided	by	
AbCam	International,	were	characterised	by	SDS-PAGE	analysis	with	heavy	and	light	
chain	 domains	 observed	 at	 ~50	 and	 25kDa,	 respectively,	 and	 no	 notable	
contaminating	bands	present.	
• The	 immobilisation	 of	 the	 14-8	 monoclonal	 anti-TAP	 IgG	 capture	 antibody	 in	 a	
competitive	ELISA	test	format	utilising	a	TAP-HRP	conjugate	competing	with	“free”	
TAP	 calibrator	 standard	 demonstrated	 insufficient	 sensitivity	 due	 to	 the	 limited	
discrimination	between	calibrator	standards.	
• An	 alternative	 ELISA	 format	 using	 biotinylated	 monoclonal	 anti-TAP	 IgG	 capture	
antibody	 and	 a	 streptavidin-coated	 microtitre	 plate	 demonstrated	 clear	
discrimination	 between	 calibrator	 standards	 and	 increased	 TAP-HRP	 conjugate	
dilution.	 Three	 individual	 lots	 of	 biotinylated	 monoclonal	 anti-TAP	 IgG	 capture	
antibody	produced	comparable	standard	curves.	
• Freeze-thaw	stability	of	the	TAP	antigen	was	demonstrated	in	both	urine	and	dH2O,	
indicating	that	clinical	urine	samples	could	be	collected	and	stored	at	-20°C	without	
degradation	of	the	peptide	structure.	Stability	in	dH2O	would	allow	for	reproducible	
stock	dilutions	of	calibrator	standards	from	-20°C	storage.	
• The	standard	curve	dynamic	measuring	range	was	selected	as	0	–	400	nmol/L	with	a	
back-calculated	TAP	antigen	recovery	of	100	±	10%.	
• The	 intra-	 and	 inter-assay	precision	 (%CV)	of	 the	ELISA	prototype	was	established	
using	quality	control	 (QC)	urine	samples	spiked	with	TAP	antigen	and	ranged	from	
1.7	–	10.1%	and	4.8	–	10.4%,	respectively.	
• A	positive	control	 (PC)	sample,	consisting	of	TAP	antigen	spiked	 into	a	proprietary	
diluent	 to	maximize	 stability,	 was	 established	with	 a	mean	 concentration	 of	 62.5	
nmol/L.	 A	 controlled	 concentration	 range	 of	 50	 –	 75	 nmol/L	 was	 established	 for	
future	use	of	this	sample	in	ELISA	prototype	testing.	
• The	Limit	of	Blank	(LoB),	Limit	of	Detection	(LoD)	and	Limit	of	Quantification	(LoQ)	
of	the	ELISA	were	established	as	1.2,	2.3	and	2.3	nmol/L,	respectively.	
• The	 linear	measuring	 range	was	 determined	 to	 be	 between	 10.2	 –	 175.5	 nmol/L	
from	dilution	of	 the	highest	urinary	QC	sample	 (QC4)	concentration.	The	 linear	 fit	
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was	 R2	=	 0.9916	 with	 variability	 (%CV)	 between	 replicates	 ≤10%	 for	 each	 sample	
level.	
• The	streptavidin-coated	microtitre	plate	was	estimated	to	be	stable	for	at	least	one	
year	at	4°C	from	an	accelerated	stress	study	at	37°C.	
• A	 “normal”	 reference	 range	 for	 urinary	 TAP	 was	 established	 from	 an	 apparently	
healthy	donor	group	as	0	–	5.3	nmol/L.		
	
Chapter	4.	Development	of	an	anti-TAP	lateral	flow	test	strip	device		
	
• Technical	 evaluation	 of	 the	MICT®	 instrument	 using	 a	 commercially	 available	 test	
for	the	detection	of	cardiac	troponin	I	(cTnI)	demonstrated	acceptable	performance	
(intra-/inter-assay	 precision,	 LoQ,	 linearity,	 reference	 range,	 spike-recovery	 and	
sample	 freeze	 thaw	 stability)	 for	 use	 of	 the	 MICT®	 system	 as	 a	 development	
platform.	
• An	 optimised	 conjugation	 protocol	 for	 the	 coupling	 of	 polyclonal	 rabbit	 IgG	 and	
chicken	IgY	to	superparamagnetic	particles	(SPMPs)	as	“control”	conjugates	and	TAP	
antigen	 to	 SPMPs	 as	 a	 “test”	 conjugate	 was	 established.	 An	 optimised	 dilution	
buffer	formulation	was	also	selected	for	use	with	the	SPMP	conjugates	in	the	LFIA	
prototype.	
• Spotting	and	striping	of	capture	antibodies	onto	the	nitrocellulose	(NC)	membrane	
at	 separate	 test	 and	 control	 line	 positions	 was	 investigated	 and	 optimised	 with	
regard	 to	 stock	 concentrations,	 application	 methods	 and	 volumes,	 and	 drying	
conditions.	 The	 test	 line	 comprised	 immobilised	 streptavidin	 and	 biotinylated	
monoclonal	anti-TAP	 IgG	capture	antibody.	The	control	 line	comprised	either	goat	
anti-rabbit	IgG	(Prototype	1)	or	goat	anti-chicken	IgY	(Prototype	2).	
• Dose	 response	 curves	 using	 urinary	 QC	 samples	 with	 known	 TAP	 concentrations,	
which	 were	 previously	 established	 with	 the	 ELISA	 prototype,	 were	 analysed	 via	
striped	 and	 spotted	 LFIA	 devices.	 Results	 indicated	 that	 discrimination	 between	
varying	 urinary	 TAP	 concentrations	was	 possible	 using	 the	 LFIA	 device	 and	 paved	
the	way	for	preliminary	feasibility	testing	with	TAP	positive	and	TAP	negative	clinical	
samples.	
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Chapter	5.	Clinical	Evaluation	of	anti-TAP	ELISA	and	LFIA	prototypes	
	
• An	 exploratory	 clinical	 study	 of	 urine	 samples	 from	 15	 patients	 with	 AP	 was	
designed	in	collaboration	with	the	Adelaide	and	Meath	National	Children’s	Hospital	
(AMNCH),	 Tallaght	 to	 assess	 the	 clinical	 utility	 of	 the	 TAP	 biomarker	 for	 the	
detection	and	prediction	of	AP	severity.	
• The	analysis	of	this	patient	cohort	was	completed	using	the	ELISA	prototype	and	the	
results	for	the	TAP	biomarker	were	scrutinized	against	the	clinical	criteria	employed	
by	 AMNCH,	 Tallaght	 and	 the	 international	 Atlanta	 classification	 guideline	 for	 the	
stratification	of	patients	according	to	AP	severity.	
• Using	 the	TAP	biomarker	with	 the	Atlanta	 classification	definition	of	 severity,	one	
patient	was	 determined	 to	 be	 a	 false	 negative	 (Patient	M)	 and	 no	 patients	were	
determined	 to	 be	 falsely	 positive.	 The	 sensitivity,	 specificity,	 negative	 predictive	
value	(NPV)	and	positive	predictive	value	(PPV)	of	TAP	to	predict	the	development	
of	 moderate	 AP	 at	 48h	 after	 admission	 was	 85.7%,	 100.0%,	 90.0%	 and	 100%,	
respectively.	The	areas	under	the	receiver	operator	characteristic	(ROC)	curve	were	
0.81,	0.94	and	0.80	at	0h,	24h	and	48h,	respectively.	Mean	TAP	values	for	mild	AP	
were	0h	=	2.7;	24h	=	1.5;	48h	=	1.2	nmol/L,	and	for	moderate	AP	were	0h	=	5.5;	24h	
=	10.5;	48h	=	12.5	nmol/L.		
• Using	 the	 C-reactive	 protein	 (CRP)	 biomarker	 with	 the	 Atlanta	 classification	
definition	of	severity,	one	patient	was	determined	to	be	a	false	negative	(Patient	M)	
and	four	patients	were	determined	to	be	false	positives	(Patients	E,	G,	J,	and	K).	The	
sensitivity,	specificity,	NPV	and	PPV	of	CRP	to	predict	the	development	of	moderate	
AP	 at	 48h	 after	 admission	was	 85.7%,	 69.2%,	 90.0%	 and	 60.0%,	 respectively.	 The	
areas	 under	 the	 ROC	 curve	 were	 0.52,	 0.52	 and	 0.79	 at	 0h,	 24h	 and	 48h,	
respectively.	Mean	CRP	values	for	mild	AP	were	0h	=	23.1;	24h	=	79.3;	48h	=	147.2	
mg/L,	and	for	moderate	AP	were	0h	=	45.9;	24h	=	101.1;	48h	=	261.2	mg/L.	
• TAP	was	superior	to	CRP	for	the	stratification	of	patients	with	mild	and	moderate	AP	
and	also	for	ability	to	predict	the	development	of	moderate	AP.	
• The	 striped	 and	 spotted	 LFIA	 prototype	 devices	 (Prototype	 2)	 adequately	
distinguished	between	TAP	positive	and	TAP	negative	 clinical	 urine	 samples	when	
using	the	“test”	conjugate	only.	
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• The	 TAP	 negative	 clinical	 urine	 sample	 analysed	 using	 both	 TAP-SPMP	 “test”	 and	
chicken	 IgY-SPMP	 “control”	 conjugates	 returned	 a	 reduced	 test	 line	 response	 for	
both	 the	 striped	 and	 spotted	 devices	 when	 compared	 to	 previous	 testing	 during	
development.	 This	 difference	 in	 signal	 response	 may	 have	 risen	 from	 analysis	 of	
alternative	 urine	 matrices	 (apparently	 healthy	 donor	 versus	 clinical,	 diseased)	 or	
potential	variability	 in	 the	antibody	application	method.	However,	 the	control	 line	
response	for	the	striped	and	spotted	devices	was	similar	to	previous	device	testing	
during	development	for	Prototype	2.		
• A	sample	flow	issue	was	observed	for	testing	of	the	TAP	positive	urine	sample	and	
resulted	 in	 a	 signal	 response	 considerably	 lower	 than	 expected.	 A	 lack	 of	 visual	
development	at	the	test	and	control	lines	further	implied	that	the	sample/conjugate	
mixture	 had	 not	 migrated	 across	 the	 entire	 device.	 Unfortunately,	 there	 were	
insufficient	project	materials	available	to	repeat	this	analysis.	
	
	
6.2	FUTURE	WORK	
	
The	keys	aspects	of	any	 future	work	undertaken	 in	 relation	 to	 this	project	would	 include	
the	following	important	areas	detailed	below.	
	
6.2.1	 Further	performance	testing	of	ELISA	prototype	in	preparation	for	
commercialisation	as	a	Research	Use	Only	(RUO)	product	
• Interference	testing	for	possible	endogenous	interfering	substances	found	in	human	
urine,	including	lipids	and	bilirubin.	
• Accelerated	stress	stability	study	of	biotinylated	anti-TAP	IgG	capture	antibody.	
• Further	characterisation	of	biotinylated	anti-TAP	IgG	capture	antibody	using	GE	
Healthcare	BiaCore	system	to	analyse	the	affinity	and	interaction	with	the	TAP	
antigen.	
• Real-time	stability	study	of	urinary	QC	panel	samples	stored	at	-20°C.	
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6.2.2	 Optimisation	of	lateral	flow	test	strip	device	
• Finalise	conjugate	dilution	when	using	test	and	control	conjugates	concurrently	with	
test	device.	
• Real-time	stability	study	of	SPMP	conjugate	stocks.	
• Use	of	specialised	instrumentation	commonly	used	for	preparation	of	lateral	flow	
test	strips,	e.g.	IsoFlowTM	reagent	dispenser	and	precision	testing	to	demonstrate	
robustness	of	manufactured	devices.	
• Preparation	and	selection	of	standard	curve	measuring	range	for	use	in	the	
conversion	of	magnetic	signal	into	a	quantifiable	TAP	concentration.	
• Method	comparison	of	finalised	LFIA	prototype	with	ELISA	reference	method	for	the	
quantification	of	the	TAP	biomarker	in	urine.	
	
6.2.3	 Clinical	evaluation	of	large-scale	patient	cohort	containing	a	minimum	of	50	
patients	
• Confirmation	 of	 initial	 exploratory	 study	 findings	 through	 continued	 patient	
recruitment,	sample	collection	and	biomarker	analysis	using	ELISA	“gold	standard”.	
• Confirmation	of	LFIA	prototype	capability	 to	distinguish	between	TAP	positive	and	
TAP	negative	clinical	urine	samples.	
• Evaluation	of	LFIA	prototype	performance	in	ongoing	exploratory	clinical	study.		
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Appendix	8.1	Polyclonal	anti-TAP	ELISA	performance	characteristics	taken	directly	from	the	
Biotrin	International	“Trypsinogen	Activation	Peptide	ELISA”	product	insert.	
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Appendix	 8.2	 Receiver	 operator	 characteristic	 (ROC)	 curves	 for	 prediction	 of	 moderate	
acute	pancreatitis	(AP)	by	trypsinogen	activation	peptide	(TAP)	and	C-reactive	protein	(CRP)	
biomarkers.	Both	TAP	and	CRP	are	graphed	with	(a)	=	0h;	(b)	=	24h;	(c)	=	48h	after	hospital	
admission.	The	area	under	the	ROC	curve	for	TAP	was	0.81,	0.94	and	0.80	at	0h,	24h	and	
48h,	respectively,	and	for	CRP	was	0.52,	0.52	and	0.79	at	0h,	24h	and	48h,	respectively.	
	
(c)	
